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ABSTRACT 
In Parkinson’s disease (PD), dopaminergic cells in the degenerating substantia nigra (SN) 
exhibit low copper ion (Cu) levels. Initial clinical testing of the Cu compound Cu2+diacetyl-
bis(4-methyl-thiosemicarbazonato) (CuATSM) for PD reports some clinical benefits but its 
mechanism of action is not fully understood. This may be investigated in PD animal models, 
but none currently model Cu deficiency. Thus, this thesis combined the classic 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) dopaminergic neurotoxin with a copper transport 1 
knockdown (Ctr1+/–) mouse to produce a model exhibiting Cu deficiency and nigrostriatal 
degeneration, which was then used to test the efficacy of CuATSM. 
 
CuATSM (30 mg/kg/day) administered for 20 days increased Cu to supraphysiological levels 
in normal (WT) and Ctr1+/– mouse brains but did not affect the nigrostriatal system. CuATSM 
further increased brain Cu following MPTP and reduced SN cell loss in WT but not Ctr1+/– 
mice, which may relate to the larger fold increase in Ctr1+/– brain Cu. This is supported by 
treatment with a CuATSM derivative that reduced SN cell loss in MPTP treated Ctr1+/– mice 
by increasing Cu to physiological levels. Thus, elevating Cu above physiological levels in Cu 
deficient brains may be detrimental and this has implications for current PD clinical trials. 
 
Changes in brain metal ion levels with age are also reported in the C57Bl/6 mouse. Iron levels 
were homogenous across brain regions and exhibited a similar rate of increase with age; Cu 
levels were heterogeneously distributed and only increased in the striatum and cerebellum with 
age; zinc levels were heterogeneously distributed but remained constant with age. 
 
This work describes a novel Cu deficient PD mouse model and age associated changes in 
mouse brain metal levels that may be used to aid in the design and interpretation of future 
metal-related murine studies to improve the validity and reliability of basic research for better 
translation into the human condition. 
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1 INTRODUCTION 
1.1 Parkinson’s disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide 
that in 2014 was more prevalent than a number of diseases/injuries considered national health 
priorities in Australia (Figure 1.1). In the same year, it was estimated that 1 in 340 Australians 
had PD, 82% of which were over the age of 65, that resulted in an estimated total economic 
cost of $9.9 billion (Deloitte, 2015). PD is characterised as a slowly progressive 
neurodegenerative disorder that is caused by a deficiency in the neurotransmitter dopamine in 
the basal ganglia as a result of dopaminergic cell loss in the substantia nigra pars compacta 
(SN) (DeMaagd & Philip, 2015). The SN is part of the midbrain that connects to the basal 
ganglia via the dorsal striatum (containing the caudate nucleus and putamen) to form the 
nigrostriatal pathway, an anatomical circuit that plays a role in movement, learning, memory, 
and expression of behavioural and cognitive habits (Alcaro, Huber, & Panksepp, 2007). It is 
not surprising then that PD is associated with a number of non-motor symptoms including 
olfactory dysfunction, rapid eye movement sleep behaviour disorders, autonomic dysfunction 
(e.g. constipation, orthostatic hypotension, bladder dysfunction), and mood disorders 
(depression and anxiety) that may develop years prior to clinical diagnosis or manifests with 
disease progression (Obeso et al., 2017). Typically though, clinical diagnosis of PD occurs 
when patients develop the classic Parkinsonian motor symptoms including bradykinesia, 
muscular rigidity, resting tremor, postural and gait impairments, which occurs when 50-70% 
of the SN dopaminergic neurons are lost (DeMaagd & Philip, 2015). However, as other 
diseases such as multiple system atrophy, progressive supranuclear palsy, and corticobasal 
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degeneration also present with parkinsonian symptoms, a clinically observable  response to 
dopaminergic medication (i.e. patients experience an improvement or amelioration of motor 
symptoms upon taking dopaminergic medication) is also required for PD diagnosis (Williams 
& Litvan, 2013).  
 
Figure 1.1 Prevalence of diseases and injuries considered national health priorities in 
Australia (2013-2014). There was an estimated 69, 208 people living with Parkinson’s disease 
(highlighted green) in Australia in 2013-2014, which was the second highest neurological 
disorder behind dementia. Figure adapted from Deloitte (2015). 
 
Current treatment strategies for PD aim to elevate brain dopamine levels to control the motor 
symptoms that develop due to insufficient dopamine levels in the striatum caused by the loss 
SN dopaminergic neurons (Oertel & Schulz, 2016). The most successful and widely used 
compound to elevate patient dopamine levels is levodopa, which is metabolised to dopamine 
via aromatic amino acid decarboxylase found in both central and peripheral organs (You et al., 
2018). Peak plasma concentrations of levodopa are reached by 60 minutes, however its 
relatively short half-life (~90 minutes) coupled by its extensive metabolism in peripheral 
organs limit the efficacy of levodopa and may result in unwanted side effects including 
orthostatic hypotension and gastrointestinal symptoms (Tambasco, Romoli, & Calabresi, 2018; 
You et al., 2018). To address this, amino acid decarboxylase inhibitors (e.g. carbidopa and 
benserazide) are routinely coadministered with levodopa to minimise peripheral dopaminergic 
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side effects and increase levodopa entry into the central nervous system, (Tambasco et al., 
2018). Additionally, the effectiveness of levodopa can be prolonged if coadministered with 
compounds that prevent dopamine metabolism such as catechol-o-methyltransferase (COMT; 
e.g. entacapone and tolcapone) and MAO-B (e.g. selegeline and rasagiline) inhibitors (You et 
al., 2018). Patients typically experience good control of motor symptoms using levodopa in the 
early stages of PD. However, up to 75% of patients develop treatment-induced motor 
complications (motor fluctuations and dyskinesia) after 4-6 years of treatment (Tambasco et 
al., 2018). Motor fluctuations are characterised by the re-emergence of parkinsonian motor 
symptoms (“off” state) before the next scheduled dose of levodopa; and dyskinesias are 
abnormal movements of the body that occurs at peak plasma concentrations of levodopa and/or 
when plasma levodopa levels are low (at the beginning and end of a dose) (You et al., 2018). 
While the mechanisms that cause these motor complications are still debated, it is likely that 
as dopamine replacement therapies do not treat the underlying cause of dopaminergic neuronal 
death, the brains ability to produce, store, and release dopamine diminishes, resulting in the 
role of exogenous levodopa changing from complementing endogenous dopamine function, to 
being the sole source with disease progresses (Tambasco et al., 2018). As such, patients require 
more frequent doses and/or higher concentrations of individual doses of levodopa in order to 
manage their parkinsonian motor symptoms (Freitas, Hess, & Fox, 2017). There are currently 
no approved disease modifying therapies for PD, however the need of such treatments is 
becoming increasingly apparent with current projections indicating the incidence rate of PD 
worldwide is expected to double to 9.3 million people by 2030 as a result of longer life 
expectancy (Deloitte, 2015). The difficulties in identifying a disease modifying treatment for 
PD is primarily due to its multifactorial nature, where an undetermined cause (likely a 
combination of environmental and genetic influences) triggers neurodegeneration of the 
nigrostriatal pathway by promoting oxidative stress, mitochondrial dysfunction, protein 
aggregation, and neuronal inflammation (Schapira & Jenner, 2011). Metal ions such as iron 
(Fe), copper (Cu), and zinc (Zn) have been found to be functionally important in approximately 
one-third of all proteins in the human body (Lothian et al., 2013). It is not surprising then that 
brain metal dyshomeostasis is associated with a number of neurodegenerative disorders 
including PD, and so represent a novel target to simultaneously target several cell death 
pathways. 
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1.2 Parkinson’s disease and metal ions 
Several epidemiological studies have shown a significant association between long-term (two 
or three decades) chronic exposure to metal ions such as mercury, lead, manganese, Fe, Zn, 
and Cu and the onset of PD or development of parkinsonism as reviewed by Bjorklund et al., 
(2018). However, examination of metal levels in post-mortem PD brains compared to healthy 
controls have largely focused on Fe, Cu, and Zn, largely due to their abundance and importance 
in a number of biochemical processes in the human brain.  
 
The most abundant metal ion in the brain is Fe, which is found in high concentrations in brain 
regions associated with motor function including the SN, putamen, globus pallidus, and locus 
coeruleus (Popescu & Nichol, 2011); and is an important cofactor for neurotransmitter 
synthesis/metabolism, myelin synthesis, mitochondrial respiration, and oxygen transport 
(Ward, Zucca, Duyn, Crichton, & Zecca, 2014). Dysregulation of Fe in the PD brain was first 
reported in the 1920s, where Fe levels were found to be increased compared to healthy controls 
(Lhermitte, Kraus, & McAlpine, 1924). Subsequent studies have since identified that the 
elevation in Fe levels predominantly occurs in the SN of PD patients, as summarised by recent 
meta-analyses (Genoud, Senior, Hare, & Double, 2019; Wang et al., 2016). While Fe levels 
have been found to increase in all brain regions with healthy human aging (Ramos et al., 
2014b), the aberrant accumulation of Fe in PD is thought to occur due to increased expression 
of the Fe import protein divalent metal transporter 1, decreased expression of the Fe export 
protein ferroportin, and reduction in the specific activity (but not levels) of the ferroxidase 
ceruloplasmin as found in PD animal and cell models (Li & Reichmann, 2016). The elevations 
in Fe is believed to contribute to PD pathology by increasing oxidative stress through Fenton 
chemistry, where redox-active metals catalyse hydrogen peroxide into reactive hydroxyl 
radicals; and Fe induced lipid peroxidation, both of which contribute to degeneration of 
dopaminergic neurons (Lan, Chen, Chai, & Hu, 2016). Elevated Fe levels can also promote the 
translation and aggregation of a-synuclein to form Lewy bodies, another key pathological 
feature of PD (Chen, Miah, & Aschner, 2016).  
 
Zn is the second most abundant metal ion in the brain, with the highest concentrations found 
in the hippocampus and cortex suggesting a role in memory and cognition. It is also a vital 
structural component for ~70% of all brain proteins and has been found to regulate synaptic 
transmission and neuronal plasticity (Portbury & Adlard, 2017). The role of Zn dyshomeostasis 
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in PD is contentious, with some reporting either elevated or unchanged Zn levels in the PD SN 
however, a recent meta-analysis reported that overall results from Zn levels in the SN, serum, 
and CSF of PD patients were no different to healthy controls (Genoud et al., 2019). The link 
between PD and Zn dyshomeostasis appears to stem from studies of ATP13A2 (PARK9), a P5-
type ATPase that is involved in the transport of cations such as Zn (Park, Blair, & Sue, 2015). 
PARK9 is ubiquitously expressed in the central nervous system, particularly in dopaminergic 
neurons of the SN (Ramirez et al., 2006) and mutations in this transporter results in Kufor-
Rakeb syndrome, an autosomal recessive disorder that presents with L-DOPA responsive 
parkinsonism (Park et al., 2015). This mutation causes reduction in PARK9 expression, 
resulting in increased intracellular Zn levels that is associated with lysosomal dysfunction, 
mitochondrial dysfunction, and increased a-synuclein expression and subsequent 
accumulation (Park, Koentjoro, Veivers, Mackay-Sim, & Sue, 2014; Tsunemi & Krainc, 2014). 
Interestingly, surviving dopaminergic neurons in the SN of sporadic PD patients were found to 
have elevated PARK9 mRNA and protein levels compared to healthy controls (Ramirez et al., 
2006; Ramonet et al., 2012), and this may be a protective response as elevated expression of 
PARK9 in vitro increased export of a-synuclein and therefore may lower a-synuclein 
associated toxicity (Kong et al., 2014). 
 
While not as abundant as either Fe or Zn in the brain, Cu is an important cofactor and structural 
component for a number of enzymes involved in energy production, antioxidant defence, Fe 
homeostasis, and neurotransmitter synthesis (described in more detail below) (Scheiber, 
Mercer, & Dringen, 2014). Similar to Fe, the highest concentrations of Cu are found in brain 
regions associated with motor function including the SN, locus coeruleus, dentate nucleus, and 
cerebellum (Popescu & Nichol, 2011). Previous work in our group identified that intracellular 
Cu levels are significantly reduced in the degenerating SN and locus coeruleus (by 45% and 
55% respectively) of PD patients compared to age-matched healthy controls, while 
neighbouring non-degenerating brain regions such as the ventral tegmental area and retrorubral 
field contained normal Cu levels (Davies et al., 2014). This suggests that Cu dyshomeostasis 
may play a role in the region specific loss of cells observed in PD. Cu deficient brain regions 
were associated with reduced expression of the copper transport 1 (Ctr1) protein, while other 
Cu transporters such as ATP7A and ATP7B were unchanged (Davies et al., 2014). While it 
has yet to be determined whether Cu deficiency is the primary cause or secondary consequence 
of Ctr1 dysregulation, Cu dyshomeostasis may be an early indicator of PD pathology as similar 
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reductions in Ctr1 protein and Cu levels were observed in the post-mortem SN and locus 
coeruleus of patients with incidental Lewy body disease (Davies et al., 2014), an accepted 
preclinical form of PD that only exhibits a 40% loss of nigral cell compared to an 82% loss 
observed in PD (Iannaccone et al., 2013). Cu deficiency is associated with motor impairments, 
mitochondrial dysfunction, Fe accumulation, and reduced antioxidant activity as demonstrated 
in various in vitro and in vivo studies (reviewed in Davies, Mercer, Chen, & Double, (2016)).  
 
Thus, dyshomeostasis of brain metal ion levels appears to underlie a number of cell death 
pathways associated with PD pathology, and normalisation of brain metal levels may be an 
appropriate target for therapeutics. Indeed, the removal of excess Fe has been tested in clinical 
trials for PD using the Fe chelator deferiprone (ClinicalTrials.gov identifier: NCT02655315). 
It was found that a 30 mg/kg/day deferiprone treatment in early stage PD patients significantly 
reduced SN Fe levels after 6 months of therapy and was associated with significant motor 
improvements that persisted for the duration of the study (18 months) and provided preliminary 
evidence for disease modifying effects (Devos et al., 2014). However, a follow up study using 
similar methods reported 6 months of deferiprone treatment reduced SN Fe levels in only a 
portion of PD patients, and only a trend towards improvement in motor performance was 
observed (Martin-Bastida et al., 2017). Thus, further studies involving a longer treatment 
duration and recruitment of more patients is needed to properly determine the efficacy of 
deferiprone in the treatment of PD. Nevertheless, the positive results associated with 
deferiprone use suggest that restoration of metal homeostasis in PD is an appropriate 
therapeutic strategy. The restoration of Cu in PD may be beneficial as the Cu deficiency 
observed in degenerating PD brain regions was found to reduce the activity, but not protein 
level, of vital cuproproteins associated with Fe homeostasis and antioxidant defence including 
ceruloplasmin, whose reduced ferroxidase activity resulted in Fe accumulation (Ayton, Lei, et 
al., 2013); and Cu/Zn superoxide dismutase 1 (SOD1), where a lack of Cu reduced its 
antioxidant activity and resulted in the misfolding and aggregation of SOD1 similar to what is 
seen in familial amyotrophic lateral sclerosis (Trist et al., 2017). Additionally, Cu deficiency 
was found to promote mitochondrial dysfunction and increase oxidative stress by reducing the 
activity of cytochrome C oxidase (complex 4) in vivo and in vitro (Rossi, Lombardo, Ciriolo, 
& Rotilio, 2004). Thus, restoring Cu levels in the PD brain may provide a way to placate several 
of the major dysregulated pathways believed to contribute to PD pathology and progression. 
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1.3 Copper ion handling in the brain 
Cu is an essential micronutrient in humans that plays an important role in development and 
normal cellular function. This is related to its ability to readily cycle between its oxidised (Cu2+) 
and reduced (Cu+) states, allowing Cu to act as an electron carrier and redox catalyst in a 
number of biological processes (Festa & Thiele, 2011). While valuable, this same redox 
capacity can be detrimental if not regulated properly, with free Cu able to facilitate the 
formation of oxidative species through participation in Fenton chemistry or direct oxidation of 
dopamine (Pham, Xing, Miller, & Waite, 2013; Spencer, Jeyabalan, Kichambre, & Gupta, 
2011). 
 
For Cu to reach the brain, it must first be taken up by enterocytes found in the intestines. This 
is largely mediated by the high affinity plasma membrane Cu+ importer Ctr1 (Abou Zeid & 
Kaler, 2019), which is found on the apical side of enterocytes; and facilitated by the STEAP 
family of metalloreductases found on the cell surface to ensure Cu is in its reduced state 
(Ohgami, Campagna, McDonald, & Fleming, 2006). From the cytoplasm, Cu is exported into 
the blood by the Cu transporter P-type ATPase, ATP7A, found on the basolateral surface of 
enterocytes, where it is bound by various low molecular weight ligands such as albumin, 
transcuprein, and various amino acids for delivery to the liver via portal circulation (Linder et 
al., 1998). As the major regulator of Cu homeostasis in the body, the liver determines whether 
Cu is stored in hepatocytes; excreted out of the body in the form of bile; or redistributed to 
other organs through the action of ceruloplasmin via the bloodstream (Abou Zeid & Kaler, 
2019). The entry of Cu into the brain is mediated by the same Cu/metal transporters described 
for enterocytes but now located on the endothelial cells that make up the blood brain barrier 
(Scheiber et al., 2014) i.e. Ctr1 transports Cu+ from the blood into endothelial cells, which is 
then exported into the brain parenchyma via ATP7A. Excess Cu diffuses into the cerebrospinal 
fluid, where it can be taken up and stored by the polarized epithelial cells of the choroid plexus 
via Ctr1 for transport back into the cerebrospinal fluid via ATP7B, or exported into the blood 
stream by ATP7A (Figure 1.2; Scheiber et al., 2014).  
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Figure 1.2 Uptake and efflux of copper in the brain. Endothelial cells form the blood brain 
barrier (BBB), which take up Cu in the blood through the action of Cu transport 1 protein 
(Ctr1). Cu is then exported to the brain parenchyma by ATP7A where it can be utilised by brain 
cells. Excess Cu is released into the cerebrospinal fluid (CSF) where it can be taken up and 
stored by polarised epithelial cells of the choroid plexus that form the blood CSF barrier (BCB) 
via Ctr1. From here, Cu can be transported back into the CSF by ATP7B or released into the 
blood by ATP7A. Figure from Scheiber et al., (2014). 
 
Cu uptake into brain cells is also mediated by Ctr1 and once inside, free Cu is quickly bound 
by various metallochaperone proteins for incorporation into various organelles or sequestered 
by Cu storage proteins to prevent participation in Fenton chemistry (Figure 1.3). The 
cytochrome C oxidase Cu chaperone protein (Cox) 17 is responsible for the transport of 
cytoplasmic Cu into the mitochondrial intermembrane space (Matson Dzebo, Ariöz, & 
Wittung-Stafshede, 2016), where it transfers Cu to Sco1 (synthesis of cytochrome C oxidase 
subunit 1) and Cox11 (Horng, Cobine, Maxfield, Carr, & Winge, 2004). These chaperones then 
transfer Cu to activate the catalytic core of Complex 4, a multimeric Cu heme A terminal 
oxidase that facilitates the final step in the mitochondrial respiratory chain (Montes, Rivera-
Mancia, Diaz-Ruiz, Tristan-Lopez, & Rios, 2014). 
 
The Cu chaperone for SOD1 (CCS) is responsible for the transport of cytosolic Cu to SOD1 
(Culotta et al., 1997), a key antioxidant protein that mitigates oxidative damage by catalysing 
superoxides into molecular oxygen and hydrogen peroxide (Perry, Shin, Getzoff, & Tainer, 
2010). Human SOD1 is a homodimeric metalloprotein that is found primarily in the neuronal 
cytoplasm, but has also been found in the nucleus, lysosomes, and intermembrane space of 
mitochondria (Crapo, Oury, Rabouille, Slot, & Chang, 1992; Sturtz, Diekert, Jensen, Lill, & 
Culotta, 2001). Each monomer of SOD1 contains one Cu (catalytic role) and one Zn (structural 
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role) ion (Rakhit & Chakrabartty, 2006), hence Cu plays an important role in the biological 
activity of SOD1.  
 
 
 
Figure 1.3 Copper handling inside the cell. Once Cu2+ is reduced to Cu+, it is brought inside 
of the cell by Ctr1 where it can be bound to various Cu chaperones including Cox17 for 
transport into the mitochondria; CCS1 for transport to the antioxidant Cu/Zn SOD1; and Atox1 
for transport into the trans-golgi network for incorporation into other cuproproteins. Excess Cu 
can be stored by metallothionein or exported out of the cell via ATP7A. Abbreviations: Atox1: 
Antioxidant 1 protein; CCS1: Copper chaperone for SOD1; Cox17: cytochrome C oxidase Cu 
chaperone protein 17; Ctr1: Copper transport 1 protein; Cu: Copper; SOD1: Superoxide 
dismutase 1. From Davies et al., (2016).
 
Cytosolic Cu can be transported to the trans-Golgi network via antioxidant protein 1 (Atox1), 
where it transfers Cu to ATP7A and ATP7B for incorporation into cuproproteins (discussed 
below) (Pierson, Lutsenko, & Tümer, 2015; Scheiber et al., 2014). As its name suggests, Atox1 
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was initially identified as an antioxidant due to its ability to improve cellular resistance to 
oxidative species in the absence of SOD1 and SOD2 in yeast saccharomyces cerevisiae and 
homologues subsequently identified in multicellular eukaryotes including plants and humans 
(Lin & Culotta, 1995). Atox1 has since been found to interact with a number of cellular 
processes including those involved in DNA/RNA synthesis, ubiquitination, metal binding, and 
cell proliferation, differentiation, and migration (Öhrvik & Wittung-Stafshede, 2015), many of 
which appear to be Cu dependent.  
 
Once Cu is transported into the trans-Golgi apparatus, it can be incorporated into several 
different cuproproteins. Ceruloplasmin is a Cu containing ferroxidase that plays an important 
role in Fe homeostasis (Scheiber et al., 2014). The importance of ceruloplasmin is seen in 
aceruloplasminemia, an autosomal recessive disorder caused by a loss of functional 
ceruloplasmin (Takahashi et al., 1996). The loss of functional ceruloplasmin leads to the 
accumulation of Fe in the brain and other tissues, resulting in neurological abnormalities such 
as dysarthria, dystonia, and mild dementia (Gonzalez-Cuyar et al., 2008). Cu can also be 
incorporated into Dopamine-β-monoxygenase, which is involved in the final step of 
norepinephrine synthesis (Kim et al., 2002); peptidylglycine-α-amidating monoxygenase, 
which amidates peptide precursors so they can play a role in neuronal proliferation, energy 
metabolism, and neuromodulation (Bousquet-Moore, Mains, & Eipper, 2010); lysyl oxidase, 
which promotes the cross-linking of collagen and elastin in order to stabilise collagen fibrils 
and mature elastin (Lucero & Kagan, 2006); sulfhydryl oxidase, plays a role in keratin 
synthesis (Alibardi, 2017); and tyrosinase, which is involved in melanin production (Pierson 
et al., 2015). 
 
If free Cu is not bound to the above mentioned Cu chaperones, it is sequestered by 
metallothionein and/or glutathione in order to prevent free Cu from causing cellular damage 
(Scheiber et al., 2014). Metallothionein is a low molecular weight protein that in addition to its 
role in metal ion homeostasis (including Cu, Zn, cadmium, mercury, nickel, and cobalt) is 
involved in antioxidant defence, inhibition of apoptosis, mitigates inflammation, and promotes 
regeneration in the central nervous system (Swindell, 2011). Glutathione plays an important 
protective role against reactive oxygen and nitrogen species (Martin & Teismann, 2009), and 
can form complexes with Cu+ for storage or transfer to metallothionein, SOD1 (independent 
of CCS), and Atox1 (Scheiber et al., 2014). However, glutathione’s ability to store Cu is likely 
to only be for short periods as the glutathione-Cu complex is still redox active and can promote 
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oxidative stress either by reacting with oxygen to form superoxides (Aliaga, López-Alarcón, 
Barriga, Olea-Azar, & Speisky, 2010); or facilitate Fe release from ferritin for participation in 
Fenton chemistry (Aliaga, Carrasco-Pozo, López-Alarcón, Olea-Azar, & Speisky, 2011). In 
contrast, the chelation of Cu by metallothionein has been found to protect cells from Cu toxicity 
by inhibiting its interaction with other cellular components (Tapia et al., 2004), thus 
metallothionein is a more appropriate long-term storage protein for Cu. 
 
When cellular Cu levels are raised above a certain threshold, ATP7A and ATP7B reversibly 
translocate from the trans-Golgi apparatus to the plasma membrane, where it can export Cu 
into the extracellular space (Scheiber et al., 2014). From here, Cu can be taken up by astrocytes 
through the action of prion proteins or Ctr1 (Brown, 2004; Scheiber, Mercer, & Dringen, 2010). 
Astrocytes are believed to play an important role in regulating brain Cu levels as their close 
proximity to the blood brain barrier make them the first brain cells to encounter metals that 
enter the brain (Serlin, Shelef, Knyazer, & Friedman, 2015). Furthermore, their close proximity 
to neuronal cells allows them to regulate neuronal Cu levels by suppling Cu via ATP7A when 
neuronal Cu levels are low (Scheiber, Schmidt, & Dringen, 2012); or protecting neurons from 
Cu toxicity by releasing antioxidants or Cu chelating ligands (Scheiber et al., 2014). Astrocytes 
also demonstrate a greater storage capacity for Cu then other neuronal cells, as they have been 
found to accumulate large amounts of Cu when supraphysiological levels are reached in vitro 
(Brown, 2004) and in vivo (Haywood, Paris, Ryvar, & Botteron, 2008). This protective 
response by astrocytes is derived from their inherent high expression of metallothionein and 
glutathione, which can be further upregulated under supraphysiological Cu levels, thus giving 
astrocytes a high capacity to store Cu and mitigate Cu induced oxidative stress (Scheiber et al., 
2014). 
 
Cu is an important component of a number of proteins involved in normal cellular function and 
maintenance. It is not surprising then that Cu dyshomeostasis as a result of changes to Cu 
uptake, storage, and transport can have deleterious effects that if left untreated, leads to 
neurodegeneration. The potential benefits of normalising brain Cu levels to prevent 
neurodegeneration is made apparent in the treatment of primary Cu deficient 
neurodegenerative disorders Menkes disease and acquired Cu deficiency myelopathy. 
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1.4 Disorders of Cu deficiency 
Menkes disease is an infantile onset X-linked recessive disorder that is caused by mutations in 
the ATP7A transporter, causing inefficient uptake of Cu from the gut and subsequent reduction 
in total Cu levels and cuproproteins in the body. Affected infants appear healthy from birth to 
approximately 2-4 months, after which infants develop hypotonia, seizures, and failure to 
thrive, with infant life expectancy being approximately three years as a result of infection, 
vascular complications, or neurodegeneration (Kaler, 2011). Although the clinical presentation 
of Menkes disease is variable, patients often exhibit neurological symptoms (such as mental 
retardation, seizures, hypothermia, and muscle tone changes), connective tissue symptoms 
(including twisted blood vessels, loose skin and joints, skeletal changes, hernia, and bladder 
problems), and wiry/twisted hair (pili torti), which is the most prominent feature that often 
leads to diagnosis at 3-6 months, (Pierson et al., 2015). Serum Cu and ceruloplasmin levels are 
also reduced in Menkes disease and can be measured to provide validation of the diagnosis 
however, neonatal measurements (before clinical presentation) of serum Cu or ceruloplasmin 
is problematic at this age as serum levels are low in healthy newborns (Kanakoudi et al., 1995). 
A number of the symptoms/pathology of Menkes disease can be attributed to low Cu levels 
and associated cuproproteins e.g. lack of ceruloplasmin leads to Fe accumulation and 
neurological damage (Gonzalez-Cuyar et al., 2008); lack of COX leads to impaired 
mitochondrial activity, which is associated with brain abnormalities, hypothermia, and muscle 
weakness (Pierson et al., 2015); lack of sulfhydryl oxidase leads to irregular cross-linking of 
keratin, which could explain abnormal hair (Alibardi, 2017). Menkes disease is treated with 
small Cu complexes, such as Cu chloride, Cu gluconate, and Cu sulphate, which have been 
shown to enhance survival, reduce seizures, and in some cases, normalise infant neuronal 
development (Kaler, 2011), however the success of the treatment is dependent on early 
diagnosis, early treatment administration, and adequate activity of Cu transporters. In addition 
to genetic mutations, healthy people can also acquire Cu deficiency later in life due to impaired 
Cu absorption in the upper gut due to bariatric surgery, excessive Zn ingestion, and 
malabsorption syndromes, although there are several cases in which the cause of Cu deficiency 
is unknown (Jaiser & Winston, 2010). Acquired Cu deficiency often develops as a myelopathy 
that exhibits spastic gait and prominent sensory ataxia, and can be treated with oral Cu 
supplementation to prevent further neurological deterioration, although reports of neurological 
improvements are varied (Kumar, 2006). 
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While the restoration of brain Cu levels in Cu deficient neurological disorders may not improve 
neurological deficits, there is sufficient evidence to suggest that the restoration of Cu can 
prevent further neurodegeneration, thus halting disease progression. However, current 
clinically used Cu compounds are reliant on Cu transporters for entry into neurons (Kaler, 
2011) and so may not be appropriate in the treatment of PD that exhibits a reduction in Ctr1 
levels in degenerating brain regions (Davies et al., 2014). Furthermore, treating the localised 
Cu deficiency observed in PD with a non-specific Cu compound raises the risk of Cu overload 
in neighbouring Cu normal brain regions, the potential dangers of which are exemplified in 
Wilson’s disease, where excess accumulation of Cu in the brain is associated 
neurodegeneration and the development of movement (dystonic, ataxic, or parkinsonian 
movements) and psychiatric (personality change, anxiety, and depression) disorders 
(Bandmann, Weiss, & Kaler, 2015).  
 
1.5 Copper delivery compounds in the treatment of Parkinson’s 
disease 
Bis(thiosemicarbazonato) are ligands that can bind divalent metal ions such as Cu to form 
stable, neutral, and relatively lipophilic complexes that can enter cells independently of metal 
transporters to deposit their metal load (Helsel & Franz, 2015). A derivative from this family 
of compounds is Cu2+diacetyl-bis(4-methyl-thiosemicarbazonato) (CuATSM; Figure 1.4), 
which is the only Cu compound being tested in clinical trials for the treatment of PD 
(ClinicalTrials.gov identifier: NCT03204929).  
 
 
Figure 1.4 Structure for Cu2+bis(thiosemicarbazonato) complexes. (A) General chemical 
structure of Cu2+ bound bis(thiosemicarbazonato) where R can be replaced by various 
substituents to alter the compounds properties, and (B) the chemical structure for CuATSM. 
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Interest in the use of CuATSM as a therapeutic originated from its selective delivery of Cu to 
cells that exhibited mitochondrial dysfunction, but not normal tissue (Yoshii et al., 2012). The 
proposed mechanism of action for CuATSM will be discussed in more detail in Section 4.4.3. 
Nevertheless, as mitochondrial dysfunction is a key feature of the degenerating nigrostriatal 
pathway in PD that also exhibits Cu deficiency, CuATSM would allow targeted delivery of Cu 
to degenerating brain regions while not affecting healthy brain regions and thereby reduce the 
likelihood of Cu toxicity. In support of this, a study using positron emission tomography to 
image oxidative stress in the PD brain using radiolabelled 62CuATSM identified that compared 
to healthy controls, 62Cu accumulation was enhanced in the striatum of PD patients and the 
degree of accumulation was positively correlated with disease severity (Ikawa et al., 2011). At 
therapeutic doses (30 mg/kg daily gavage) CuATSM was found to improve motor and 
cognitive function; prevent dopaminergic cell death in the SN after cell death cascade had 
commenced; and improve striatal dopamine physiology in four different animal models of PD 
(Hung et al., 2012). These therapeutic benefits were attributed to CuATSM’s ability to 
scavenge peroxynitrite and thereby mitigate nitrosative stress and prevent the aggregation of 
a-synuclein (Hung et al., 2012). It was further demonstrated using whole genome 
transcriptomic profiling that CuATSM treatment also upregulated genes involved in dopamine 
synthesis, calcium signalling, and synaptic plasticity, which were altered in the SN following 
administration of the dopaminergic neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) (Cheng et al., 2016). These promising results prompted the testing of 
CuATSM in phase 1 clinical trial for PD. This study determined that a 72 mg/day dose of 
CuATSM, which raised patient serum concentrations to similar levels as those achieved by the 
30 mg/kg dose found beneficial in animal models (Hung et al., 2012), was well tolerated by 
patients over the 24 week study period (Evans, Rowe, Lee, & Rosenfeld, 2017). Furthermore, 
preliminary evidence suggests that CuATSM treatment was associated with improvements in 
disease severity and quality of life, as determined by the Unified PD Rating Scale and the 39 
item PD Questionnaire respectively.  
 
While these results provide support for the use of CuATSM in the treatment of PD, no studies 
have reported the effects of CuATSM on regional brain metal levels. This is potentially 
hazardous as the extent of Cu increase following CuATSM is not known and there is currently 
no accurate way to measure brain Cu levels in the living mammalian brain. As such, the only 
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way to quantify the effects of CuATSM on metal levels in the PD brain is by using an 
appropriate animal model where post-mortem analysis can be performed. 
 
1.6 Models of Parkinson’s disease 
MPTP (Figure 1.5) is the most commonly used neurotoxin to simulate PD in animals due to 
its selective toxicity for dopaminergic neurons and relative ease of administration (Meredith & 
Rademacher, 2011). MPTP was first linked to PD in 1982 when drug users inadvertently 
administered the synthetic heroin product 1-methyl-4-phenyl-4-propionoxy-piperidine (a 
meperidine analogue) that, as a by-product of synthesis, was highly contaminated with MPTP. 
This resulted in rapid development of Parkinsonian-like symptoms within a week of 
administration that included visual hallucinations, tremor, stiffness, and further slowing and 
difficulties with movement, such that they had near total immobility by the time they were 
hospitalised 14 days to 6 weeks later  (Langston, Ballard, Tetrud, & Irwin, 1983). Postmortem 
neuropathological examination of these patients (survival time ranged from 3-16 years) 
revealed moderate to severe loss of dopaminergic cells in the SN but in the absence of Lewy 
body pathology (Langston, Forno, Tetrud, & Reeves, 1999). MPTP was identified as the cause 
of the parkinsonian-like symptoms and pathology in these people, with subsequent studies 
identifying that MPTP induced the same selective degeneration of the nigrostriatal pathway in 
a number of animals including non-human primates and mice; and also induced parkinsonian-
like motor symptoms including resting tremors, rigidity, and bradykinesia in non-human 
primates, (Blandini & Armentero, 2012; Verdier et al., 2015). 
 
N+
CH3
N
CH3
MPTP MPP+ 
MAO-B 
Figure 1.5 The chemical structure for MPTP and MPP+ . MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) is metabolised by MAO-B (monoamine oxidase-B) to form the 
toxic metabolite MPP+ (1-methyl-4-phenylpyridinium ion). 
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MPTP is able to cross the blood brain barrier due to its highly lipophilic nature. In the brain, 
MPTP is taken up by astrocytes and converted to the toxic species MPP+ (1-methyl-4-
phenylpyridinium ion) by the enzyme MAO-B (Figure 1.5). MPP+ is then released back into 
the intercellular space where it is selectively taken up by dopaminergic neurons via dopamine 
transporter (DAT). Once inside, MPP+ can disrupt mitochondrial function and promote 
abnormal protein interactions resulting in increased intracellular oxidative stress, 
excitotoxicity, and inflammation, eventuating in the selective death of dopaminergic cells 
(Figure 1.6; Meredith & Rademacher, 2012). The toxic effects of MPTP have also been found 
to be dependent on the dose, dosing regime, and time after last dose, making MPTP a versatile 
toxin to investigate different stages of PD i.e. initial, ongoing, or peak degeneration (Franke et 
al., 2016; Meredith & Rademacher, 2011). 
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Figure 1.6 Mechanism of MPTP toxicity. MPTP crosses the blood brain barrier, where it is 
taken up by astrocytes and converted to MPP+ by MAO-B. MPP+ is then taken up by 
dopaminergic cells via DAT, where it can inhibit mitochondrial function, cause excitotoxicity, 
and increase oxidative stress, ultimately leading to the death of dopaminergic cells. 
Abbreviations: ATP: Adenosine triphosphate; MAO-B: Monoamine oxidase B; DAT: 
Dopamine transporter; MPP+: 1-methyl-4-phenylpyridinium ion; MPTP: 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine; ROS: Reactive oxygen species. 
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There exist several variations of the MPTP protocol that may be employed depending on the 
primary outcomes of the study, each with its own strengths and weaknesses. The most common 
protocols involve the administration of a single acute, multiple acute, sub-acute, or chronic 
dose of MPTP (Table 1.1). The single and multiple acute regimen has the benefit of inducing 
the pathological features of PD very rapidly, however as it does not mimic the slow and 
progressive nature of PD, it is likely inappropriate in the study of PD progression/pathology 
but may be appropriate for obtaining preliminary data on therapeutic efficacy at the onset of 
PD motor symptoms when striatal dopamine levels are reduced by 60-80% (DeMaagd & 
Philip, 2015). The major limitation of the single acute protocol is that the high single dose 
administered results in a high mortality rate (50%) within the first 24 hours of treatment, 
however this can be almost entirely eliminated when the same total dose is administered across 
multiple doses over a day (Duty & Jenner, 2011). This suggests that the multiple acute regimen 
is a more ethical and economical method to rapidly model the clinical PD brain compared to 
the single acute bolus. Alternatively, the chronic models utilise a lower MPTP dose that is 
administered over a longer period of time resulting in a progressive loss of dopaminergic cells 
and occasional aggregation of a-synuclein in surviving dopaminergic neurons, though these 
aggregates are different to the Lewy bodies observed in PD (Duty & Jenner, 2011; Meredith & 
Rademacher, 2011). Thus, the chronic dosing regimen may be appropriate for the investigation 
of pathways/mechanisms involved in PD progression and identification of potential therapeutic 
target. However, the testing of therapeutic compounds in this model would likely be most 
beneficial once positive preliminary data is obtained in order to reduce the risk of misadventure 
for the researcher due to the increased handling of the MPTP toxin and an extended period of 
its toxic metabolite in animals.  
 
A number of MPTP animal models exist in research, with the most accurate model of PD being 
the MPTP lesioned non-human primate. This is because in addition to exhibiting specific 
degeneration of the nigrostriatal pathway (Langston et al., 1999), it is the only model that 
recapitulates the classic Parkinsonian motor symptoms (Franke et al., 2016). However, the cost, 
management, and ethical issues involved with non-human primate studies have limited their 
use in PD research (Verdier et al., 2015), with researchers preferentially using the MPTP mouse 
model to obtain preliminary data. This is because mice have a short gestation period, are easily 
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Table 1.1 Summary of different types of MPTP regimens in mice. Adapted from Duty & Jenner, (2011) and Meredith & Rademacher, (2012) 
 
MPTP dose 
(mg/kg) 
Treatment regimen 
Striatal DA depletion 
post treatment 
SN DA cell loss Protein aggregates 
Acute Bolus 30-40 1 IP injection 
>80% after 1 day and 
>40% after 30 days 
20-30% None 
Acute multiple 12.5-30 
1 IP injections every 2 
hours over 8 hours 
60-90% after 7 days 40% None 
Sub-acute 15-40 
Daily IP injection for 5-
10 days plus probenecid 
76% in 1 week, reduced 
to 53% after 30 days 
20-40% None 
Chronic intermittent 25 
1 IP injection every 3-5 
days for 5 weeks plus 
probenecid 
95% loss in first week, 
reduced to 70-80% after 
6 months 
70% loss 3 
weeks post-
treatment 
a-synuclein positive 
aggregate but different to 
Lewy body 
Chronic escalating 
Start at 4 and 
end at 32 
Daily injections for 5 
days with dose 
increased over time 
Dependent on dose: 
>70% loss at 2 highest 
concentrations 
24% in 1 week 
and 62% after 4 
weeks post-
treatment 
Not examined 
Chronic infusion 
(Osmotic mini pump) 
20-40 
Continuous delivery for 
14-28 days 
28-90% 25-80% 
a-synuclein positive 
aggregate but different to 
Lewy body 
 
Abbreviations: DA: Dopamine; IP: Intraperitoneal; SN: Substantia nigra pars compacta. 
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managed, and can be genetically modified to further replicate the human condition. Contrary 
to non-human primates, the effects of MPTP on mouse motor function are inconsistent with 
studies reporting reduced, hyperactive, or unchanged activity (Meredith & Rademacher, 2011); 
and this is likely due to a difference in central locomotive control between mice and humans 
or non-human primates (Meredith & Kang, 2006; Verdier et al., 2015). Nevertheless, the 
administration of MPTP in various mouse strains results in the accurate modelling of many 
known biochemical features of PD including loss of dopaminergic cells in the SN, depletion 
of dopamine in the striatum, elevation in SN glutamate levels, reductions in SN glutathione 
levels, and elevations in striatal and SN neuroinflammatory markers (Duty & Jenner, 2011; 
Meredith & Rademacher, 2011). 
 
Other neurotoxins used to study PD include 6-hydroxydopamine (a hydroxylated analogue of 
dopamine that has a high affinity for the dopamine transporter DAT), paraquat (herbicide), and 
rotenone (herbicide and pesticide), all of which have been found to cause degeneration of the 
nigrostriatal pathway by increasing oxidative stress (Blandini & Armentero, 2012; Blesa, 
Phani, Jackson-Lewis, & Przedborski, 2012). The major limitation with the 6-
hydroxydopamine model is the toxin cannot cross the blood brain barrier and requires direct 
injection into the SN, which can be problematic as toxicity is dependent on accuracy of 
injection and may be troublesome when dealing with smaller brains (Blandini & Armentero, 
2012). Paraquat and rotenone have been reported to induce Lewy body-like aggregations 
(Manning-Bog et al., 2002; Pan-Montojo et al., 2010) however, the amount of damage to the 
nigrostriatal pathways and dopamine levels are highly variable, and its use may affect other 
organs (Blesa et al., 2012). Transgenic mice have also been developed to study the role of 
specific genes in PD progression (including mutations in α-synuclein, LRRK2, and Parkin), 
but these models produce limited and inconsistent neuronal damage in the nigrostriatal pathway 
(Blandini & Armentero, 2012; Blesa et al., 2012).  
 
While there are many rodent models of PD that can accurately model degeneration of the 
nigrostriatal pathway, current models including the MPTP and 6-hydroxydopamine models do 
not have an effect on SN Cu levels (Hare et al., 2010; Matusch et al., 2010), and so do not 
accurately replicate the Cu deficiency observed in the PD SN (Davies et al., 2014). In order to 
properly determine whether Cu restoration by CuATSM is efficacious in the PD brain, a mouse 
model of PD with low SN Cu levels is required. An animal model that exhibits a reduction in 
total brain Cu levels is the Ctr1 heterozygous (+/−) mouse, where genetic knockdown of the 
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Ctr1 coding exon in one locus reduced Ctr1 transcript levels by 50% in all organs (Lee, 
Prohaska, & Thiele, 2001). While this did not cause obvious growth or developmental 
abnormalities, these mice exhibited a ~50% reduction in total Cu levels in the brain and spleen 
but no changes in the liver or kidneys (key Cu sensing organs). While the absence of Cu 
deficiency in all organs of the Ctr1+/− mouse has not been investigated, it is possible that some 
organs have normal Cu levels because they exhibit some form of compensatory mechanism. 
For example, in tamoxifen-inducible cardiomyocyte specific Ctr1 knockout mice, Cu levels in 
the heart was reduced however expression of the Cu exporter ATP7A were elevated in the 
intestine and liver alongside increased serum Cu levels, suggesting that low cardiac Cu may 
promote Cu export from other organs to increase circulating Cu for uptake by the heart (Wang, 
Hodgkinson, Zhu, Weisman, & Petris, 2011). Nevertheless, the brain Cu deficient Ctr1+/− mice 
can be combined with the acute MPTP toxin regimen to provide a novel model that accurately 
mimics both degeneration of the nigrostriatal pathway as well as a central Cu deficiency 
mediated by Ctr1 knockdown as observed in PD (Davies et al., 2014). Thus, this may provide 
a more relevant model to test the efficacy of Cu modulating compounds such as CuATSM.  
 
1.7 Aging as a factor for experimental design 
Age is the most significant risk factor for a range of neurodegenerative disorders (Hou et al., 
2019) but is an often overlooked factor in experimental designs. Mice are the most commonly 
cited animals in research (Johnson, 2012), however disparity exists between the age at which 
mice are defined as “adults”, which can range from 6 to 20 weeks (Jackson et al., 2017). 
Adulthood is biologically defined as the age at which sexual maturity is reached in humans or 
other organisms, and in mice, this occurs anywhere from 5-10 weeks of age (Dutta & Sengupta, 
2016). A limitation of this definition is that many biological systems and structures are still 
developing during this period, which continue to exhibit relatively rapid growth until ~12 
weeks of age (Flurkey, Mcurrer, & Harrison, 2007). The difference in system maturity may 
thus impact the outcomes of rodent studies which may increase variability between research 
groups using different aged mice in the same experimental paradigm and adversely affect 
scientific validity (Jackson et al., 2017). Furthermore, very few studies were reported to use 
mice over the age of 4 months to model a disease that is associated with older age in humans 
(Jackson et al., 2017), and this may contribute to the poor translation of results from animal 
models to the human condition, especially in the pharmaceutical field (Wong, Siah, & Lo, 
2019). Determination of equivalent ages between rodents and humans are typically done by 
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comparing the survival rates between the species, with Flurkey et al. (2007) defining: “mature” 
age as the time past development but in the absence of senescent markers (as reviewed by 
Chinta et al. 2015), which is 3-6 months in C57Bl/6 mouse and 20-30 years in humans; 
“middle” aged when senescent markers can be detected in some but not all processes, which is 
10-14 months in mice and 38-47 years for humans; and “old” when senescent markers are 
detected in almost all biological processes, which is 18-24 months in mice and 56-69 years for 
humans. Based on this study, the use of mice below the age of 3 months may be inappropriate 
to model a human adult disease, and mice below the age of 18 months may not be appropriate 
to model neurological conditions such as Alzheimer’s disease or PD that typically develop past 
the age of 65 years (Hou et al., 2019). While the use of older mice may improve the quality of 
results and thereby increase the likelihood of translation into older human conditions, it is likely 
impractical to use aged mice to obtain preliminary data as researchers would need to invest a 
long time before starting a study and commit a large portion of funding to basic maintenance 
and care (Jackson et al., 2017). Nevertheless, identifying the differences between the young 
and old mouse brain would allow future experiments to take these differences into 
consideration in order to improve experimental design and interpretation of results.  
 
Metal concentrations in the human brain are known to change with healthy aging in a regional 
manner (Ramos et al., 2014a, 2014b), however there is scarce information regarding the age 
associated changes in mouse brain metal levels, which typically report changes in the whole 
brain (Maynard et al., 2006, 2002; Portbury et al., 2017). Determining the regional changes in 
brain metal levels in the mouse with healthy aging may provide knowledge on the metal 
requirements of each brain region and determine how comparable the metal distribution is 
between the young and old mouse brain. This information would be useful in determining 
whether age should be factored into murine studies that aim to investigate or manipulate brain 
metal pathways, especially in long-term studies. Furthermore, this mouse data may be 
compared to the existing human data in order to determine the similarities and/or differences 
between regional brain metal distribution and subsequent changes with age between the two 
species. This would provide an indication on whether the mouse can be used to accurately 
model human aging and provide a basis to determine the mouse age that best represents the 
brain metal landscape of the human condition being investigated. 
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1.8 Project summary 
PD is the second most common neurodegenerative disorder worldwide and currently does not 
have any disease modifying therapies. Cu is an essential transition metal that is reduced in 
surviving dopaminergic cells of PD and incidental Lewy body disease brains, but is unchanged 
in neighbouring non-degenerating regions (Davies et al., 2014). This suggests that endogenous 
Cu levels may play a role in PD development or disease progression and therefore presents a 
novel target for therapeutic intervention. CuATSM is a Cu compound that has demonstrated 
neuroprotective effects in models of PD (Hung et al., 2012) and coupled with its selective 
accumulation in degenerating PD brain regions (Ikawa et al., 2011), has led to the clinical 
testing of CuATSM in the treatment of PD (ClinicalTrials.gov identifier: NCT03204929). 
Despite entering clinical trials, there are currently no reports regarding the extent of Cu increase 
in the brain following CuATSM treatment. Furthermore, current animal studies do not emulate 
the reduced brain Cu levels observed in PD, thus the effectiveness of CuATSM in a Cu 
deficient system has yet to be determined.  
 
To address these deficits, this thesis characterised a Ctr1-mediated Cu deficient mouse model 
of PD, which was used to determine whether Cu deficiency would alter the neuroprotective 
effects of CuATSM. The effects of CuATSM on regional brain metal levels is also reported 
for the first time in vivo. Following this initial study, the CuATSM derivative CuATSM-But 
was then tested in both Cu normal and Cu deficient mouse models of PD to determine whether 
addition of functional groups to the backbone of CuATSM would alter its pharmacokinetics to 
improve the efficacy of the compound. Finally, the changes in brain metal levels from maturity 
to old age are reported for WT and Ctr1+/− mice to provide a valuable resource to aid in the 
planning and interpretation of future mouse-based studies that investigate brain metal 
pathways.  
 
1.9 Aims and hypotheses 
1. The effects of Ctr1 knockdown on MPTP metabolism (Chapter 3) 
1.1. Aim: To determine whether knockdown of Ctr1 in C57Bl/6 mice would alter the 
metabolism rate of MPTP by comparing MPP+ levels between WT and Ctr1+/− mice at 
1 and 2 hrs post MPTP injection.  
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Hypothesis: The amount of brain MPP+ will be similar between WT and Ctr1+/− mice 
at both timepoints. 
 
2. Characterisation of a novel Cu deficient model of PD and subsequent testing of CuATSM 
(Chapter 4) 
2.1. Aim: To investigate whether knockdown of Ctr1 would alter brain metal levels, SN 
cell number, or striatal dopaminergic function by comparing unlesioned Ctr1+/− mice 
to unlesioned WT mice. 
Hypothesis: Knockdown of Ctr1 will reduce Cu levels in all brain regions however, 
it will not alter other brain metal levels, SN cell number, or striatal dopaminergic 
function. 
 
2.2. Aim: To determine whether the effects of MPTP on brain metal levels, SN cell 
number, or striatal dopaminergic function will be affected by knockdown of Ctr1 by 
comparing MPTP lesioned mice (WT and Ctr1+/− mice) to their respective unlesioned 
controls. 
Hypothesis: MPTP will not affect brain metal levels in WT or Ctr1+/− mice however, 
MPTP will cause reductions in SN cell number and striatal dopaminergic function in 
WT mice, and to a greater extent in Ctr1+/− mice. 
 
2.3. Aim: To quantify the effects of CuATSM on regional brain metal levels, SN cell 
number, and striatal dopaminergic function in unlesioned WT mice and determine 
whether the changes observed are the same in unlesioned Ctr1+/− mice. 
Hypothesis: CuATSM will not affect brain metal levels, SN cell number, or striatal 
dopaminergic function in either unlesioned WT or Ctr1+/− mice. 
 
2.4. Aim: To determine whether Ctr1 knockdown would alter the effects of CuATSM in 
MPTP lesioned mice by comparing brain metal levels, SN cell number, and 
dopaminergic function between CuATSM treated and untreated MPTP lesioned WT 
and Ctr1+/− mice respectively. 
Hypothesis: CuATSM will increase brain Cu levels in MPTP lesioned WT mice and 
prevent the loss of SN cells and striatal dopaminergic function. These results will also 
be observed in CuATSM treated MPTP lesioned Ctr1+/− mice but to a lesser extent as 
total Ctr1+/− Cu levels will not reach the same level as those observed in WT mice. 
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3. Testing a novel CuATSM derivative in Cu normal and Cu deficient mouse models of PD 
(Chapter 5) 
3.1. Aim: To quantify the effects of the novel CuATSM derivative Cu2+diacetyl-4-butyric 
acid-4’-methylbis(thiosemicarbazonato) (CuATSM-But) on regional brain metal 
levels, SN cell number, and striatal dopaminergic function in unlesioned WT mice and 
determine whether the changes observed are the same in unlesioned Ctr1+/− mice. 
Hypothesis: CuATSM-But will increase regional brain Cu levels in unlesioned WT 
mice but have no effect on SN cell number or striatal dopaminergic function. 
CuATSM-But will have similar effects in unlesioned Ctr1+/− mice but brain Cu levels 
will be lower than similarly treated WT mice. 
 
3.2. Aim: To determine whether CuATSM-But would reduce the effects of MPTP on Cu 
normal and Cu deficient mice by comparing brain metal levels, SN cell number, and 
striatal dopaminergic function between CuATSM-But-treated and untreated MPTP 
lesioned WT and Ctr1+/− mice respectively. 
Hypothesis: CuATSM-But will increase brain Cu levels and prevent the loss of SN 
cells and striatal dopaminergic function in MPTP lesioned WT mice. CuATSM-But 
will have similar effects in MPTP lesioned Ctr1+/− mice but brain Cu levels will be 
lower than similarly treated WT mice. 
 
4. Age related changes to Fe, Cu, and Zn in the mouse brain (Chapter 6) 
4.1. Aim: To quantify regional brain metal levels in the C57Bl/6 throughout its adult 
lifespan. 
Hypothesis: The C57Bl/6 mouse brain will exhibit region specific changes in metal 
levels during healthy aging 
 
4.2. Aim: To determine whether knockdown of Ctr1 in C57Bl/6 mice will affect the age 
related changes in regional brain metal levels 
Hypothesis: Ctr1 knockdown mice will have lower Cu levels in all brain regions at all 
ages compared to C57Bl/6 mice, but other metals will not be affected. 
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1.10 Conclusion 
Abundant evidence implicates Cu deficiency in the dysfunction of a number of cell death 
pathways that contribute to the degeneration the nigrostriatal pathway in PD. However, current 
in vivo investigations that report the efficacy of Cu restorative compounds in the treatment of 
PD are limited by not replicating the Cu deficiency observed in the human disorder. The 
characterisation of a novel Cu deficient mouse model of PD may provide insights on the role 
of Cu in the specific degeneration of the SN in PD and provide a more accurate model of the 
disorder. The testing of Cu compounds, such as CuATSM and its derivatives, in such a model 
may further validate the use of these compounds in the treatment of PD and provide data that 
can be used to aid in the design of future in vivo studies or clinical trials. Furthermore, an 
investigation of age associated changes in metal levels in the healthy C57Bl/6 mouse brain 
could be used to form a reference guide, which may be used to reduce variability between 
studies and thus improve scientific validity. 
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2 GENERAL EXPERIMENTAL 
PROCEDURES 
This chapter provides a general detailed description of the techniques and equipment used 
throughout the thesis. Specific details or alterations to these procedures are described in 
appropriate chapters. 
 
2.1 Animals 
All methods conformed to the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes (National Health and Medical Research Council, 2013), with protocols 
approved by the Animal Ethics Committee at the Florey Institute of Neuroscience and Mental 
Health, under approval 15-072-FINMH. 
 
Ctr1+/− mice were purchased from The Jackson Laboratories (Slc31a1tm2.Djt/J; Bar Harbour, 
Maine, USA), and a colony maintained by breeding transgenic mice with C57Bl/6 wild-type 
(WT) littermates. Mice were housed in individually ventilated cages (2-5 mice/box) with 
access to standard laboratory chow and water ad libitum and maintained under a 12 hour 
light/dark cycle. Bedding consisted of sawdust and shredded paper, with facial tissues and 
plastic hutches provided for animal enrichment. Tail snips were obtained from each mouse 
prior to weaning age (~3 weeks) and sent to Transnetyx, Cordova, Tennessee, USA for 
commercial genotyping of Ctr1 status.  
 
2.2 MPTP lesioning regimen 
Prof David I. Finkelstein from the Florey Institute of Mental health, Melbourne University, 
Vic, prepared and administered MPTP with the assistance of the candidate. Mice were injected 
with four doses of MPTP (dose specified in subsequent chapters; Sigma-Aldrich, Castle Hill, 
AUS), or saline intraperitoneally at 2 hour intervals, and maintained at 21-23°C to 
accommodate the expected reduction in body temperature after treatment. 
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2.3 Brain collection 
Twenty-one days post lesion, mice were euthanised by an overdose of sodium pentobarbitone 
(100 mg/kg Lethabarb; Jurox, East Tamaki, Auckland, NZ) and perfused through the heart with 
0.1 M phosphate buffered saline (PBS; 0.1 M sodium dihydrogen phosphate monohydrate, 0.1 
M disodium hydrogen phosphate dehydrate, 0.9% w/v sodium chloride; all compounds from 
Sigma-Aldrich, AUS), pH 7.4. Whole intact brains were isolated, with further processing 
dependent on subsequent experiments. Where brain regions needed to be isolated, a mouse 
brain slicer/matrix was used to produce thick (2 mm) coronal sections for visual identification 
of brain areas according to the mouse brain atlas of Paxinos & Franklin (2012), which could 
then be manually dissected using a scalpel.  
 
2.4 Quantifying brain metal levels 
Frozen brain regions were weighed and transferred into metal-free polypropylene tubes 
(TechnoPlas, St. Marys, South Australia) and lyophilised using a freeze dryer (CoolSafe 4 L, 
LaboGene, Bjarkesvej, Denmark) set to 2.379 hPa for approximately 20 hours. Lyophilised 
tissue was treated with 50 uL of nitric acid (70% v/v, ≥99.999% trace metals basis; Sigma-
Aldrich, AUS) and digested at room temperature overnight. Samples were then further digested 
by heating at 70°C for 30 minutes, after which 50 μL of hydrogen peroxide (30% v/v, 
ultratrace; Sigma-Aldrich, AUS) was added, and incubated at 70°C for 60 minutes. Samples 
were cooled and 900 μL of 1% v/v nitric acid (HNO3) was added before transferring to a new 
polypropylene tube. Samples were stored at room temperature until analysis using inductively 
coupled plasma-mass spectrometry (ICP-MS). 
 
The candidate conducted ICP-MS (Agilent Technologies, Mulgrave, Australia) under the 
supervision of A/Prof David Bishop from the Elemental Bio-Imaging Facility, University of 
Technology Sydney, Sydney, Australia. Samples were introduced via a micromist concentric 
nebuliser (Glass Expansion, West Melbourne, Australia) and a Scott type double pass spray 
chamber cooled to 2°C, and the sample solution and the spray chamber waste were carried with 
the aid of a peristaltic pump. The ICP-MS extraction lenses were optimised to maximise the 
sensitivity of a 1% v/v HNO3:HCl solution containing 1 ng/mL of  lithium, cobalt, yttrium, 
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cerium, and thallium with helium was added into the octopole reaction cell to reduce 
interferences. A multi-element calibration standard (2A; Agilent technologies, Santa Clara, 
California, USA), was used to prepare the calibration standards at concentrations of 0, 1, 10, 
50, 100, 500, and 1000 ppb. Calibration curves for 63Cu, 66Zn, and 57Fe were constructed and 
the results analysed using Agilent Technologies Masshunter software. Results from ICP-MS 
were normalised to lyophilised tissue weight. 
 
2.5 Determining striatal dopamine physiology  
Frozen striatum was homogenised by pulse sonication (40% duty cycle, output 4, 2 × 30 second 
intervals; Sonifier, Branson Ultrasonics, Connecticut, USA) in a solution of 150 mM 
phosphoric acid, and 500 μM diethylenetriaminepentaacetic acid (Sigma-Aldrich, AUS). The 
homogenate was spun at 18,000 g for 25 minutes at 4°C (Centrifuge 5430R, Eppendorf, 
Hamburg, Germany). The supernatant was collected, and 20 μL was taken to determine total 
protein levels via a bicinchoninic acid (BCA) assay. The remaining supernatant was transferred 
into a 3K cut-off Amicon® centrifugal filter tubes (Merck, Bayswater, Victoria, AUS), and 
spun at 14,000 g at 4°C for 90 minutes (Centrifuge 5415R, Germany). The filtrate was 
collected, aliquoted, and stored at -80°C.  
 
Levels of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) 
were determined using a reverse-phase high performance liquid chromatography (HPLC) 
system coupled with an electrochemical detector. The mobile phase consisted of 0.01 M 
sodium phosphate monobasic, 0.1 mM EDTA, 0.65 mM octanesulfonic acid, 16% v/v 
methanol, and 0.5 mM triethylamine (all from Sigma-Aldrich, AUS) pH 3.8, and was filtered 
(0.22 μm filter circles; Whatman®, Maidstone, UK) and degassed (Prominence DGU-20A3; 
Shimadzu Corporation, Kyoto, Japan) prior to pumping through the system at a flow rate of 
1.0 ml/min using a HPLC pump (Prominence LC-20AD, Shimadzu, Japan). An autosampler 
(Prominence SIL-20A; Shimadzu, Japan) was used to introduce 20 μl of sample into a Gemini 
C18 110A column (5 μm; LC column 150 ×	4.6 mm; Phenomenex, Torrance, California, USA) 
fitted with a guard column. Molecules were detected using an electrochemical detector with a 
glassy carbon-working electrode maintained at +0.82 V against an Ag/AgCl reference 
electrode (VT-03; Antec-Leyden, Zoeterwoude, Netherlands). Both column and detector were 
maintained at 40°C. Molecules of interest were identified by retention times as set by known 
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standards (Dopamine, DOPAC, and HVA; Sigma-Aldrich, AUS). Area under the curve for 
each peak of interest was calculated using LabSolutions software (Version 5.57; Shimadzu, 
Japan), and data was normalised to the total protein concentration of each sample. 
 
2.6 Histology and stereological cell counts 
For fixed tissue analysis, whole brain hemispheres were placed in 50 mL of chilled 4% w/v 
paraformaldehyde (Sigma-Aldrich, AUS) in 0.1 M PBS overnight (4°C; Sigma-Aldrich, AUS), 
pH 7.4. Brains were then removed and placed in 50 mL of 30% w/v sucrose (domestic grade) 
in 0.1 M PBS and left at 4°C (minimum 2 nights with one change of sucrose solution) before 
being snap frozen using dry ice-chilled hexane (Sigma-Aldrich, AUS). Brains were sectioned 
on a cryostat at -20°C to produce coronal 30 μm thickness in a 1:3 series from bregma -2.70 
mm to -3.80 mm to collect the SN (Paxinos & Franklin, 2012), and mounted immediately onto 
Superfrost Ultra Plus microscope slides (Thermo Fisher Scientific, NSW, AUS), where they 
were left to dry at room temperature overnight to ensure adherence to the slide. Sections were 
then dehydrated and rehydrated through incubation in a gradient of increasing and decreasing 
alcohol concentrations respectively (50% to 100% v/v ethanol, and xylene; Thermo Fisher 
Scientific, Scoresby, Victoria, AUS) in order to achieve better adherence of brain section to 
slide, followed by incubation in cresyl violet solution (pH 3.9; 0.5% w/v cresyl violet, 60 mM 
sodium acetate, 340 mM acetic acid; all from Sigma-Aldrich, AUS). Once desired stain 
intensity was achieved, stains were dehydrated and coverslipped using DPX mounting media 
(Sigma-Aldrich, AUS). Cresyl violet was used as previous studies have reported similar 
neuronal numbers in the SN as those identified by tyrosine hydroxylase staining (Eilam et al., 
1998). Neurons in the SN were identified in cresyl violet stained sections by morphology as 
described by Fu et al. (2011), and estimated using a stereological software package (Stereology 
Investigator 7; MBF Bioscience, Williston, Vermont, USA) coupled to a Leica DMLB 
microscope (Leica, Wetzlar, Germany). The SN was traced in 9 consecutive sections using a 
4´ objective, and stereological counting was conducted using a 60´ objective. A grid (single 
cell consisting of x=120 μm, y=120 μm) was automatically placed over the traced SN, with an 
unbiased counting frame (45 × 35 μm) placed at the centre of each cell. The average cresyl 
violet penetration for each section was ~13 μm, therefore the counting depth (optical dissector 
height) for each section was set to 8 μm, with a top and bottom guard zone of 2 μm respectively. 
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2.7 Statistical analysis 
Statistical analysis was performed by the candidate using SPSS statistics program (IBM SPSS 
Statistics for Macintosh version 24.0, released 2016, Armonk, New York, USA). Data points 
within each treatment group were visualised using boxplots and values greater than 1.5 
standard deviations from the edge of the box were considered outlier values and removed prior 
to analysis. Further details regarding the number of values removed and type of analysis 
performed can be found in their respective chapters. Data in the thesis is reported as mean ± 
SEM unless otherwise stated and statistical significance was accepted at p < 0.05. Graphs were 
generated using GraphPad Prism 7 (GraphPad Software, USA). 
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3 THE EFFECTS OF CTR1 
KNOCKDOWN ON MPTP 
METABOLISM 
3.1 Introduction 
MPTP is a pro-toxin that due to its highly lipophilic nature, is able to cross the blood brain 
barrier. In the brain, MPTP is metabolised into the toxin MPP+ in astrocytes by the action of 
MAO-B, before being released into the intercellular space via the organic cation transporter-3 
(Cui et al., 2009). MPP+ is transported into dopamine neurons by DAT, where cytosolic MPP+ 
is concentrated in the mitochondrial matrix through membrane potential-dependent uptake 
(Ramsay & Singer, 1986). Inside the cell and mitochondria, MPP+ initiates a cascade of events 
that leads to the selective death of dopaminergic cells as described in Chapter 1 (Figure 1.6).  
 
In C57Bl/6 WT mice, MPP+ levels are detectable throughout the brain within a few minutes of 
MPTP administration (Markey, Johannessen, Chiueh, Burns, & Herkenham, 1984), and soon 
after, accumulates in brain regions that contain high densities of catecholamine transporters 
including the olfactory bulb, striatum, nucleus accumbens, hippocampus, locus coeruleus, 
substantia nigra, and ventral tegmental area (Kadar et al., 2014). Peak levels of MPP+ are 
reached between 90-120 minutes post injection (Huang et al., 2017; Jackson-Lewis & 
Przedborski, 2007), with MPTP and its metabolites cleared from the brain within 12 hours 
(Jackson-Lewis & Przedborski, 2007; Meredith & Rademacher, 2011). 
 
Various mouse strains have different sensitivities to MPTP that affect the degree of striatal 
dopamine depletion and number of dopamine neurons lost in the SN (Meredith & Rademacher, 
2011). The reason for strain variability is not fully understood, however a possible explanation 
is that MPTP sensitivity is controlled by the expression and interaction of “susceptible” and 
“resistant” alleles (Hamre, Tharp, Poon, Xiong, & Smeyne, 1999; Sedelis et al., 2000a). It is 
therefore imperative that studies utilising MPTP in novel transgenic mice determine toxin 
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metabolism in order to ensure findings are attributed to genetic manipulation rather than 
different MPTP toxicokinetics. In most cases though, manipulation of one gene does not alter 
MPTP metabolism (Chen et al., 2009; Oeckl & Ferger, 2016; Wu et al., 2002). 
 
There is currently no literature reporting the effects of Ctr1 knockdown on MPTP toxicity in 
vivo. Therefore, the aim of this preparative study was to determine whether knockdown of Ctr1 
would alter the peak amount of MPP+ levels in the brain at 1 and 2 hours post lesion. It is 
hypothesised that Ctr1+/− mice will have similar MPP+ levels as WT mice at both timepoints. 
 
3.2 Experimental procedures 
3.2.1 MPTP lesioning 
Ctr1+/− mice and their WT littermates were injected with a single 20 mg/kg dose of MPTP 
(Sigma-Aldrich, USA) intraperitoneally, and then sacrificed by an overdose of sodium 
pentobarbitone (100 mg/kg Lethabarb, NZ) at 1 or 2 hours post lesion. Mice were 
immediately perfused through the heart with 0.1 M PBS (pH 7.4, 4°C), and whole brains 
were removed and frozen on dry ice. Group numbers are reported in Table 3.1. 
 
Table 3.1 Treatment group sizes. 
Time after lesion (hour) WT Ctr1+/− 
1 5 5 
2 5 5 
 
3.2.2 Measuring MPP+ levels in the whole mouse brain 
The candidate provided whole mouse brains to analytical chemist Dr Amy Heffernan (Florey 
Institute of Neuroscience and Mental Health, Melbourne University, Melbourne, Australia) for 
measurement of MPP+ levels. Solid MPP+ (iodide salt, ≥98%; Sigma-Aldrich, AUS) was 
diluted in water to make a 1 mg/mL stock solution. Whole brains were bisected, and samples 
were prepared as described in (Zhang, Kagan, Sung, Zaleska, & Monaghan, 2008). The right 
hemisphere (200-300 mg tissue) was homogenised by pulse sonication (70% amplitude, with 
1 second pulses for 2 minutes; Sonifier, Branson Ultrasonics, USA) in 0.4 M perchloric acid 
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(60%; VWR International, Tingalpa, Queensland, AUS). The homogenate was neutralised by 
diluting in 10 fold volume of 0.2 M phosphate buffer (0.2 M sodium dihydrogen 
orthophosphate, 0.1 M disodium hydrogen phosphate; both ≥99%, Sigma-Aldrich, AUS) and 
transferred into centrifuge tubes with in-built filters (0.2 µm) for centrifuging and filtration at 
14,000 rpm (4°C) for 10 minutes. The supernatant was transferred to a 2 mL glass HPLC vial 
for analysis, and matrix-matched calibration standards were prepared using brain homogenate 
from control tissue. 
 
The analytical system consisted of an Agilent 1260 Infinity HPLC coupled to a 6490 triple 
quadrupole mass spectrometer (QQQ-MS; Agilent Technologies, Melbourne, Australia).  
Chromatographic separation was achieved with a Zorbax Eclipse XBD-C18 column, 2.1 × 100 
mm, 1.8 µm, (Agilent Technologies, Melbourne, Australia), fitted with a pre-column filter and 
maintained at 40°C, with a flow rate of 0.5 mL/min and injection volume of 5 µL. Mobile 
phases consisted of water:formic acid (1000:1, v/v; >98%, Sigma-Aldrich, AUS) (A), and 
acetonitrile:formic acid (1000:1, v/v; 99.9%, LiChrosolv®; Merck, Darmstadt, Germany) (B) 
with a gradient elution profile: 0 min, 2%B; 0.5 min, 2%B; 10 min, 80%B; 10.1 min, 2%B; 12 
min, 2%B. The QQQ-MS was fitted with electrospray ionization interface and operated in 
positive ion mode using the following settings: gas flow, 15 L/min; nebulizer, 30 psi; sheath 
gas temperature, 250°C; sheath gas flow, 11 L/min, capillary voltage, 3000 V. The MS was 
operated in multiple reaction monitoring mode monitoring the following transitions: 
170.1/127.9 (quantifier), and 170.1/155.0 and 170.1/128.9 (as first and second qualifiers, 
respectively), with the fragmentor voltage (380 V), collision energy (38/38/34 V) and cell 
accelerator voltage (5 V) optimized for each transition. Dwell time was set at 20 milliseconds. 
Analytes were identified based on retention time (±2 %RSD) and ion ratio (±20 %RSD) 
compared with the analytical standard and quantified via external calibration. Data acquisition 
and processing was carried out using MassHunter software (version B.07.00, Agilent 
Technologies). 
 
3.2.3 Statistical analysis 
Outliers were not removed from the data due to small group size. A two-way analysis of 
variance (ANOVA) was performed to examine the effects of genotype (WT or Ctr1+/−) and 
time (1 or 2 hours post MPTP injection) on MPP+ levels. 
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3.3 Results 
No statistically significant interaction effect of genotype and time was found for MPP+ levels 
(p = 0.138), indicating that whole brain MPP+ levels were similar between WT and Ctr1+/− 
mice at both times post MPTP lesion. To determine whether genotype alone altered MPP+ 
levels, an analysis of main effects was performed. No statistical difference was found in MPP+ 
levels between WT and Ctr1+/− mice (p = 0.586), indicating that MPTP metabolism is similar 
between the genotypes (Figure 3.1). 
 
 
Figure 3.1 Amount of whole brain MPP+ was no different between WT and Ctr1+/− mice. 
Whole brain MPP+ levels were similar between Ctr1+/− and WT mice following a 20 mg/kg 
dose of MPTP as determined by a two-way ANOVA. MPP+ levels were measured in the whole 
right hemisphere of the mouse brain using high performance liquid chromatography coupled 
to a quadrupole mass spectrometer. Abbreviations: Ctr1+/−: Ctr1 heterozygous; MPP+: 1-
methyl-4-phenylpyridinium ion; MPTP; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; WT: 
Wild-type. 
3.4 Discussion 
While MPP+ levels were found to be present in the WT brain 1 and 2 hours post MPTP 
injection, it was unexpected that MPP+ levels were similar between the two timepoints. This is 
because in similarly designed studies, MPP+ levels were found to peak 1 hour post MPTP 
injection, followed by a rapid decline in the second hour (up to 50% clearance), and then a 
slower decline eventuating in the complete clearance of MPP+ from the brain by 12 hours 
(Lehner et al., 2011; Zhang et al., 2008). It is possible that due to the rapid decline in MPP+ 
levels between the first and second hour, delays in brain collection could result in missing the 
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peak i.e. Ctr1+/− mice were culled first, thus delaying the culling of WT mice such they were 
closer to the 2 hour timepoint, and so the MPP+ levels in the 1 hour group would be similar to 
those in the 2 hour group for WT mice. Nevertheless, the aim of this chapter was to determine 
whether levels of MPP+ would be similar between WT and Ctr1+/− mice, and while MPP+ levels 
were noted to be more variable between the two time points in the Ctr1+/− mice, the overall 
data demonstrated that production of the toxin MPP+ from the pro-toxin MPTP is not dependent 
on Ctr1 expression. Thus it was concluded that our established MPTP dosing regimen (Castro-
Hernández, Adlard, & Finkelstein, 2017) could be used in future experiments to achieve 
comparable lesion sizes in both mouse strains. This model will subsequently be used to test the 
potential of copper restoring compounds as a neuroprotective agent. 
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4 CHARACTERISATION OF A 
NOVEL CU DEFICIENT MODEL 
OF PARKINSON’S DISEASE 
AND SUBSEQUENT TESTING OF 
CUATSM 
4.1 Introduction 
The literature review presented in Chapter 1 demonstrates that reduced bioavailability of Cu 
in dopaminergic neurons in the SN may contribute to neurodegeneration in PD and suggests 
that targeted restoration of Cu in affected brain regions may slow the degenerative process. 
Following the initial report from our group demonstrating a significant Cu deficiency in the 
degenerating SN in postmortem PD brains (Davies et al., 2014), little progress has been made 
to investigate the role of Cu on regional vulnerability in PD. Furthermore, while CuATSM has 
been found to improve motor performance and prevent neuronal death in the SN of four mouse 
models of PD through peroxynitrite scavenging (Hung et al., 2012), interpretation of these 
results are limited as Cu levels were not measured and the observed Cu deficiency in the PD 
SN was not modelled.  
 
In order to address these limitations, this chapter characterises the Ctr1+/− mouse to investigate 
the effects of Cu deficiency on the nigrostriatal pathway and determine whether regional brain 
Cu levels will influence the vulnerability of the nigrostriatal pathway to MPTP, one of the most 
commonly used toxins to model PD (Konnova & Swanberg, 2018). Additionally, this chapter 
describes the effects of CuATSM on regional brain concentrations of Cu, Fe, and Zn to 
determine how changes to these metal ion concentrations may influence the nigrostriatal 
pathway in the healthy and degenerating mouse brain. The establishment of a well 
characterised Cu deficient mouse model of PD will provide an invaluable tool to investigate 
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the role of Cu in cellular survival in the mammalian SN. Additionally, this model may be used 
as a platform to test Cu modulating compounds to identify potential benefits and determine 
their biochemical effects in vivo, as currently there is no method that is able to quantify brain 
Cu levels in living mammalian brains. Thus, the primary outcomes for this chapter was to 
characterise the Ctr1+/− mouse; investigate the effects of CuATSM on regional brain metal 
concentrations in the healthy and degenerating WT mouse; and determine whether the effects 
of CuATSM would be different in Ctr1+/− mice. The secondary outcomes for this study was to 
investigate the effects of altered brain metal levels on the nigrostriatal pathway. 
 
4.2 Experimental procedures 
4.2.1 Animals 
MPTP administration and tissue collection was performed as described in Chapter 2. Age-
matched Ctr1+/− mice and WT littermates (5-7 months) of both sexes were either lesioned with 
four intraperitoneal injections of MPTP (15 mg/kg) or sham injected with saline. A total dose 
of 60 mg/kg MPTP was used as this dose was reported to elicit ~50% reduction in neurons in 
the SN (Main et al., 2016), thus mimicking the amount of neuronal loss observed in the SN of 
postmortem PD brains (Grosch, Winkler, & Kohl, 2016). Twenty-four hours post lesion, mice 
began a 20 day daily gavage regimen of either 30 mg/kg CuATSM suspended in standard 
suspension vehicle (SSV; 0.9% w/v sodium chloride, 0.5% w/v sodium-
carboxymethylcellulose, 0.5% v/v benzyl alcohol, 0.4% v/v Tween 80; all compounds from 
Sigma-Aldrich, AUS), or only SSV as a control treatment. Treatment group sizes per genotype 
are shown in Table 4.1. The CuATSM used in this study was kindly synthesised by Dr Michael 
Gotsbacher (University of Sydney), and the dose and duration of treatment was chosen based 
on a previous study where these parameters significantly reduced MPTP associated dopamine 
cell loss in the Cu normal C57Bl/6 mice (Hung et al., 2012), the same background of mouse 
used in this study. Twenty-one days post lesion, mice were euthanised and isolated brains were 
hemisected. The entire right hemisphere was processed for immunohistochemistry and the left 
hemisphere was further dissected into cortex, striatum, midbrain, and cerebellum for 
biochemical analysis as described in Chapter 2. The amount of striatum collected from the left 
hemisphere for biochemical analysis was not enough for both ICP-MS and HPLC analysis thus, 
to answer the primary outcomes of this study striatal metal levels were prioritised over 
dopamine physiology. 
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Table 4.1 Treatment group sizes. 
    Genotype 
Lesion Treatment WT Ctr1+/− 
Saline SSV 10 10 
Saline CuATSM 10 10 
MPTP SSV 10 9 
MPTP CuATSM 12 13 
Abbreviations: Ctr1+/−: Ctr1 heterozygous; CuATSM: Cu2+diacetyl-bis(4-methyl-
thiosemicarbazonato); MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SSV: Standard 
suspension vehicle; WT: Wild-type. 
 
4.2.2 Measuring brain metal levels 
The candidate prepared and quantified metal levels in the cortex (25 mg), striatum (10 mg), 
midbrain (10 mg), and cerebellum (20 mg) from all mice using ICP-MS (Agilent Technologies 
7700 ICP-MS, Agilent Technologies, Mulgrave, Australia) as described in Section 2.4. 
 
4.2.3 Determining striatal dopamine physiology 
Sample preparation and HPLC was conducted by Veronica Cottam (University of Sydney) on 
the remaining striatal tissue as described in Section 2.5. 
 
4.2.4 Histology and stereological cell counts 
Tissue sectioning and unbiased stereological cell counts of cells within the SN was conducted 
by the candidate and cresyl violet staining was performed by Veronica Cottam (University of 
Sydney) as described in Section 2.6. Adjacent sections from an untreated (Saline and SSV) 
WT mouse was stained with tyrosine hydroxylase by Veronica Cottam, and the candidate 
captured low (4´ objective) and high (60´ objective) magnification images to confirm the 
region outlined and cells counted during stereological counting in cresyl violet stained sections 
as the SN and dopaminergic neurons (Figure 4.1). Formalin-fixed slide-mounted sections were 
dehydrated and rehydrated through incubation in a gradient of increasing and decreasing 
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alcohol concentrations respectively (50% to 100% v/v ethanol, and xylene; Thermo Fisher 
Scientific, AUS). Antigen retrieval was performed in citrate buffer (pH6.0; 1% citrate buffer, 
0.05% tween-20 solution; Fronine, Aus) at 95°C for 30 minutes, and sections were quenched 
in solution of 3% hydrogen peroxide in 50% ethanol for 30 minutes at room temperature. Non-
specific antigen sites were blocked using a blocking solution (0.5% casein, 1% bovine serum 
albumin, 0.05% tween-20 in 0.1M PBS) for 1 hour at room temperature. Sections were then 
stained with tyrosine hydroxylase (1:1000 in blocking solution; Merck, Massachusetts, USA; 
Catalogue# ab152) overnight at 4°C, before incubation with biotinylated anti-rabbit secondary 
antibody (1:200 in blocking solution; Vector Laboratories, California, USW; Catalogue# BA-
100) for 2 hours at room temperature. Staining was visualised using a 3,3’-diaminobenzidine 
tetrahydrochloride solution (DAB; 0.67mg DAB, 0.02% hydrogen peroxide in 0.1M PBS; 
Sigma-Aldrich, AUS; Catalogue# D5905) and counter-stained with cresyl violet (as described 
in Section 2.6). Due to time constraints, only a portion of the animals in each experimental 
group were counted using unbiased stereology (see Appendix 1 for group size).  
 
4.2.5 Statistics 
Outliers were identified and removed as described in Section 2.7 and analysis group sizes are 
summarised in Appendix 1. A three-way ANOVA was performed by the candidate to 
determine the interaction of mouse genotype (WT or Ctr1+/−), lesion (Saline or MPTP), and Cu 
treatment (SSV or CuATSM) on measured variables. A statistically significant three-way 
interaction indicated that WT and Ctr1+/− mice responded differently to the two-way interaction 
of lesion and treatment, while no statistical three-way interaction indicated a similar response 
between the genotypes. To determine the specific effects of lesion and Cu treatment on 
measured variables both within mouse strain groups and between mouse strains, unadjusted 
pairwise comparisons were made. Multiple comparisons were not adjusted in order to avoid 
missing a possible effect i.e. avoid a type II error, however doing so does increase the chance 
for type I errors (Armstrong, 2014). 
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Figure 4.1 Identification of the mouse substantia nigra and its cells. Representative images 
at low (4´ objective) and high (60´ objective) magnification of cresyl violet stained sections 
used in unbiased stereological counting identifying the substantia nigra pars compacta (A; 
delineated in black) and morphology of cells counted (B; arrows). Adjacent sections were 
stained with tyrosine hydroxylase (brown) to verify the substantia nigra (C) and dopaminergic 
neurons (D) identified in cresyl violet stained sections. Arrows indicate examples of cells 
counted. 
 
4.3 Results 
4.3.1 Effects of Ctr1 knockdown on mouse response to lesion and Cu treatment 
To explore whether Ctr1+/− mice respond differently to WT mice when treated with any 
combination of lesion and Cu treatment, a 3-way ANOVA was performed on the measured 
variables of regional brain metal levels, SN cell number, and striatal dopaminergic function 
(Table 4.2). A statistically significant three-way interaction was found between mouse 
genotype, lesion, and Cu treatment for striatal Cu (p = 0.021), striatal Zn (p = 0.039), and 
midbrain Zn (p = 0.015) levels. No significant interaction was found for regional Fe levels, SN 
A
C
B
D
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cell number, striatal dopamine levels, or dopamine turnover ratio; although a statistically 
significant interaction was found for the dopamine metabolite DOPAC (p = 0.001) and HVA 
(p = 0.049) levels. Together the data suggests that knockdown of the Ctr1 gene in C57Bl/6 
mice alters the effect of MPTP lesion and/or Cu treatment on some variables of interest. 
Unadjusted pairwise comparisons were performed to identify the nature of these effects. 
Table 4.2 Summary of three-way ANOVA 
Variable Brain Region F-Statistic P-Value 
Iron Cortex F(1,70) = 0.002 0.968 
 Striatum F(1,74) = 0.012 0.911 
 Midbrain F(1,66) = 1.582 0.213 
  Cerebellum F(1,71) = 1.223 0.273 
Copper Cortex F(1,66) = 2.143 0.148 
 Striatum F(1,63) = 5.578 0.021 * 
 Midbrain F(1,53) = 0.621 0.434 
 Cerebellum F(1,66) = 0.001 0.979 
Zinc Cortex F(1,68) = 0.009 0.924 
 Striatum F(1,70) = 4.410 0.039 * 
 Midbrain F(1,66) = 6.295 0.015 * 
  Cerebellum F(1,70) = 3.161 0.08 
Dopamine Striatum F(1,59) = 0.225 0.637 
DOPAC  F(1,51) = 11.56 0.001 * 
HVA  F(1,56) = 4.061 0.049 * 
Turnover  F(1,43) = 0.633 0.431 
Cell count SN F(1,27)=0.018 0.895 
*p < 0.05 for interaction effect of genotype, lesion, and copper treatment 
4.3.2 Knockdown of Ctr1 gene reduces Cu levels in all brain regions  
The effects of Ctr1 gene knockdown on measured variables of interest was examined. Regional 
Fe and Zn levels did not differ between WT and Ctr1+/− mice and they exhibited a similar 
pattern of metal distribution (Figure 4.2A-D, I-L; Table 4.3), with both genotypes exhibiting 
the highest Fe levels in the striatum and cerebellum, and the lowest in the cortex and midbrain; 
while Zn levels were highest in the cortex, and lowest in the midbrain. The regional distribution 
of Cu was also similar between the genotypes, with the highest and lowest levels found in the 
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cerebellum and midbrain respectively (Figure 4.2E-H; Table 4.3), though Ctr1+/− mice 
exhibited markedly lower Cu levels (52 to 67% less) compared to WT mice in all brain regions 
(overall p < 0.05), except for striatum where a non-significant 42% reduction was observed. 
The extent of Cu reduction in Ctr1+/− mice was consistent with the reduction observed by Lee, 
Prohaska, & Thiele (2001), who reported a 50% decrease in whole brain Cu levels. 
Interestingly, Ctr1+/- mice exhibited a small (15%) but significant increase in SN cell number 
compared to WT mice (p = 0.034); and while no differences in striatal dopamine or HVA levels 
were found between the genotypes, Ctr1+/− mice exhibited a 39% reduction in striatal DOPAC 
levels (p = 0.025), though this did not affect dopamine turnover ratio (Figure 4.3; Table 4.4). 
These results confirm that knockdown of the Ctr1 gene resulted in a marked reduction in Cu 
levels in all brain regions but has minimal effects on brain Fe or Zn levels. Furthermore, the 
observed reduction in brain Cu levels in Ctr1+/− mice did not considerably affect striatal 
dopamine levels or overall dopamine turnover rate.
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Figure 4.2 CuATSM increases Cu levels in the mouse brain. Regional Fe (A-D), Cu (E-H), and Zn (I-L) levels were quantified using ICP-MS. Specific 
unadjusted pairwise comparisons were made using the error value from the three-way ANOVA. vp < 0.05 vs. WT saline SSV group; #p < 0.05 vs. Ctr1+/− saline 
SSV group; up < 0.05 vs. respective SSV group; *p < 0.05 vs. respective saline CuATSM group. Group sizes are reported in Table 4.1. Abbreviations: Ctr1+/−: Ctr1 
heterozygous; CuATSM: Cu2+ bis(thiosemicarbazone) complex; ICP-MS: Inductively coupled plasma-mass spectrometer; MPTP: 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; SSV: Standard suspension vehicle; WT: Wild-type.
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Regional brain Fe, Cu, and Zn levels were quantified in WT and Ctr1+/− mice using ICP-MS and normalised to lyophilised tissue weight. Specific unadjusted 
pairwise comparisons were made using the error value from the 3-way ANOVA. Green and red shaded values indicate a significant increase and decrease 
respectively. *p < 0.05, **p < 0.005, ***p < 0.001 vs. specified group. Group sizes are reported in Table 4.1. Abbreviations: Ctr1+/−: Ctr1 heterozygous; 
CuATSM: Cu2+ bis(thiosemicarbazone) complex; ICP-MS: Inductively Coupled Plasma-Mass Spectrometer; MPTP: 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; SSV: Standard Suspension Vehicle; WT: Wild-type.
Variable Brain region WT Ctr1+/−
% Diff
Ctr1+/− VS. WT
WT % diff VS. WT Untreated Ctr1
+/− % diff VS. 
Ctr1+/− Untreated
WT % diff VS. WT Untreated Ctr1
+/− % diff VS. 
Ctr1+/− Untreated
WT % diff VS. WT CuATSM Ctr1
+/− % diff VS. 
Ctr1+/− CuATSM
% Diff
Ctr1+/− VS. WT
Cortex 60.32 ± 2.10 58.73 ± 1.99 ↓ 3% 61.22 ± 1.99 ↑ 1% 58.54 ± 2.23 0% 62.50 ± 1.99 ↑ 4% 59.57 ± 1.99 ↑ 1% 59.14 ± 1.99 ↓ 5% 54.88 ± 1.90 ↓ 8% ↓ 7%
Striatum 69.06 ± 3.88 65.94 ± 3.88 ↓ 5% 65.80 ± 4.09 ↓ 5% 62.39 ± 4.09 ↓ 5% 72.97 ± 4.09 ↑ 6% 72.99 ± 3.88 ↑ 11% 63.95 ± 3.54 ↓ 12% 62.46 ± 3.40 ↓ 14% * ↓ 2%
Midbrain 62.54 ± 3.36 55.46 ± 3.54 ↓ 11% 67.98 ± 3.36 ↑ 9% 64.27 ± 3.76 ↑ 16% 59.94 ± 3.54 ↓ 4% 63.48 ± 4.76 ↑ 14% 63.39 ± 3.21 ↑ 6% 57.46 ± 3.07 ↓ 9% ↓ 9%
Cerebellum 69.11 ± 2.55 67.84 ± 2.42 ↓ 2% 68.78 ± 2.42 0% 69.36 ± 2.55 ↑ 2% 70.11 ± 2.71 ↑ 1% 74.14 ± 2.55 ↑ 9% 66.58 ± 2.31 ↓ 5% 64.77 ± 2.13 ↓ 13% * ↓ 3%
Cortex 15.63 ± 2.47 7.48 ± 2.35 ↓ 52% * 15.68 ± 2.47 0% 8.90 ± 2.62 ↑ 19% 76.41 ± 2.62 ↑ 389% *** 58.30 ± 2.80 ↑ 679% *** 70.51 ± 2.24 ↓ 8% 64.01 ± 2.14 ↑ 10% ↓ 9% *
Striatum 11.36 ± 2.84 6.59 ± 2.68 ↓ 42% 15.34 ± 2.84 ↑ 35% 6.20 ± 3.04 ↓ 6% 65.34 ± 2.84 ↑ 475% *** 47.05 ± 2.84 ↑ 614% *** 64.64 ± 2.43 ↓ 1% 60.28 ± 2.32 ↑ 28% ** ↓ 7%
Midbrain 8.26 ± 1.04 3.07 ± 1.34 ↓ 63% ** 6.97 ± 1.09 ↓ 15% 3.12 ± 1.64 ↑ 2% 42.45 ± 1.24 ↑ 414% *** 36.58 ± 1.46 ↑ 1091% *** 48.59 ± 1.09 ↑ 14% *** 41.26 ± 0.99 ↑ 13% * ↓ 15% ***
Cerebellum 27.15 ± 1.78 8.96 ± 1.78 ↓ 67% *** 21.65 ± 1.99 ↓ 20% * 11.58 ± 2.30 ↑ 29% 77.35 ± 1.99 ↑ 185% *** 60.16 ± 1.99 ↑ 572% *** 75.33 ± 1.70 ↓ 3% 66.41 ± 1.56 ↑ 10% * ↓ 12% ***
Cortex 67.79 ± 2.96 70.04 ± 2.65 ↑ 3% 71.55 ± 2.96 ↑ 6% 74.03 ± 2.79 ↑ 6% 81.95 ± 2.65 ↑ 21% ** 77.30 ± 2.65 ↑ 10% 76.89 ± 2.42 ↓ 6% 73.22 ± 2.79 ↓ 6% ↓ 5%
Striatum 50.21 ± 2.61 50.19 ± 2.61 0% 57.11 ± 2.61 ↑ 14% 48.98 ± 2.91 ↓ 2% 61.08 ± 2.75 ↑ 22% * 51.30 ± 3.12 ↑ 2% 63.95 ± 2.49 ↑ 5% 61.98 ± 2.29 ↑ 21% * ↓ 3%
Midbrain 40.59 ± 1.94 36.65 ± 1.84 ↓ 10% 38.85 ± 2.06 ↓ 4% 43.16 ± 2.06 ↑ 18% * 39.09 ± 1.94 ↓ 4% 42.09 ± 2.06 ↑ 15% 46.39 ± 1.76 ↑ 19% * 43.93 ± 1.76 ↑ 4% ↓ 5%
Cerebellum 58.93 ± 1.92 53.58 ± 1.82 ↓ 9% * 57.55 ± 2.04 ↓ 2% 57.87 ± 1.92 ↑ 8% 64.61 ± 1.92 ↑ 10% * 66.34 ± 1.82 ↑ 24% *** 62.97 ± 1.74 ↓ 3% 61.04 ± 1.66 ↓ 8% * ↓ 3%
Iron 
(µg/g dry weight)
Untreated MPTP CuATSM MPTP+CuATSM
Copper
(µg/g dry weight)
Zinc
(µg/g dry weight)
Table 4.3 Effects of MPTP and CuATSM on regional metal levels in WT and Ctr1+/− mice. 
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Figure 4.3 The protective effects CuATSM are diminished in Cu-deficient mice. SN cell 
number (A) was determined using unbiased stereological counts of cresyl violet stained cells; 
Dopamine (B), DOPAC (C), and HVA (D) levels were measured using HPLC; and Dopamine 
turnover (E) was calculated by dividing the sum of DOPAC and HVA by Dopamine levels. 
Specific unadjusted pairwise comparisons were made using the error value from the three-way 
ANOVA. vp < 0.05 vs. WT Saline SSV group; #p < 0.05 vs. Ctr1+/− saline SSV group; up < 0.05 
vs. respective SSV group; *p < 0.05 vs. respective saline CuATSM group. Group sizes are 
reported in Table 4.1. Abbreviations: Ctr1+/−: Cu transport protein 1 knockdown mouse; 
CuATSM: Cu2+ bis(thiosemicarbazone) complex; DOPAC: 3,4-Dihydroxyphenylacetic acid; 
HPLC: High Performance Liquid Chromatography; HVA: Homovanillic acid; MPTP: 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SSV: Standard Suspension Vehicle; WT: Wild-
type. 
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SN cell number was determined using unbiased stereological counts of cresyl violet stained cells; Dopamine, DOPAC, and HVA levels were measured using 
HPLC; and Dopamine turnover was calculated by dividing the sum of DOPAC and HVA by Dopamine levels. Specific unadjusted pairwise comparisons were 
made using the error value from the three-way ANOVA. Green and red shaded values indicate a significant increase and decrease respectively. *p < 0.05, **p < 
0.005, ***p < 0.001 vs. specified group. Group sizes are reported in Table 4.1. Abbreviations: Ctr1+/−: Ctr1 heterozygous; CuATSM: Cu2+ bis(thiosemicarbazone) 
complex; DOPAC: 3,4-Dihydroxyphenylacetic acid; HPLC: High performance liquid chromatography; HVA: Homovanillic acid; MPTP: 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine; SN: Substantia nigra pars compacta; SSV: Standard suspension vehicle; WT: Wild-type. 
 
 
 
Variable Brain region WT Ctr1+/−
% Diff
Ctr1+/− VS. WT
WT % diff VS. WT Untreated Ctr1
+/− % diff VS. 
Ctr1+/− Untreated
WT % diff VS. WT Untreated Ctr1
+/− % diff VS. 
Ctr1+/− Untreated
WT % diff VS. WT MPTP Ctr1
+/− % diff VS. 
Ctr1+/− MPTP
% Diff
Ctr1+/− VS. WT
Dopamine
(ng/mg protein) Striatum 68.69 ± 9.76 61.96 ± 8.61 ↓ 10% 17.54 ± 9.76 ↓ 75% *** 15.25 ± 9.76 ↓ 75% ** 74.28 ± 9.13 ↑ 8% 84.94 ± 8.17 ↑ 37% 16.29 ± 8.17 ↓ 7% 19.28 ± 8.61 ↑ 26% ↑ 18%
DOPAC
(ng/mg protein) 6.46 ± 0.80 3.94 ± 0.75 ↓ 39% * 3.59 ± 0.86 ↓ 44% * 3.67 ± 0.86 ↓ 7% 4.58 ± 0.94 ↓ 29% 8.80 ± 0.70 ↑ 123% *** 3.49 ± 0.70 ↓ 3% 2.68 ± 0.70 ↓ 27% ↓ 23%
HVA
(ng/mg protein) 5.27 ± 0.52 4.79 ± 0.43 ↓ 9% 3.09 ± 0.52 ↓ 41% * 3.62 ± 0.48 ↓ 24% 5.26 ± 0.45 0% 6.33 ± 0.41 ↑ 32% * 3.13 ± 0.41 ↑ 1% 2.58 ± 0.45 ↓ 29% ↓ 17%
Dopamine 
Turnover 0.17 ± 0.05 0.16 ± 0.04 ↓ 2% 0.36 ± 0.05 ↑ 118% * 0.38 ± 0.06 ↑ 135% ** 0.19 ± 0.04 ↑ 13% 0.25 ± 0.04 ↑ 57% 0.35 ± 0.04 ↓ 4% 0.34 ± 0.04 ↓ 11% ↓ 3%
Estimated 
Cell Count SN 6487.0 ± 313.0 7476.2 ± 313.0 ↑ 15% * 5212.8 ± 285.8 ↓ 20% * 5071.6 ± 313.0 ↓ 32% *** 7026.0 ± 495.0 ↑ 8% 7492.5 ± 495.0 0% 6402.0 ± 313.0 ↑ 23% * 5875.8 ± 313.0 ↑ 16% ↓ 8%
MPTP+CuATSMUntreated MPTP CuATSM
Table 4.4 Effects of MPTP and CuATSM on SN cell number and striatal dopamine physiology in WT and Ctr1+/− mice. 
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4.3.3 Endogenous brain Cu levels do not alter the toxicity of MPTP 
It is well established that MPTP inhibits mitochondrial function and increases oxidative stress 
resulting in the death of dopaminergic neurons in the SN (Blesa, Trigo-Damas, Quiroga-
Varela, & Jackson-Lewis, 2015). As Cu plays an important role in mitochondrial function and 
antioxidant defence (Davies et al., 2016), the Ctr1+/− mouse was used to investigate whether 
Cu deficiency increases SN cell susceptibility to MPTP by comparing Saline SSV groups to 
MPTP SSV groups both within, and between mouse genotypes. MPTP did not affect regional 
brain metal levels in either mouse genotype (Figure 4.2; Table 4.3), with the exception of a 
small (18%) increase in Zn levels in the Ctr1+/− midbrain (p = 0.021); a small (20%) reduction 
in Cu levels in the WT cerebellum (p = 0.044); and a moderate (35%) but non-significant 
increase in Cu levels in WT striatum. These differential responses to MPTP between mouse 
genotypes likely explain why a significant three-way interaction effect was observed for these 
variables (Table 4.2).  
 
As expected, MPTP significantly reduced cell number in the SN of both genotypes (Figure 
4.3A; Table 4.4), with lesioned Ctr1+/− mice exhibiting a 32% reduction (p < 0.001) and 
lesioned WT mice exhibiting a 20% reduction (p = 0.006) in SN cell number compared to their 
respective untreated control groups. Consistent with the marked loss of SN cells following 
MPTP, there was a marked reduction in striatal dopamine levels in both WT (75% reduction; 
p < 0.001) and Ctr1+/− (75% reduction; p = 0.001) mice compared to respective untreated 
controls (Figure 4.3B; Table 4.4). MPTP also reduced DOPAC and HVA levels in WT mice 
(44% and 41% reduction respectively; overall p < 0.05) resulting in a 118% increase in WT 
dopamine turnover ratio (p = 0.005) (Figure 4.3B-E; Table 4.4). Ctr1+/− DOPAC levels were 
unchanged following MPTP but there was a trend towards a significant loss of HVA (24% 
reduction), which coupled with the sizeable reduction in dopamine levels resulted in a 135% 
increase in dopamine turnover in Ctr1+/− mice (p = 0.004) (Figure 4.3B-E; Table 4.4). 
Together, these results indicate that the response of Ctr1+/− mice to MPTP is similar to that of 
WT mice. 
 
 48 
4.3.4 CuATSM markedly increases Cu levels in all brain regions but does not 
alter the nigrostriatal pathway in unlesioned mice 
CuATSM is reported to selectively accumulate in regions of high oxidative stress (Ikawa et al., 
2011) or mitochondrial dysfunction (Donnelly et al., 2012), however the amount of Cu that 
accumulates in brain regions following CuATSM treatment has not been quantified in vivo. To 
investigate whether CuATSM would alter metal levels in other brain regions and also 
determine whether its accumulation would be affected by endogenous Cu levels, Saline SSV 
groups were compared to Saline CuATSM groups within and between mouse genotypes. Fe 
levels were unchanged following CuATSM treatment in all brain regions investigated in both 
genotypes (Figure 4.2A-D; Table 4.3). CuATSM increased Zn levels in three of the four WT 
brain regions: 21% in the cortex (p = 0.001), 22% in the striatum (p = 0.005), and 10% in the 
cerebellum (p = 0.04); but only increased cerebellar Zn levels in Ctr1+/- mice (24% increase; p 
< 0.001) (Figure 4.2I-L; Table 4.3). The absence of response in Ctr1+/− striatal Zn levels 
following CuATSM treatment likely underlie the significant three-way interaction reported in 
Table 4-2.  
 
CuATSM treatment increased Cu levels in all brain regions of both genotypes though the 
magnitude of Cu increase was different (Figure 4.2E-H; Table 4.3). CuATSM treatment 
increased WT brain Cu levels by 185 to 475% (overall p < 0.001), with the smallest increase 
observed in the cerebellum, while the largest increases were observed in the striatum and 
midbrain. The degree of Cu increase coincided with endogenous Cu concentrations of each 
brain region i.e. the smallest change occurred in the region with the highest Cu levels, while 
the largest changes occurred in regions with the lowest, though the overall ranking of regions 
based on Cu content did not change. Ctr1+/− Cu levels were increased by 572 to 1091% (overall 
p < 0.001) following CuATSM treatment, with the cerebellum and midbrain exhibiting the 
smallest and largest changes respectively, though in contrast to WT mice, Ctr1+/− Cu levels 
increased more uniformly, with the exception of the midbrain. While the magnitude of Cu 
increase was much greater in Ctr1+/− mice compared to WT mice following CuATSM 
treatment, total Ctr1+/− Cu levels remained ~20% lower in all brain regions compared to WT 
mice (overall p < 0.005). Nevertheless, CuATSM treatment increased the Cu levels of both 
genotypes far above those of untreated WT mice (Figure 4.2E-H; Table 4.3), indicating that 
regional brain Cu levels in this treatment group were far in excess of physiological levels. 
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SN cell number was unaffected by CuATSM treatment in unlesioned animals of either 
genotype (Figure 4.3A; Table 4.4). Striatal dopamine and dopamine metabolite levels in WT 
mice were unaffected by CuATSM treatment (Figure 4.3B-E; Table 4.4). In contrast, 
CuATSM appeared to mediate a modest increase in Ctr1+/− striatal dopamine turnover (57% 
increase; p = 0.08), which is primarily driven by an increase in dopamine metabolite levels i.e. 
123% increase in DOPAC (p < 0.001) and 32% increase in HVA (p = 0.02) (Figure 4.3B-E; 
Table 4.4). 
 
In summary, CuATSM treatment markedly increased regional brain Cu levels in both 
genotypes above those of untreated animals. Though this increase in Cu levels did not alter 
dopaminergic physiology in WT mice, it was associated with moderate changes in striatal 
dopamine metabolism in Ctr1+/− mice. 
 
4.3.5 CuATSM mediated neuroprotection is attenuated in the Cu deficient 
MPTP mouse model 
To determine whether knockdown of Ctr1 would alter the effects of CuATSM in MPTP 
lesioned mice, MPTP SSV groups were compared with MPTP CuATSM groups both within 
and between genotypes. CuATSM treatment increased Cu levels in all brain regions of both 
genotypes following MPTP lesion however, compared to CuATSM treatment in unlesioned 
animals, Cu levels were further increased in the midbrain of WT mice (14% increase; p < 
0.001); and in the Ctr1+/− striatum (28% increase; p = 0.001), midbrain (13% increase; p = 
0.01), and cerebellum (10% increase; p = 0.016) (Figure 4.2E-H; Table 4.3).  
 
As in unlesioned WT mice, CuATSM had no effect on regional brain Fe levels in lesioned WT 
mice (Figure 4.2A-D; Table 4.3). CuATSM treated lesioned Ctr1+/− mice exhibited lower 
striatal and cerebellar Fe levels (14% and 13% decrease; overall p < 0.05) compared to 
CuATSM treated unlesioned Ctr1+/− mice, but this appears to be negating a small (not 
significant) increase of Fe observed in the latter group as absolute Fe levels in CuATSM treated 
lesioned Ctr1+/− mice were no different to untreated Ctr1+/− mice (Figure 4.2A-D; Table 4.3). 
MPTP did not further enhance the CuATSM associated increase in regional Zn levels observed 
in untreated WT mice, though the lesioned midbrain now exhibited a 19% increase in Zn levels 
(p = 0.007) (Figure 4.3K; Table 4.3). In Ctr1+/− mice, MPTP appears to facilitate a CuATSM 
associated increase in striatal Zn levels (21% increase; p = 0.007) that was not observed in 
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treated unlesioned Ctr1+/− mice; furthermore, MPTP appears to diminish the CuATSM 
associated increase in cerebellar Zn levels observed in unlesioned Ctr1+/− mice (8% decrease; 
p = 0.035), though absolute Zn levels in this group remain slightly higher than untreated Ctr1+/− 
levels (Figure 4.2J, L; Table 4.3). Thus, the effects of CuATSM on regional brain metal levels 
appears to be affected by MPTP lesion in both genotypes. Of particular note is that MPTP 
enhanced the CuATSM associated increase in Cu levels in the midbrain of both genotypes 
which includes the SN, a known region to be affected by MPTP (Meredith & Rademacher, 
2011). 
 
Consistent with the results of Hung et al., (2012) CuATSM was associated with an apparent 
neuroprotective effect in MPTP lesioned WT mice (23% more cells compared to untreated 
lesioned WT mice; p = 0.009), resulting in cell numbers in this treatment group being similar 
to untreated WT mice (Figure 4.3A; Table 4.4), though striatal dopamine and dopamine 
metabolite levels were unchanged from those in untreated lesioned WT group (Figure 4.3B-
E; Table 4.4). In contrast, CuATSM was noted to have a smaller non-significant protective 
effect in lesioned Ctr1+/− mice (16% increase compared to untreated lesioned Ctr1+/− mice), 
with SN cell numbers in this group remaining 21% lower than untreated Ctr1+/− mice (Figure 
4.3A; Table 4.4). Modest but non-significant changes in striatal dopamine (26% increase), 
DOPAC (27% reduction), and HVA (29% reduction) were noted in CuATSM treated lesioned 
Ctr1+/− mice compared to untreated lesioned Ctr1+/− group (Figure 4.3B-E; Table 4.4). Thus, 
the neuroprotective effects of CuATSM appear to be influenced by endogenous Cu levels 
within the nigrostriatal pathway following MPTP-lesion. 
 
Key findings 
• Knockdown of the Ctr1 resulted in a ~50% reduction in regional brain Cu levels 
• Reduced brain Cu levels did not enhance the effects of MPTP on SN cell number or 
striatal dopamine levels  
• CuATSM increased brain Cu levels to supraphysiological levels in the healthy brains 
of both mouse genotypes with the extent of increase dependent on endogenous Cu 
levels 
• The amount of Cu increased by CuATSM was enhanced in degenerating brain regions  
• CuATSM prevented MPTP associated cell loss in the WT SN but this neuroprotective 
effect was attenuated in lesioned Ctr1+/− mice  
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• CuATSM did not improve striatal dopamine physiology in either mouse genotype 
lesioned with MPTP 
 
4.4 Discussion 
4.4.1 Reduced brain Cu levels does not affect the nigrostriatal pathway 
Ctr1 is considered the main importer of Cu in eukaryotic cells and its translocation to the cell 
membrane surface is regarded as the major determinant of intracellular Cu levels (Kardos et 
al., 2018). Alterations in Ctr1 protein expression can lead to dyshomeostasis of intracellular 
Cu levels and this is apparent in cases of PD, where a 50% reduction in Ctr1 protein expression 
was associated with a 50% reduction in Cu levels in dopaminergic neurons in the SN (Davies 
et al., 2014). A similar reduction in intracellular Cu levels is seen in cases of incidental Lewy 
body disease, considered to represent a preclinical form of PD (Frigerio et al., 2011), 
suggesting that cellular Cu deficiency may precede neurodegeneration of the nigrostriatal 
pathway. To determine the effects of Cu deficiency on the nigrostriatal pathway, this study 
investigated regional brain metal levels and the integrity of the nigrostriatal pathway in the 
Ctr1+/− mouse, a transgenic mouse that exhibits a 50% reduction in Ctr1 mRNA in the liver, 
kidney, spleen, and brain, but only exhibits a reduction in total Cu levels in the brain and spleen 
(Lee et al., 2001). Consistent with this finding and in support of hypothesis 2.1, the current 
study found Cu levels were ~50% lower in all brain region of Ctr1+/− mice compared with those 
in WT mice, with no sizeable changes observed in regional Fe or Zn levels. It was unexpected 
that the 50% reduction in Ctr1+/− Cu levels had no effect on Fe homeostasis as Cu deficient 
diets have been found to elevate brain Fe levels in vivo (Prohaska & Gybina, 2005). This may 
be related to the function of the cuproprotein ceruloplasmin as loss of ceruloplasmin activity 
leads to Fe accumulation in the brain (Harris, 2019), and the ferroxidase activity of 
ceruloplasmin is dependent on Cu levels (Zheng et al., 2018).  As no changes in brain Fe levels 
was observed in Ctr1+/− mice, it is possible that the activity of ceruloplasmin is largely 
unaffected by the reduction in brain Cu levels in these mice though to date, the activity of 
ceruloplasmin or any other cuproprotein in the Ctr1+/− mouse has not been investigated. It is 
reasonable to suggest that the observed reduction in brain Cu levels reflects, in part, a depletion 
of the labile Cu pools in the brain, while Cu bound more tightly to cuproproteins such as 
ceruloplasmin may not be affected due to their importance in cell survival and function. To 
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validate this hypothesis, the levels and metalation status of various cuproproteins would need 
to be determined alongside accurate measurements of intracellular labile Cu pools. 
 
Cu levels differed between brain regions in WT mice and this pattern of distribution was 
retained in Ctr1+/− mice, suggesting a unique functional requirement for Cu in each region that 
may be regulated by varying regional levels of Ctr1 protein expression. This study relied on 
the genotyping results obtained from Transnetyx (described in Section 2.1) to determine mouse 
Ctr1 expression in transgenic mice as current Ctr1 antibodies are reported to lack specificity, 
making interpretation and reproducibility difficult (Quail, Tsai, & Howell, 2014). In this study, 
2 polyclonal and 1 monoclonal Ctr1 antibody were trialled in western blot analysis in an 
attempt to quantify regional brain Ctr1 protein levels, however all antibodies yielded 
inconsistent results i.e. signals at multiple bands often as a smear (results not shown). 
Nevertheless, the combination of genotyping data and brain metal levels indicate that the 
observed reduction in brain Cu levels in Ctr1+/− mice is consistent with an effective knockdown 
of the Ctr1 gene in these animals. 
 
Some enzymes involved in the metabolism of dopamine are cuproproteins (Figure 4.4) and so 
Cu deficiency may alter the activity of these enzymes. However, in support of hypothesis 2.1, 
Cu deficiency in the Ctr1+/− striatum did not affect striatal dopamine levels and this is consistent 
with a study investigating brain catecholamine levels in diet and genetically induced Cu 
deficient mice (Prohaska & Smith, 1982). However, Ctr1+/− DOPAC levels were reduced and 
this could be due to the reduced activity of the cuproenzymes MAO-B and semicarbazide-
sensitive amine oxidase (SSAO), which metabolise dopamine to 3,4-
dihydroxyphenylacetaldehyde (DOPAL) before conversion to DOPAC via aldehyde 
dehydrogenase (Obata, 2002; Qi, Miller, & Voit, 2008; Segura-Aguilar, 2019; Yamada & 
Yasunobu, 1962). HVA levels were unaltered in Ctr1+/− mice, possibly because the enzyme 
COMT is not a cuproprotein, and HVA can be made independently of DOPAC by the 
metabolism of dopamine to 3-methoxytyramine by COMT (Juárez Olguín, Calderón Guzmán, 
Hernández García, & Barragán Mejía, 2016). Pilot data regarding the number of SN cells 
identified using cresyl violet found that Ctr1+/− mice had slightly (15%) higher cell numbers 
than WT mice. It is possible that changes in the number of non-neuronal cells or non-
dopaminergic neurons may have contributed to this finding, as cresyl violet is a non-specific 
stain for all brain cell types (García-Cabezas, John, Barbas, & Zikopoulos, 2016). However, 
the morphology of the counted cresyl violet-positive cells was consistent with that of tyrosine 
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hydroxylase-positive dopaminergic neurons (Figure 4.1) and cell counts from cresyl violet 
staining have been found to be comparable to those using tyrosine hydroxylase staining to 
quantify loss of SN dopaminergic neurons following MPTP lesioning (Battaglia et al., 2006; 
Eilam et al., 1998; You et al., 2015). Nevertheless, this result should be interpreted with caution 
as a post hoc power analysis using G*power (Faul, Erdfelder, Lang, & Buchner, 2007)  
determined there was only moderate power (0.65) to detect the calculated effect size of 1.4 
(calculated from mean and SEM reported in Table 4.4) at the significance level of 5% between 
untreated WT and Ctr1+/− mice (n = 5/group). Quantification of SN cell number in the full 
cohort of animals (n = 10/group) would have provided strong power (0.92) to identify a 
statistical difference based upon the effect size of 1.4, and planned future experiments will 
utilise unbiased stereological counting of tyrosine hydroxylase-stained sections of the full 
study cohort to confirm the effects of Cu deficiency on SN dopaminergic neuron number.  
 
Together, this data demonstrates that the Ctr1+/− mouse replicates the reduction in brain Cu 
levels observed in the degenerating SN in PD (Davies et al., 2014) however, the preserved 
integrity of the nigrostriatal pathway in Ctr1+/− mice suggests that a reduction in brain Cu levels 
of this magnitude does not significantly compromise these pathways. 
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Figure 4.4 Dopamine synthesis and metabolism highlighting the involvement of copper. Blue 
boxes are Cu containing enzymes; orange stars are reactive species; bold arrows indicate favourable 
reactions; dashed arrows indicate unfavourable reactions. Abbreviations: 3-MT: 3-methoxytyramine; 
AADC: Aromatic L-amino acid decarboxylase; ALDH: Aldehyde dehydrogenase; COMT: Catechol-
o-methyltransferase; DOPAC: 3,4-dihydroxyphenylacetic acid; DOPAL: 3,4-
dihydroxypenylacetaldehyde; HVA: Homovanillic acid; MAO: Monoamine oxidase; SSAO: 
Semicarbazide-sensitive amine oxidase; TH: Tyrosine hydroxylase. Information was integrated from 
Pham & Waite, (2014) and Villar, Lubenia, Mendoza, & Pilar-Arceo, (2019). 
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4.4.2 Endogenous brain Cu levels does not alter the toxicity of MPTP 
The effects of MPTP are highly dependent on dose and dosing regimen (Meredith & 
Rademacher, 2011). For this study, an acute model of MPTP (4 ´ 15 mg/kg given every 2 
hours) was used as this regimen is reported to cause 40-50% loss in SN dopaminergic neurons 
and depletion of striatal dopamine levels (Ayton et al., 2013; Jackson-Lewis & Przedborski, 
2007; Qi et al., 2016) similar to that in PD patients at the onset of clinical motor symptoms 
(Grosch et al., 2016). In this study, MPTP lesion resulted in a smaller loss (20%) of SN cells 
in WT mice then previously reported, though this loss was similar to a 30% loss reported in a 
recent study using a similar regimen (4 ´ 16.25 mg/kg MPTP given every 2 hours) in C57Bl/6 
mice (Gotsbacher et al., 2017). It is not uncommon for the MPTP lesion size to vary between 
studies as MPTP is known to exhibit batch-to-batch variability in toxicity (Kordower et al., 
2006; Main et al., 2016), however the reduction in dopamine, DOPAC, and HVA levels in the 
striatum of WT mice following MPTP lesion in this study was similar to those reported in other 
studies (Miller et al., 2011; Yabe et al., 2009). While Cu deficiency was found to promote 
mitochondrial dysfunction and increase oxidative stress by reducing the activity of complex 4 
in vivo and in vitro (Rossi et al., 2004), hypothesis 2.2 was not supported as MPTP induced SN 
cell loss and changes in striatal dopamine and dopamine turnover were no different between 
WT and Ctr1+/– mice suggesting that a ~50% reduction in Cu levels in these regions does not 
increase the susceptibility of the nigrostriatal pathway to MPTP. This is likely because of the 
sequential nature of the electron transport chain, as MPTP inhibits mitochondrial complex 1 
(Franco-Iborra, Vila, & Perier, 2015; Schildknecht, Di Monte, Pape, Tieu, & Leist, 2017) and 
so the impaired activity of Cu deficient complex 4 would not further exacerbate MPTPs 
disruption of the mitochondrial respiratory chain. In support of this hypothesis, a study in 
isolated rat synaptosome showed that a 40% inhibition of complex 1 by MPTP was sufficient 
to induce glutamate release from nerve terminals to induce excitotoxicity, while a 90% 
inhibition of complex 4 activity was needed to produce the same toxic effect (Kilbride, 
Gluchowska, Telford, O’Sullivan, & Davey, 2011; Kilbride, Telford, Tipton, & Davey, 2008). 
Furthermore, the acute MPTP regimen may have caused too rapid and severe degeneration in 
the SN that cellular antioxidants such as Cu/Zn SOD1 were unable to mitigate the loss. Given 
that this experiment used only one dose of MPTP, an experiment using different doses of MPTP 
(but lower than the one used in this study) to compare the rate of dopaminergic neuronal loss 
between Cu normal and Cu deficient cell culture and/or animal models would provide more 
 56 
robust data to determine whether Cu deficiency does increase the susceptibility of 
dopaminergic neurons to MPTP. 
 
The acute MPTP dosing regimen used in this study did not markedly alter Fe, Cu, or Zn levels 
in the cortex, striatum, midbrain, or cerebellum of WT mice, which was in support of 
hypothesis 2.2 and consistent with another study that used laser ablation-ICP-MS to investigate 
the effects of a subchronic MPTP regimen on C57Bl/6 mice (Matusch et al., 2010). These 
results confirm that the classic MPTP mouse model does not reproduce the reduction in SN Cu 
levels observed in PD (Davies et al., 2014) and so is likely to be inappropriate to investigate 
the effects of Cu therapies on dopaminergic neuron survival. The MPTP lesioned Ctr1+/− mouse 
characterised in this study exhibits a similar reduction in brain Cu levels to that observed in 
PD, while MPTP induces the loss of dopaminergic neurons in the SN thus, this model more 
closely represents the human disease and may be more appropriate for the testing of Cu 
therapeutics. 
 
4.4.3 CuATSM increases Cu levels in all brain regions of healthy mice 
The progression of CuATSM into clinical trials has been based on the findings that Cu content 
and activity of cuproproteins are specifically reduced in the postmortem SN of PD patients 
(Davies et al., 2014); a positive correlation between CuATSM accumulation in the striatum 
and disease severity in living PD patients (Ikawa et al., 2011); and CuATSM prevented the loss 
of dopaminergic cells in the SN of four different mouse models of PD (Hung et al., 2012). 
However, the effects of therapeutic doses of CuATSM on regional brain Cu levels had not been 
quantified in either healthy or degenerating animal models. In this study, 30 mg/kg daily 
treatment of CuATSM over 20 days markedly increased total Cu levels in all brain regions of 
unlesioned WT and Cu deficient Ctr1+/− mice to levels well above physiological levels, which 
did not support hypothesis 2.3 and contrasted to the proposed selective accumulation of 
CuATSM in brain regions that exhibit high oxidative stress (Ikawa et al., 2011), or 
mitochondrial dysfunction (Donnelly et al., 2012). This raises concerns over the recommended 
dose of CuATSM determined in phase 1 clinical trial for PD that aims to achieve a plasma 
concentrations of 30 mg/kg CuATSM (Evans et al., 2017) as it may elevate patient brain Cu 
levels to supraphysiological levels. Although caution must be used when extrapolating rodent-
based research into potential affects in humans.  
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High Cu concentrations in the nigrostriatal pathway have been found to be damaging, as 
intranigral injection of copper sulphate (50 nmol) in Wistar rats depleted striatal dopamine 
levels, reduced density of tyrosine hydroxylase-positive striatal axons, and decreased levels of 
tyrosine hydroxylase mRNA in the SN 7 days post injection (Yu, Jiang, Wang, & Xie, 2008). 
Furthermore, elevated brain Cu levels is a key feature of Wilson’s disease, a disorder where 
patients can present with a range of motor and psychiatric symptoms (Bandmann et al., 2015). 
In support of hypothesis 2.3 however, the marked increase in regional brain Cu levels following 
CuATSM treatment in unlesioned WT and Ctr1+/− mice (3-6 fold and 2-5 fold increase 
compared to untreated WT mice respectively) did not adversely affect SN cell number or 
striatal dopamine physiology (further discussed below). This is consistent with investigations 
in 12 month old foster-nursed toxic milk mice (mouse model of Wilson’s disease) that showed 
elevations in whole brain Cu levels (~5 fold increase) did not alter neuron number (Terwel et 
al., 2011) and only caused a minor reduction in striatal dopamine levels (Przybyłkowski et al., 
2013). Though the toxic milk mouse did not show overt degeneration of the nigrostriatal 
pathway, they exhibited an increase in number of activated astrocytes and microglia in the 
striatum, alongside increased levels of cytokines, chemokines, and inflammatory enzymes 
(Terwel et al., 2011) indicating that elevated brain Cu levels promotes inflammation in the 
brain. While the magnitude of Cu increase by CuATSM was not deleterious to the nigrostriatal 
pathway within the short duration of this study (3 weeks), further studies are needed to 
determine the long-term effects of elevated Cu levels on the brain given that CuATSM 
treatment in PD patients is likely to extend over a number of years as the average life 
expectancy following diagnosis is 12.4 years (Deloitte, 2015). However, as there is currently 
no way to accurately measure brain Cu levels in living mammalian brains, these studies would 
need to be conducted in an appropriate animal model. 
 
The perceived selective delivery of CuATSM to cells/tissue of high oxidative stress and/or 
mitochondrial dysfunction is largely due to a number of studies that investigated the use of 
CuATSM as a hypoxic imaging agent in vitro (Fujibayashi et al., 1997; Xiao, Donnelly, 
Zimmermann, & Wedd, 2008; Yoshii et al., 2012) and in vivo (Ikawa et al., 2011; Jalilian et 
al., 2009; Lewis, McCarthy, McCarthy, Fujibayashi, & Welch, 1999). These studies typically 
report the ratio of radioactive Cu in a cell/tissue to circulating radiation levels or a reference 
region, and so do not provide a clear indicator of the amount of Cu change from baseline. 
Additionally, examination of the proposed mechanisms involved in Cu dissociation from 
CuATSM (Figure 4.5) does not indicate that dissociation only occurs in environments with 
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abnormally high cellular oxidants. One pathway for Cu dissociation from CuATSM is through 
the action of cellular reductants such as NADH-dependent reductases (e.g. NADH-cytochrome 
b5 reductase and NADPH-cytochrome p450 reductase) and thiol-bearing biomolecules (e.g. 
glutathione) that reduce Cu2+ to Cu+ to form the less lipophilic molecule [Cu+ATSM]− 
(Dearling & Packard, 2010). This less lipophilic molecule has a longer retention time in the 
cell allowing for acid-catalysed reactions (i.e. protonation) to produce the intermediates [Cu+-
ATSMH] or [Cu-ATSMH2]+, eventuating in the dissociation of Cu+ from the ATSMH2 
molecule (Zeglis, Houghton, Evans, Viola-Villegas, & Lewis, 2014). Additionally, a recent 
study has found that cellular oxidants, including chlorinating agents (e.g. hypochlorous acid) 
and peroxynitrite species, can directly act on the ATSM ligand to facilitate the dissociation of 
Cu2+ from the ligand (Sirois et al., 2018) (Figure 4.5). Together these studies indicate that 
entry of CuATSM is not limited to cells that exhibit mitochondrial dysfunction and normal 
cellular conditions are capable of causing dissociation of Cu from CuATSM. However, the 
amount of Cu retained is likely dependent on the levels of endogenous reductants and oxidants 
expressed in the cell or brain region. It is not surprising then that cells/tissue that exhibit high 
oxidative stress typically have elevated levels of endogenous reductants and oxidants (Liguori 
et al., 2018), which could explain why CuATSM has been found to accumulate more in 
degenerating brain regions compared to non-degenerating regions (Ikawa et al., 2011). 
However, as this study did not determine whether Cu was actually dissociated from the ligand, 
it is possible that the increase in Cu levels is due to accumulation of CuATSM in brain regions 
(see Lambert et al., 2013) and further experiments are needed to clarify this, possibly using 
mass spectrometry.
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Figure 4.5 Possible mechanisms for the dissociation of Cu from CuATSM inside the cell. The 
lipophilicity of CuATSM allows it to freely diffuse in and out of the cell. Intracellularly (green box), 
Cu can dissociate from CuATSM via reduction (left) of Cu2+ to Cu+ by oxidants including thiol-bearing 
molecules and NADH-dependent reductases resulting in dissociation and trapping of Cu+; and also by 
direct oxidation (right) of the ATSM ligand by reductants such as reactive oxygen and nitrogen species, 
resulting in the dissociation and trapping of Cu2+. Information was integrated from Sirois et al., (2018) 
and Zeglis, Houghton, Evans, Viola-Villegas, & Lewis, (2014) 
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While ICP-MS was not sensitive enough to determine the cellular destination of Cu delivered 
by CuATSM inside the brain, it is likely that once Cu dissociates from CuATSM inside the 
cell, it is bound by small molecules such as glutathione, as an in vivo study found that 
intracellular glutathione levels, but not Atox1 or CCS, positively influenced the uptake of Cu 
into the cell (Maryon, Molloy, & Kaplan, 2013). Cu can then be transferred to other Cu 
chaperones for delivery to specific cuproproteins or stored by metallothionein (Bulcke, 
Dringen, & Scheiber, 2017). However, excess intracellular Cu causes translocation of ATP7A 
transporters from the golgi apparatus to the cell membrane, resulting in Cu export to the 
extracellular space (Migocka, 2015). This triggers prion protein-mediated uptake of Cu into 
astrocytes (Brown, 2004) which, as described in Chapter 1, are better equipped to handle 
excess Cu due to their greater antioxidant potential and Cu storage capacity (Scheiber & 
Dringen, 2013). The proportional increase in regional Cu levels following CuATSM treatment 
was greater in Ctr1+/− mice compared to CuATSM treated WT mice, although total Cu levels 
remained lower in Ctr1+/− mice. The expression of glutathione and metallothionine mRNA are 
reported to be increased following Cu deficiency in vitro (Ogra, Aoyama, & Suzuki, 2006; Pi 
Yu Chao & Allen, 1992), thus Ctr1+/− mice may express a larger pool of these Cu storage 
proteins, however levels of these proteins were not measured in the current study. Despite the 
elevated Cu levels in the midbrain of both genotypes, no statistically significant changes in SN 
cell number was observed, which as mentioned above, may be because excess Cu is being 
stored in astrocytes, thus protecting neurons from Cu toxicity. This finding is consistent with 
the results from in vitro treatment of dopaminergic cells with copper sulphate (Paris et al., 
2001), and mouse models of Wilson’s disease (Buiakova et al., 1999; Huster, 2019; 
Przybyłkowski et al., 2013; Terwel et al., 2011), which show that elevations in Cu levels does 
not always lead to neuronal loss. However, it should be noted that while the Cu storage ability 
of astrocytes to mediate excess Cu is large, it has been found that an 8 fold increase in astrocyte 
Cu content causes astrocytes to rapidly generate oxidative species, increase lipid peroxidation, 
and compromise overall cell viability in vitro (Bulcke & Dringen, 2016; Scheiber & Dringen, 
2013), and this is consistent with reports that neurological and motor symptoms typically 
manifest in Wilson’s disease patients when brain Cu levels are 8 fold greater than normal 
(Litwin et al., 2013; Walshe & Gibbs, 1987). Thus, while CuATSM treatment increased brain 
Cu levels to supraphysiological levels in unlesioned WT and Ctr1+/− mice, these Cu 
concentrations were still below toxic levels. The elevated Cu levels in the striatum did not alter 
WT dopamine and dopamine metabolite levels however, CuATSM treatment was associated 
with an increase in Ctr1+/− DOPAC and HVA levels. The increase in Ctr1+/− DOPAC levels 
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may be due to the restored activity of cuproproteins MAO and SSAO which may have been 
inhibited by low Cu levels (as discussed earlier); and the increase in HVA levels is likely due 
to increased activity of COMT in response to an increase in DOPAC substrate. 
 
The elevated Cu levels following CuATSM treatment in unlesioned WT and Ctr1+/− mice did 
not affect regional Fe levels and this was consistent with a study in rats that showed Cu lactate 
treatment (0.15 mg Cu/100 g body weight, daily intraperitoneal injection for 90 days) increased 
Cu levels in all measured brain regions (cortex, striatum, and cerebellum) but did not alter brain 
Fe levels (Pal et al., 2013; Pal & Prasad, 2016). Zn levels were increased following CuATSM 
treatment in WT mice, which could possibly result from an upregulation of metallothionein 
isoforms (MT) -1 and -2 synthesis, which are reported to be upregulated under elevated brain 
Cu conditions in vivo (Huster, 2019), and can bind both Zn2+ and Cu+ ions (Calvo, Jung, & 
Meloni, 2017). Thus, while the majority of MT-1/-2 may sequester the large amounts of Cu, 
the elevated levels of MT-1/-2 may also inadvertently bind Zn resulting in an increase in 
cellular Zn levels. On the contrary, elevated Cu levels in Ctr1+/− mice was not associated with 
altered Zn levels, possibly because Cu deficiency can also increase metallothionein synthesis 
in vitro (Ogra et al., 2006), though why untreated Ctr1+/− mice do not exhibit higher Zn levels 
than untreated WT mice is not known. It should be noted that while there is little evidence to 
suggest a causative relationship between Zn and Cu levels in the brain, an imbalance in Cu and 
Zn serum levels has been associated with a number of neurological conditions including 
schizophrenia, depression, and dementia (Osredkar, 2011), thus the CuATSM associated 
changes in Zn levels warrants further investigation. 
 
Together, these data suggest that CuATSM markedly increases regional brain Cu levels in both 
Cu normal and Cu deficient animals, although the extent of Cu increase in the brain was larger 
in animals with an initial Cu deficiency. This finding confirms the value of using a model 
system that exhibits a brain Cu deficiency to investigate the effects of CuATSM in PD. 
 
4.4.4 Endogenous Cu levels alters the protective effects of CuATSM  
As described previously, the dissociation of Cu from CuATSM can occur under any cellular 
condition and it is the levels of endogenous reductants and oxidants that determines the extent 
of Cu retained in the brain region or cell. In this study, the extent of Cu increase following 
CuATSM treatment in the midbrain was greater in MPTP lesioned WT mice compared to the 
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unlesioned WT mice. This is likely because MPTP increases levels of the reductant NADH 
through inhibition of complex I (Giordano, Lee, Darley-Usmar, & Zhang, 2012), which can 
act individually or in tandem with NADH-dependent reductases to promote the reduction of 
CuATSM for Cu+ release and retention (Colombié et al., 2015). MPTP may also promote the 
oxidation of CuATSM by increasing reactive nitrogen species (Liberatore et al., 1999; 
Przedborski & Jackson-Lewis, 1998) and promoting hypochlorous acid synthesis and release 
from astrocytes (Choi et al., 2005). While the toxicity of MPTP may explain the greater extent 
of increase following CuATSM treatment in the degenerating midbrain of lesioned WT mice, 
this was not observed in the striatum of these mice, despite it being another region affected by 
MPTP (Kolacheva, Kozina, Volina, & Ugryumov, 2014). A possible explanation could be 
dysfunctional axonal transport, as MPP+ increases retrograde (to cell body) but decrease 
anterograde (to axon) transport of vesicles in vitro (Morfini et al., 2007). Thus, MPP+ can be 
rapidly transported to cell bodies in the SN to promote Cu dissociation from CuATSM in this 
region; while the loss of dopaminergic axons and diminished anterograde transport prevents 
the delivery of newly synthesised antioxidants and/or Cu-binding proteins from the SN to the 
striatum, which could explain why glutathione is depleted in the mouse striatum following 
MPTP (Chen, Yin, Hsu, & Liu, 2007). 
 
In Ctr1+/− mice, the extent of Cu increase following CuATSM treatment was greater in lesioned 
mice compared to unlesioned mice and this occurred in the striatum, midbrain, and cerebellum. 
The toxic effects of MPTP on mouse midbrain and striatum are well established but effects on 
the cerebellum are less established, with some studies reporting no effect (Choi et al., 2005), 
while others report MPTP associated degeneration (Munabi et al., 1990; Takada, Sugimoto, & 
Hattori, 1993). Nevertheless, it is plausible that the biochemical changes caused by MPTP 
increases levels of oxidants and reductants in the cell to promote the dissociation of Cu from 
CuATSM in these brain regions as described above. Although Cu levels in CuATSM treated 
lesioned Ctr1+/− mouse remained below those in CuATSM-treated lesioned WT mice, the 
extent of Cu increase was much greater in the Cu deficient mice, and this may be due to Ctr1+/− 
mice having a higher baseline levels of glutathione and metallothionein as described earlier 
(Ogra et al., 2006). Thus, the amount of Cu that is retained following CuATSM treatment may 
be dependent on the inherent levels of Cu storage proteins in the different brain regions. The 
larger increase in striatal Cu levels following CuATSM treatment in lesioned compared to 
unlesioned Ctr1+/− mice is also consistent with greater accumulation of CuATSM in the 
striatum of PD patients compared to healthy controls (Ikawa et al., 2011). This suggests that 
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the MPTP lesioned Ctr1+/− mouse model characterised in this study may more accurately model 
the biodistribution of CuATSM in human PD compared to the traditional MPTP model, as this 
increase was not observed in the striatum of CuATSM treated lesioned WT mice.  
 
The potential of CuATSM to protect the degenerating nigrostriatal pathway was assessed by 
commencing CuATSM treatment 24 hours post lesion. This delay ensured that any apparent 
protective effects would not result from an inhibition of the toxic actions of MPTP as both 
MPTP and MPP+ are cleared from the brain by 24 hours post lesion (Meredith & Rademacher, 
2011), and degeneration of the nigrostriatal pathway has begun but not peaked (Kolacheva et 
al., 2014). Consistent with the study conducted by Hung et al., (2012) and in partial support of 
hypothesis 2.4, this study found that 30 mg/kg daily treatment of CuATSM for 20 days was 
able to prevent the loss of SN cells associated with MPTP lesioning in WT mice but did not 
improve striatal dopamine and dopamine metabolite levels, which remained well below 
unlesioned WT levels. Normal SN cell number but depleted dopamine levels may indicate that 
the dopaminergic cells saved by CuATSM are senescent, a characteristic that may contribute 
in the pathology of PD (Riessland et al., 2019). However, while not determined in this study, 
CuATSM treatment was found to prevent the loss of tyrosine hydroxylase protein and mRNA 
levels in SN of MPTP lesioned WT mice (Hung et al., 2012). In fact, CuATSM has been found 
to promote the expression of a number of genes involved in dopamine synthesis, and general 
neuronal health (Cheng et al., 2016). Furthermore, the acute dosing regimen of MPTP induces 
dopaminergic neuron loss in the SN with concomitant reduction in tyrosine hydroxylase protein 
(Kolacheva et al., 2014; Kolacheva & Ugrumov, 2018) and mRNA (Kozina et al., 2014; Xu, 
Cawthon, McCastlain, Slikker, & Ali, 2005). Together, these findings suggest that the cells 
present in the SN of CuATSM treated lesioned WT mice are likely to be viable tyrosine 
hydroxylase producing cells that have yet to sufficiently recover to produce dopamine, or other 
undefined mechanisms, such as down regulation of tyrosine hydroxylase, are preventing the 
restoration of dopamine levels in this model. The low striatal dopamine levels in CuATSM 
treated lesioned WT mice may be caused by the dramatic increase in Cu levels following 
CuATSM treatment, as intranigral injection of copper sulphate (50 nmol) in Wistar rats 
depleted striatal dopamine levels (Yu et al., 2008). Cu can catalyse the breakdown of dopamine 
to reactive o-quinones/semiquinones in the presence of molecular oxygen (Figure 4.4), thus it 
is possible that the large increase in striatal Cu coupled with MPTP promoting the release of 
dopamine into the extracellular space (Choi et al., 2015) may prevent striatal dopamine 
recovery.  
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In support of hypothesis 2.4 but in contrast to an apparent protection of SN cells observed in 
MPTP lesioned WT mice, CuATSM treatment was not associated with an equivalent protective 
effect in lesioned Ctr1+/− mice and this may be related to the observed greater proportional 
increase in midbrain Cu levels in lesioned Ctr1+/− mice compared to lesioned WT mice. The 
larger amount of Cu is likely to further promote the oxidation of extracellular dopamine to 
reactive o-quinones/semiquinones (Figure 4.4), which produces superoxide as a by-product 
(Pham & Waite, 2014; Zhang, Wang, & Wang, 2019); and the increased levels of o-quinones 
can also prevent glutathione from binding excess Cu (Paris et al., 2001; Zhang et al., 2019) 
resulting in the increase of free Cu that can produce hydroxyl radicals through Fenton 
chemistry (Pham et al., 2013). Thus, the absence of CuATSM associated protection in lesioned 
Ctr1+/− midbrain may be due to a much higher level of oxidative stress compared to lesioned 
WT mice as a result of a larger proportional increase in midbrain Cu levels, however further 
studies measuring oxidative stress markers are needed to determine this. Nevertheless, these 
results demonstrate that too large an increase in Cu levels can be deleterious to the nigrostriatal 
pathway and degenerating Cu deficient brain regions are more prone to a greater increase in 
Cu levels. The elevated Cu levels in the midbrain and striatum may promote the depletion of 
dopamine, which may be hazardous to PD patients who already exhibit low levels of 
endogenous dopamine (Fearnley & Lees, 1991). Furthermore, elevated Cu levels may have an 
adverse effect on levodopa treatment, which manages PD patient symptoms by increasing 
dopamine levels. Thus, it is imperative for future studies to determine whether co-
administration of CuATSM will alter the efficacy of levodopa. As only 1 dose of CuATSM 
was used in this study, lower doses of CuATSM should be tested in the Cu deficient MPTP 
lesioned Ctr1+/− mouse to determine the minimum dose of CuATSM needed to prevent the 
degeneration of the nigrostriatal pathway, with particular attention placed on striatal dopamine 
physiology. 
 
In summary, MPTP mediated upregulation of cellular oxidants and reductants may promote 
the dissociation of Cu from CuATSM resulting in a greater retention of Cu in degenerating 
brain regions. However, this large increase in Cu levels was ineffective in preventing cell loss 
in the Cu deficient SN and did not restore striatal dopamine levels. This indicates that too large 
an increase in Cu levels may be harmful to the Cu deficient nigrostriatal pathway however, to 
test this hypothesis, a lower dose of CuATSM should be tested in future in vivo studies. 
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4.4.5 Study limitations not discussed elsewhere 
While PD is known to exhibit a sex difference in humans (extensively reviewed by Jurado-
Coronel et al., 2018), there is no consensus on whether MPTP affects male and female C57Bl/6 
mice differently, with studies reporting increased sensitivity in male mice (Miller, Ali, 
O’Callaghan, & Laws, 1998), increased sensitivity in female mice (Ookubo, Yokoyama, Kato, 
& Araki, 2009), or equal effect between sexes (Sedelis et al., 2000b). Thus, this study utilised 
mice of both sexes which also reduced total mouse breeding. While this study is the first to 
successfully model a Ctr1 mediated Cu deficiency similar to what is observed in human PD, 
the global Cu deficiency observed in this model does not replicate the specific regional Cu 
deficiency observed in PD (Davies et al., 2014). A more accurate model of PD associated 
changes in Cu would involve generation of a model where the Cu deficiency is restricted to the 
nigrostriatal pathway and is induced during adulthood. Nevertheless, the results presented here 
demonstrate that brain Cu deficiency alters the apparent neuroprotective effects of CuATSM 
in MPTP lesioned mice and so demonstrates the importance of testing Cu therapeutics in an 
appropriate Cu deficient model. 
 
4.4.6 Conclusion 
While clinical trials of CuATSM in PD have commenced, a number of basic biological 
questions remain unanswered including the effects of CuATSM on biometals in the brain and 
the role of Cu deficiency in regional vulnerability in PD. This study provides the first in vivo 
data to show CuATSM increases Cu levels throughout the healthy and Cu deficient brain to 
supraphysiological levels, and this is enhanced in degenerating brain regions. The novel MPTP 
lesioned Ctr1+/− mouse was characterised in this chapter to investigate the effects of Cu 
deficiency on the nigrostriatal pathway and the importance of endogenous Cu levels in cell 
survival. The data presented demonstrates that a 50% reduction in brain Cu levels alone does 
not alter the nigrostriatal pathway or increase vulnerability to MPTP. Nevertheless, the MPTP 
lesioned Ctr1+/− mouse models both the degeneration of the nigrostriatal pathway and a Ctr1 
mediated Cu reduction present in the human parkinsonian brain. Testing CuATSM in this novel 
model revealed a difference in neuroprotective effects compared to the traditional MPTP 
mouse model, demonstrating that excessively increasing brain Cu levels may be deleterious in 
degenerating Cu deficient regions. Thus, the MPTP lesioned Ctr1+/− mouse represents a 
valuable model to investigate the relationship between Cu levels and nigrostriatal health and 
provides a more accurate model to test Cu modulating therapies. 
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5 TESTING A NOVEL CUATSM 
DERIVATIVE IN CU NORMAL 
AND CU DEFICIENT MOUSE 
MODELS OF PARKINSON’S 
DISEASE 
5.1 Introduction 
From Chapter 4, it is apparent that CuATSM increases brain Cu levels magnitudes above 
physiological levels in healthy mouse brains and this increase was further potentiated in brain 
regions that exhibited degeneration. While the large increase in brain Cu levels was associated 
with attenuation of cell loss in the degenerating SN of WT mice, this effect was mitigated in 
the SN of Ctr1+/− mice. This suggests that the Cu deficiency in Ctr1+/− mice may alter some, as 
yet undefined physiological pathway that reduces the apparent neuroprotective effects of 
CuATSM in this brain region. A possible explanation is the greater proportional increase in the 
Cu content of Ctr1+/− mice compared to WT mice following CuATSM treatment, which may 
further promote the formation of oxidative species and neuroinflammation that overburden the 
potentially compromised protective mechanisms of the Cu deficient SN (as discussed in 
Section 4.4).  Thus, increasing Cu levels in the Cu deficient brain by a smaller amount than 
that achieved in Chapter 4 may be a more effective treatment strategy. One approach to achieve 
this is by reducing the dose of CuATSM however, a potential alternative is to modify CuATSM 
to reduce Cu delivery into the brain while also providing additional benefits, such as improved 
tissue targeting. A number of studies have added functional groups to the backbone of 
CuATSM in order to enhance the selectivity of the compound to a target proteins e.g. addition 
of benzothiazole and styrylpyridine for targeted binding to amyloid beta plaques in 
Alzheimer’s disease (Hickey et al., 2013); nitroimidazole to enhance hypoxic selectivity for 
tumour imaging (Bonnitcha et al., 2010); octreotide to target tumours with high concentration 
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of somatostatin receptors (Cowley, Dilworth, Donnelly, Heslop, & Ratcliffe, 2007); and 
bombesin for targeted binding to tumours overexpressing gastrin-releasing peptide (Paterson, 
Karas, Scanlon, White, & Donnelly, 2010). Though these CuATSM derivatives were 
developed for diagnostic imaging purposes, they may also have therapeutic potential. Hence, 
the modification of CuATSM by adding different functional groups may alter the 
pharmacological properties of the compound that also modulates the amount of Cu delivered 
into the brain.  
 
The lipophilicity of CuATSM allows it to easily cross the blood brain barrier and cellular 
membranes, however this also makes the compound poorly water soluble (Buncic et al., 2011; 
Dearling, Lewis, Mullen, Welch, & Blower, 2002; Djoko et al., 2015), a property often 
associated with difficulties in clinical administration. Indeed, the current administration 
strategy for CuATSM in a phase 2 study in amyotrophic lateral sclerosis (ClinicalTrials.gov 
identifier: NCT04082832) requires patients to resuspend 72 mg of CuATSM in 30 mL of 
excipient daily for oral administration, the inconvenience of which may lead to poor patient 
compliance over a prolonged treatment period (Merisko-Liversidge & Liversidge, 2008). 
Reducing the lipophilicity of CuATSM may serve a dual role to simplify compound 
preparation for potential patient administration and limit the amount of Cu that enters the brain. 
 
This can be achieved by adding different functional groups to the terminal amino position of 
CuATSM (R4 terminus; Figure 1.4), which has been found to alter the lipophilicity of 
CuATSM without affecting the stability of Cu binding to the ligand, or its electrochemical 
features i.e. reduction potential (Dearling et al., 2002; Paterson et al., 2019, 2010). For 
example, polyamines are typically added to compounds to increase their blood brain barrier 
permeability (Poduslo & Curran, 1996; Zhang, Lee, Pruess, White, & Bulaj, 2009) and water 
solubility (Luciano & Bruckner, 2017). The addition of polyamines to the R4 terminus of 
CuATSM reduced the lipophilicity of the resulting derivatives, which were able to increase 
cellular Cu content by ~36 fold compared to untreated cells but was comparatively lower than 
the 47 fold increase observed with CuATSM treatment (Paterson et al., 2019). This study 
suggests that reducing the lipophilicity of CuATSM may reduce the amount of Cu delivered 
into the cell however, given the large increase in brain Cu levels following CuATSM treatment, 
a more hydrophilic functional group may be needed to further restrict CuATSM entry into the 
brain. 
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Butyric acid is a short-chain fatty acid comprised of a 4-carbon backbone with a carboxylic 
acid functional group. This functional group is highly polar, which together with its negative 
charge at physiological pH, limits its blood brain barrier permeability (Hitchcock & 
Pennington, 2006). Butyric acid can be added to the R4 terminus of CuATSM via a reaction 
with 4-aminobutyric acid to form Cu2+diacetyl-4-butyric acid-4’-
methylbis(thiosemicarbazonato) (CuATSM-But; Figure 5.1) (Paterson et al., 2010). 
Paterson’s intention in synthesising CuATSM-But was to link biologically active molecules to 
CuATSM to improve the selective delivery of Cu to target tissue without compromising the 
biological activity of either molecule e.g. the addition of bombesin for tumour targeting. 
Kinetic studies showed that CuATSM-But has a similar reduction potential as CuATSM but is 
less lipophilic (Paterson et al., 2010) thus, CuATSM-But represents an appropriate compound 
to determine whether reducing the lipophilicity of CuATSM will modify delivery of Cu into 
the brain in vivo. 
 
 
Figure 5.1 Chemical structure for CuATSM-But. The reaction of CuATSM [Cu2+diacetyl-
bis(4-methyl-thiosemicarbazonato)] with 4-aminobutyric acid forms CuATSM-But 
[Cu2+diacetyl-4-butyric acid-4’-methylbis(thiosemicarbazonato)]. 
 
In the following chapter, CuATSM-But is tested in MPTP lesioned and unlesioned Ctr1+/− 
mice, with appropriate controls, to investigate the treatment associated changes in brain metal 
levels and any potential neuroprotective effects of this compound on MPTP induced damage 
to the nigrostriatal pathway. It is hypothesized that CuATSM-But will increase regional brain 
Cu but to levels lower than those resulting from CuATSM treatment. It is also hypothesised 
that this smaller increase will attenuate the loss of SN cells in the MPTP lesioned Cu deficient 
mouse. 
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5.2 Experimental procedures 
 
5.2.1 Animals 
CuATSM-But was kindly synthesised by Dr Michael Gotesbacher (University of Sydney) as 
described in Paterson et al. (2010). MPTP administration and tissue collection was performed 
as described in Chapter 2. Age-matched Ctr1+/− mice and WT littermates of both sexes aged 
4-7 months were either lesioned with four intraperitoneal injections of MPTP (15 mg/kg) or 
sham injected with saline. This dose of MPTP was used for consistency with Chapter 4 in 
order to allow results from the two studies to be compared. Mouse group sizes are shown in 
Table 5.1. Twenty-four hours post lesion, mice began a 20 day regimen of either 30 mg/kg 
CuATSM-But suspended in SSV, or only SSV as a control, administered by daily gavage. The 
CuATSM-But dose and duration of treatment was based on the results reported in Chapter 4, 
which showed a 30 mg/kg dose of CuATSM significantly increased brain Cu levels and this 
was associated with protection of SN cells in WT, but not in Ctr1+/−, mice. Twenty-one days 
post lesion, mice were euthanised and isolated brains were hemisected, with the entire right 
hemisphere processed for immunohistochemistry and the left hemisphere further dissected into 
the cortex, striatum, hippocampus, midbrain, and cerebellum for biochemical analysis. 
 
Table 5.1 Treatment group sizes. 
      Genotype 
Lesion Treatment WT Ctr1+/− 
Saline SSV 13 11 
Saline CuATSM-But 11 14 
MPTP SSV 9 12 
MPTP CuATSM-But 11 12 
Abbreviations: Ctr1+/−: Ctr1 heterozygous; CuATSM-But: Cu2+diacetyl-4-butyric acid-4’-
methylbis(thiosemicarbazonato); MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SSV: 
Standard suspension vehicle; WT: Wild-type. 
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5.2.2 Measuring regional metal levels 
Tissue preparation and ICP-MS machine parameters used were as described in Section 2.4. 
The candidate prepared cortex (25 mg), striatum (10 mg), hippocampus (20 mg), midbrain (10 
mg), and cerebellum (20 mg) for each animal for ICP-MS with the assistance of Honours 
student Amr Abdeen (Brain and Mind Centre, University of Sydney, Australia). ICP-MS was 
conducted by the candidate on an Agilent Technologies 7900 ICP-MS (Agilent Technologies, 
Mulgrave, Australia). 
 
5.2.3 Dopamine and dopamine metabolite measurements in the striatum 
Sample preparation and HPLC was conducted by Veronica Cottam and Amr Abdeen 
(University of Sydney) as described in Section 2.5. 
 
5.2.4 Histology and stereological cell counts 
Performed as described in Section 2.6. Tissue sectioning and unbiased stereological cell counts 
was conducted by the candidate, and cresyl violet staining was performed by Veronica Cottam 
(University of Sydney). 
 
5.2.5 Statistics 
In order to validate the Ctr1+/− MPTP model characterised in Chapter 4 and determine the 
effects of the novel compound CuATSM-But on measured variables, the candidate performed 
a three-way ANOVA with unadjusted pairwise comparisons as described in Section 4.2.5 with 
CuATSM-But replacing CuATSM as the Cu treatment variable. Outliers were identified and 
removed as described in Section 2.7 and analysis group sizes are summarised in Appendix 2. 
 
5.3 Results 
5.3.1 Validation of the MPTP lesioned Ctr1+/− mouse 
A three-way ANOVA determined both genotypes responded similarly to all combinations of 
lesion and Cu treatment as no significant three-way interactions were found between genotype, 
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lesion, and Cu treatment for any measured variable (Table 5.2), although dopamine turnover 
exhibited a strong trend towards significance (p = 0.054).  
 
Table 5.2 Summary of three-way ANOVA. 
Variable Brain Region F-Value P-Value 
Iron Cortex F(1,70) = 0.671 0.416 
 Striatum F(1,24) = 0.609 0.443 
 Hippocampus F(1,82) = 0.379 0.540 
 Midbrain F(1,79) = 2.515 0.117 
  Cerebellum F(1,71) = 0.041 0.841 
Copper Cortex F(1,70) = 0.740 0.393 
 Striatum F(1,25) = 0.093 0.763 
 Hippocampus F(1,78) = 0.003 0.954 
 Midbrain F(1,68) = 2.887 0.094 
 Cerebellum F(1,74) = 1.078 0.303 
Zinc Cortex F(1,73) = 2.984 0.088 
 Striatum F(1,25) = 1.888 0.182 
 Hippocampus F(1,78) = 0.029 0.865 
 Midbrain F(1,77) = 1.474 0.229 
  Cerebellum F(1,77) = 0.561 0.456 
Dopamine Striatum F(1,73) = 0.796 0.375 
DOPAC  F(1,77) = 1.324 0.253 
HVA  F(1,77) = 0.191 0.663 
Turnover  F(1,66) = 3.842 0.054 
Cell count SN F(1,26) = 0.501 0.485 
 
 
Specific pairwise comparisons identified that Fe and Zn levels in untreated Ctr1+/− mice did not 
differ to those in untreated WT mice in any brain region but Ctr1+/− mice exhibited markedly 
less Cu than WT mice in all brain regions (42 to 66% less; overall p < 0.05; Figure 5.2; Table 
5.3). Contrary to Section 4.3.2, cell number in the SN of Ctr1+/− mice did not differ to that in 
WT mice (Figure 5.3A; Table 5.4) suggesting that alone, the degree of Cu deficiency observed 
does not affect SN cell number.  
 72 
 
 
 
Figure 5.2  CuATSM-But increases Cu levels in the mouse brain. Regional Fe (A-E), Cu (F-J), and Zn (K-O) levels were quantified using ICP-MS. Specific 
unadjusted pairwise comparisons were made using the error value from the three-way ANOVA. vp < 0.05 vs. WT Saline SSV group; #p < 0.05 vs. Ctr1+/− Saline 
SSV group; up < 0.05 vs. adjoining SSV group; *p < 0.05 vs. respective strain Saline CuATSM-But group. Group sizes are reported in Table 5.1. Abbreviations: 
Ctr1+/−: Ctr1 heterozygous; CuATSM-But: Cu2+ bis(thiosemicarbazone)-4’-butyric acid complex; ICP-MS: Inductively coupled plasma-mass spectrometer; 
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SSV: Standard Suspension Vehicle; WT: Wild-type. 
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Table 5.3 Effects of MPTP and CuATSM-But on regional brain metal levels in WT and Ctr1+/− mice 
 
 
Fe, Cu, and Zn levels were quantified using ICP-MS for each brain region and normalised to lyophilised tissue weight. Specific unadjusted pairwise comparisons 
were made using the error value from the 3-way ANOVA. Green and red shaded values indicate a significant increase and decrease respectively. *p < 0.05, **p 
< 0.005, ***p < 0.001 vs. specified group. Group sizes are reported in Table 5.1. Abbreviations: Ctr1+/−: Ctr1 heterozygous; CuATSM-But: 
Cu2+bis(thiosemicarbazone)-4’-butyric acid complex; ICP-MS: Inductively coupled plasma-mass spectrometer; MPTP: 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; SSV: Standard Suspension Vehicle; WT: Wild-type. 
 
Variable Brain region WT Ctr1+/−
% Diff
Ctr1+/− VS. WT
WT % diff VS. WT Untreated Ctr1
+/− % diff VS. 
Ctr1+/− Untreated
WT % diff VS. WT Untreated Ctr1
+/− % diff VS. 
Ctr1+/− Untreated
WT % diff VS. WT CuATSM-But Ctr1
+/− % diff VS. 
Ctr1+/− CuATSM-But
% Diff
Ctr1+/− VS. WT
Cortex 59.32 ± 2.40 57.95 ± 2.73 ↓ 2% 53.46 ± 3.27 ↓ 10% 55.67 ± 2.88 ↓ 4% 49.99 ± 2.73 ↓ 16% * 49.61 ± 2.49 ↓ 14% * 56.35 ± 3.27 ↑ 13% 53.01 ± 2.73 ↑ 7% ↓ 6%
Striatum 84.00 ± 7.79 74.85 ± 8.99 ↓ 11% 83.37 ± 8.99 ↓ 1% 74.42 ± 6.36 ↓ 1% 81.94 ± 6.97 ↓ 2% 98.57 ± 6.97 ↑ 32% * 73.11 ± 8.99 ↓ 11% 72.11 ± 8.99 ↓ 27% * ↓ 1%
Hippocampus 48.23 ± 2.80 55.47 ± 3.19 ↑ 15% 52.20 ± 3.36 ↑ 8% 60.50 ± 2.91 ↑ 9% 39.52 ± 2.91 ↓ 18% * 46.02 ± 2.80 ↓ 17% * 50.66 ± 3.19 ↑ 28% * 52.94 ± 3.04 ↑ 15% ↑ 5%
Midbrain 73.27 ± 2.76 68.71 ± 3.19 ↓ 6% 71.59 ± 3.19 ↓ 2% 78.21 ± 2.76 ↑ 14% * 68.18 ± 2.76 ↓ 7% 70.53 ± 2.88 ↑ 3% 75.88 ± 2.88 ↑ 11% 76.31 ± 2.88 ↑ 8% ↑ 1%
Cerebellum 63.58 ± 3.38 77.47 ± 3.02 ↑ 12% 65.65 ± 3.19 ↑ 3% 73.44 ± 2.88 ↑ 3% 63.93 ± 2.88 ↑ 1% 67.38 ± 3.02 ↓ 5% 65.04 ± 2.88 ↑ 2% 67.35 ± 2.88 0% ↑ 4%
Cortex 15.27 ± 0.93 7.14 ± 1.06 ↓ 53% *** 15.08 ± 1.19 ↓ 1% 7.56 ± 1.06 ↑ 6% 22.90 ± 1.19 ↑ 50% *** 18.63 ± 1.01 ↑ 161% *** 24.92 ± 1.01 ↑ 9% 18.58 ± 1.27 0% ↓ 25% ***
Striatum 15.11 ± 3.18 5.09 ± 3.67 ↓ 66% * 25.34 ± 3.67 ↑ 68% * 9.03 ± 2.60 ↑ 78% 25.02 ± 3.18 ↑ 66% * 28.13 ± 3.18 ↑ 453% *** 29.47 ± 3.67 ↑ 18% 29.09 ± 2.60 ↑ 3% ↓ 1%
Hippocampus 17.76 ± 1.25 10.26 ± 1.25 ↓ 42% *** 17.23 ± 1.32 ↓ 3% 8.80 ± 1.19 ↓ 14% 20.67 ± 1.14 ↑ 16% 17.00 ± 1.14 ↑ 66%*** 23.51 ± 1.19 ↑ 14% 19.11 ± 1.19 ↑ 12% ↓ 19% *
Midbrain 16.22 ± 1.22 9.46 ± 1.30 ↓ 42% *** 17.32 ± 1.22 ↑ 7% 9.97 ± 1.22 ↑ 5% 24.98 ± 1.06 ↑ 54% *** 18.81 ± 1.22 ↑ 99% *** 24.51 ± 1.30 ↓ 2% 23.54 ± 1.06 ↑ 25% * ↓ 4%
Cerebellum 25.07 ± 1.62 12.54 ± 1.71 ↓ 50% *** 25.27 ± 1.71 ↑ 1% 11.57 ± 1.48 ↓ 8% 35.15 ± 1.54 ↑ 40% *** 21.75 ± 1.54 ↑ 73% *** 30.45 ± 1.54 ↓ 13% * 20.60 ± 1.71 ↓ 5% ↓ 32% ***
Cortex 75.05 ± 2.44 70.93 ± 3.11 ↓ 5% 72.28 ± 3.11 ↓ 4% 75.18 ± 2.78 ↑ 6% 67.89 ± 2.78 ↓ 10% 71.20 ± 2.54 0% 74.27 ± 2.78 ↑ 9% 70.92 ± 2.78 0% ↓ 5%
Striatum 86.13 ± 7.40 72.11 ± 8.54 ↓ 16% 95.54 ± 8.54 ↑ 11% 67.64 ± 6.04 ↓ 6% 69.87 ± 7.40 ↓ 19% 103.96 ± 6.62 ↑ 44% * 89.52 ± 8.54 ↑ 28% 80.51 ± 6.62 ↓ 23% * ↓ 10%
Hippocampus 74.97 ± 3.66 81.20 ± 4.67 ↑ 8% 78.03 ± 4.40 ↑ 4% 81.54 ± 4.17 0% 62.82 ± 3.81 ↓ 16% * 76.27 ± 3.66 ↓ 6% 62.78 ± 4.40 0% 75.48 ± 3.81 ↓ 1% ↑ 20% *
Midbrain 57.45 ± 1.76 52.77 ± 1.84 ↓ 8% 58.51 ± 2.03 ↑ 2% 53.53 ± 1.84 ↑ 1% 54.73 ± 1.93 ↓ 5% 55.90 ± 1.76 ↑ 6% 50.86 ± 2.16 ↓ 7% 58.22 ± 1.76 ↑ 4% ↓ 14% *
Cerebellum 66.61 ± 3.16 70.52 ± 3.31 ↑ 6% 67.10 ± 3.49 ↑ 1% 66.26 ± 3.49 ↓ 6% 66.19 ± 3.16 ↓ 1% 69.39 ± 2.91 ↓ 2% 62.99 ± 3.16 ↓ 5% 68.29 ± 3.16 ↓ 2% ↑ 8%
Iron
(µg/g dry weight)
Untreated MPTP CuATSM-But MPTP+CuATSM-But
Copper
(µg/g dry weight)
Zinc
(µg/g dry weight)
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Figure 5.3 CuATSM-But prevents neuronal loss in Cu deficient mice but has no effect on dopamine 
signalling pathways. SN cell number (A) was determined using unbiased stereological counts of cresyl violet 
stained neurons; Dopamine (B), DOPAC (C), and HVA (D) levels were measured using HPLC; and Dopamine 
turnover (E) was calculated by dividing the sum of DOPAC and HVA by Dopamine levels. Specific 
unadjusted pairwise comparisons were made using the error value from the three-way ANOVA. vp < 0.05 vs. 
WT Saline SSV group; #p < 0.05 vs. Ctr1+/− Saline SSV group; up < 0.05 vs. adjoining SSV group; *p < 0.05 vs. 
respective strain Saline CuATSM-But group. Group sizes are reported in Table 5.1. Abbreviations: Ctr1+/−: Ctr1 
heterozygous; CuATSM-But: Cu2+bis(thiosemicarbazone)-4’-butyric acid complex; HPLC: High 
performance liquid chromatography; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SSV: Standard 
suspension vehicle; WT: Wild-type. 
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Table 5.4 Effects of MPTP and CuATSM-But on SN cell number and striatal dopamine physiology of WT and Ctr1+/− mice. 
 
 
SN cell number was determined using unbiased stereological counts of cresyl violet stained neurons; Dopamine, DOPAC, and HVA levels were measured using 
HPLC; and Dopamine turnover was calculated by dividing the sum of DOPAC and HVA by Dopamine levels. Specific unadjusted pairwise comparisons were 
made using the error value from the three-way ANOVA. Green and red shaded values indicate a significant increase and decrease respectively. *p < 0.05, **p < 
0.005, ***p < 0.001 vs. specified group. Group sizes are reported in Table 5-1. Abbreviations: Ctr1+/−: Ctr1 heterozygous; CuATSM-But: Cu2+ 
bis(thiosemicarbazone)-4’-butyric acid complex; HPLC: High performance liquid chromatography; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SN: 
Substantia nigra pars compacta; SSV: Standard suspension vehicle; WT: Wild-type.
Variable Brain region WT Ctr1+/−
% Diff
Ctr1+/- vs WT
WT % diff WT(VS Untreated) Ctr1
+/- % diff Ctr1+/- 
 (VS Untreated)
WT % diff WT(VS Untreated) Ctr1
+/- % diff Ctr1+/- 
 (VS Untreated)
WT % diff VS. WT MPTP Ctr1
+/− % diff VS. 
Ctr1+/− MPTP
% Diff
Ctr1+/− VS. WT
Dopamine
(ng/mg protein) Striatum 59.90 ± 3.80 59.68 ± 4.25 0% 23.65 ± 4.54 ↓ 61% *** 21.78 ± 3.47 ↓ 64% *** 54.22 ± 4.01 ↓ 9% 56.07 ± 3.47 ↓ 6% 26.49 ± 3.62 ↑ 12% 16.98 ± 3.47 ↓ 22% ↓ 36%
DOPAC
(ng/mg protein) 12.99 ± 1.51 14.23 ± 1.57 ↑ 10% 5.17 ± 1.97 ↓ 60% ** 5.58 ± 1.51 ↓ 61% *** 10.64 ± 1.51 ↓ 18% 5.04 ± 1.74 ↓ 65% *** 4.43 ± 1.57 ↓ 14% 3.29 ± 1.57 ↓ 41% ↓ 26%
HVA
(ng/mg protein) 5.90 ± 0.42 6.54 ± 0.44 ↑ 11% 3.33 ± 0.59 ↓ 44% ** 3.56 ± 0.42 ↓ 46% *** 4.48 ± 0.42 ↓ 24% * 4.36 ± 0.44 ↓ 33% ** 3.63 ± 0.46 ↑ 9% 2.53 ± 0.44 ↓ 29% ↓ 30%
Dopamine 
Turnover 0.32 ± 0.05 0.28 ± 0.06 ↓ 13% 0.47 ± 0.07 ↑ 48% 0.38 ± 0.05 ↑ 39% 0.31 ± 0.05 ↓ 4% 0.18 ± 0.05 ↓ 35% 0.32 ± 0.05 ↓ 32% 0.45 ± 0.05 ↑ 18% ↑ 41%
Estimated 
Cell Count SN 6417.6 ± 203.4 6364.4 ± 203.4 ↓ 1% 4742.2 ± 203.4 ↓ 26% *** 4332.0 ± 203.4 ↓ 32% *** 6881.0 ± 321.5 ↑ 7% 7118.5 ± 321.5 ↑ 12% 6679.6 ± 203.4 ↑ 41% *** 6082.6 ± 203.4 ↑ 40% *** ↓ 9%
MPTP+CuATSM-ButUntreated MPTP CuATSM-But
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However, as discussed in Section 4.4, quantification of dopaminergic neurons in the SN 
through the use of tyrosine hydroxylase staining is needed to confirm this. Consistent with data 
presented in Section 4.3.2, measures of striatal dopamine pathways did not differ between 
untreated WT and Ctr1+/− mice (Figure 5.3B-E; Table 5.4). In particular, the reduction in 
Ctr1+/− DOPAC levels previously observed in Ctr1+/− mice was not seen in this study suggesting 
that cuproproteins involved in striatal dopamine metabolism are not affected by the degree of 
Cu deficiency present in these animals. 
 
MPTP treatment did not generally affect brain metal levels (Figure 5.2; Table 5.3), although 
some differences were observed to those reported in Section 4.3.3. This included no changes 
in cerebellar Cu levels in WT mice or midbrain Zn levels in Ctr1+/− mice, previously reported 
to be significantly decreased and increased respectively following MPTP (Table 5.3). 
Consistent with data reported in Section 4.3.3, MPTP increased midbrain Fe levels by 14% in 
Ctr1+/− mice (p = 0.027) and striatal Cu levels by 68% in WT mice (p = 0.045) (Table 5.3). As 
expected, MPTP significantly reduced SN cell number in both WT and Ctr1+/− mice (26% and 
32% loss respectively; overall p < 0.001; Figure 5.3A; Table 5.4), with associated reductions 
in striatal dopamine  (61% and 64% reduction respectively; overall p < 0.001), DOPAC (60% 
and 61% reduction respectively; overall p < 0.005), and HVA (44% and 46% reduction 
respectively; overall p < 0.005) levels (Figure 5.3B-E; Table 5.4). Consistent with findings in 
Section 4.3.3, dopamine turnover was increased in both WT (48% increase) and Ctr1+/− (39% 
increase) mice, although this change was not statistically significant. 
 
Together, these results confirm findings reported in Section 4.3 demonstrating that the MPTP 
lesioned Ctr1+/− mouse model exhibits reduced brain Cu levels and degeneration of the 
nigrostriatal pathway. 
 
5.3.2 CuATSM-But increases Cu levels in all brain regions but does not 
markedly alter dopaminergic physiology 
CuATSM-But treatment did not alter Fe and Zn levels in the striatum, midbrain, or cerebellum 
of WT mice, but was associated with small decreases in Fe levels in the cortex and 
hippocampus (16% and 18% reduction respectively; overall p < 0.05), and in Zn levels in the 
hippocampus (16% reduction; p = 0.024) in WT mice (Figure 5.2A-E, K-O; Table 5.3). 
Ctr1+/− mice also exhibited a decrease in Fe levels in the cortex and hippocampus (14% and 
 77 
17% reduction respectively; overall p < 0.05) following CuATSM-But treatment but in contrast 
to WT mice, CuATSM-But also markedly increased striatal Fe and Zn levels (32% and 44% 
increase respectively; p < 0.05) (Figure 5.2A-E, K-O; Table 5.3).  
 
CuATSM-But treatment significantly increased Cu levels in all brain regions of WT mice by 
40 to 66% (overall p < 0.05; Figure 5.2F-J; Table 5.3) excepting the hippocampus, which 
exhibited a smaller (16%), non-significant increase. Consistent with the data following 
CuATSM treatment in WT mice, the striatum and cerebellum exhibited the largest and smallest 
significant respective changes in Cu levels following CuATSM-But treatment. Regional Cu 
levels in Ctr1+/− mice were increased by 66 to 453% (overall p < 0.001) following CuATSM-
But treatment, with the smallest and largest changes observed in the hippocampus (followed 
closely by the cerebellum) and striatum respectively (Figure 5.2F-J; Table 5.3). This regional 
pattern differed to that seen in Ctr1+/− mice following CuATSM treatment, where the greatest 
increase in Cu levels was observed in the midbrain (Table 4.3). Comparison of regional Cu 
levels between CuATSM-But-treated WT and Ctr1+/− mice demonstrated that, consistent with 
CuATSM treatment, regional brain Cu levels in Ctr1+/− mice remained ~25% lower than those 
in WT mice (overall p < 0.05), excepting the striatum where Cu levels between CuATSM-But 
treated WT and Ctr1+/− mice were no different. In contrast to CuATSM treatment, which 
increased brain Cu levels to supraphysiological levels in all brain regions of both genotypes 
(Table 4.3), CuATSM-But treatment increased brain Cu levels in Ctr1+/− mice to levels similar 
to those in untreated WT mice in all brain regions except the striatum, where Cu levels were 
86% higher than that in the untreated WT mouse (Table 5.3). 
 
Consistent with CuATSM treatment, SN cell number was unchanged by CuATSM-But 
treatment alone in both genotypes (Figure 5.3A; Table 5.4). In WT mice, striatal dopamine 
levels and dopamine turnover were unchanged following CuATSM-But treatment, however 
there was a significant reduction in HVA levels (24% reduction; p = 0.019) (Figure 5.3B-E; 
Table 5.4). Similarly, CuATSM-But did not change striatal dopamine levels or dopamine 
turnover in Ctr1+/− mice, despite significant reductions in DOPAC (65% reduction; p < 0.001) 
and HVA (33% reduction; p = 0.001) (Figure 5.3B-E; Table 5.4).  
 
In summary, CuATSM-But increased Cu levels in all brain regions in Ctr1+/− mice, with some 
additional changes in regional Fe levels and striatal Zn levels. CuATSM-But treatment alone 
did not alter SN cell number, striatal dopamine, or dopamine turnover in animals of either 
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genotype. Interestingly, CuATSM-But increased regional brain Cu levels in Ctr1+/− mice to 
levels similar to those in untreated WT mice, excepting the striatum where Cu levels were 
elevated to similar levels as those in CuATSM-But treated WT mice. 
 
5.3.3 CuATSM-But prevents MPTP associated cell loss in Cu deficient mice 
Similar to when given to untreated animals, CuATSM-But increased Cu levels in all brain 
regions of both mouse genotypes following MPTP lesion (Figure 5.2F-J; Table 5.3). 
However, MPTP diminished the CuATSM-But associated increase in cerebellar Cu levels by 
13% in WT mice (p = 0.035); while further increasing Cu levels in the midbrain of Ctr1+/−  
mice by 25% (p = 0.005), resulting in Cu levels in the midbrain of Ctr1+/− mice being 145% 
greater than that in untreated WT mice. Interestingly, many of the changes observed in Fe and 
Zn levels following CuATSM-But treatment in unlesioned mice were abolished following 
MPTP (Figure 5.2A-E, K-O; Table 5.3). This included an increase in WT Fe levels in the 
cortex (13% increase; non-significant) and hippocampus (28% increase; p = 0.012); a non-
significant increase in Ctr1+/− Fe levels in the cortex (7% increase) and hippocampus (15%); 
and a marked decrease in striatal Fe (27% decrease; p = 0.029) and Zn (23%; p = 0.019) levels 
in Ctr1+/− mice. This resulted in CuATSM-But treated lesioned animals displayed similar 
regional Fe and Zn levels to those in their respective untreated control animals (Table 5.3). 
 
Compared to MPTP treatment alone, SN cell number was ~40% higher in CuATSM-But 
treated MPTP lesioned WT and Ctr1+/− mice (overall p < 0.001) and was similar to that in 
untreated mice in each respective genotype (Figure 5.3A; Table 5.4), suggesting that 
CuATSM-But was protective against MPTP in both genotypes. Interestingly though, the 
depleted levels of striatal dopamine, DOPAC and HVA associated with MPTP lesion was not 
improved by CuATSM-But treatment in either mouse genotype (Figure 5.3B-E; Table 5.4). 
The opposing non-significant reduction (32%) and increase (18%) in the dopamine turnover of 
respective CuATSM-But treated MPTP lesioned WT and Ctr1+/− mice is likely the reason a 
strong trend towards a significant 3-way interaction (p = 0.054) was observed for dopamine 
turnover.  
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Key Points 
• CuATSM-But increased Cu levels in all brain regions and reduced Fe levels in the 
cortex and hippocampus of WT and Ctr1+/− mice 
• CuATSM-But increased brain Cu levels in Cu deficient Ctr1+/− mice to equivalent 
levels as those in WT mice 
• CuATSM-But treatment significantly attenuated MPTP associated cell loss in the SN 
but did not attenuate the reduction in striatal dopamine levels in either WT or Ctr1+/− 
mice 
 
5.4 Discussion 
5.4.1 Comparison of the effects of CuATSM and CuATSM-But on untreated 
WT and Ctr1+/− mice 
Many of the changes in brain Cu levels of unlesioned WT and Ctr1+/− mice observed with 
CuATSM treatment in Chapter 4 were emulated by CuATSM-But treatment in this study, 
although the degree of changes observed in regional brain Cu levels was less marked. This may 
be attributed to the lower lipophilicity of CuATSM-But as the addition of functional groups to 
the R4 terminus of CuATSM (Figure 1.4) has been found to alter the lipophilicity of the 
compound without altering its electrochemical features (Paterson et al., 2010). This suggests 
that while CuATSM-But may exhibit decreased ability to cross the blood brain barrier or cell 
membrane, once inside, the rate of Cu dissociation by endogenous oxidants and/or reductants 
(as discussed in Section 4.4) should be similar. While permeability of CuATSM-But was not 
measured in this study, the current data is consistent with the hypothesised reduced 
permeability of CuATSM-But. To validate this hypothesis however, further experiments are 
needed to determine the rate of CuATSM-But entry into the brain, its clearance from the brain, 
and the rate of Cu dissociation from the ligand compared to CuATSM, possibly through in vivo 
radiotracer experiments (Fujibayashi et al., 1997) and mass spectrometry (Tsednee, Huang, 
Chen, & Yeh, 2016). Nevertheless, in support of hypothesis 3.1, CuATSM-But increased 
regional Cu levels in the Ctr1+/− mouse to levels similar to those in untreated WT mice (with 
the exception of the striatum), while only increasing Cu levels in the various WT brain regions 
by a small degree. The more physiological levels of regional brain Cu levels achieved 
following CuATSM-But treatment may be preferable over the marked elevations of Cu levels 
in both WT and Ctr1+/− mice following CuATSM treatment, as supraphysiological levels of 
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brain Cu may contribute to the potentially hazardous increase in oxidative stress or 
neuroinflammation (as discussed in Section 4.4). 
 
Interestingly, the extent of striatal Cu increase in unlesioned Ctr1+/− mice following CuATSM-
But treatment was markedly greater compared to other brain regions in these animals, and also 
compared to that in unlesioned WT mice. As the striatum exhibits higher mitochondrial activity 
compared to other brain regions (Pickrell, Fukui, Wang, Pinto, & Moraes, 2011), it is possible 
that the low Cu concentrations observed in the striatum of Ctr1+/− mice promotes mitochondrial 
dysfunction through reduced activity of complex 4 (Rossi et al., 2004). This results in elevated 
levels of reactive oxygen and nitrogen species in the striatum of Ctr1+/− mice compared to WT 
mice, that further promotes the dissociation of Cu from CuATSM-But through the same 
oxidative and reductive processes as CuATSM (described in Section 4.4). This does not 
however, explain why the largest increase in Cu levels following CuATSM treatment was 
observed in the midbrain. The difference in lipophilicity may explain the compounds different 
distribution patterns, as addition of polyamines to the R4 position of CuATSM is reported to 
alter the distribution of the compound in the body i.e. increased accumulation in the kidney 
and bladder compared to the liver, and greater accumulation in the brain as determined by 
positron-emission tomography imaging (Paterson et al., 2019). However, further studies will 
be needed to determine the brain distribution patterns of both CuATSM and CuATSM-But, 
possibly by quantifying labile Cu pools through the use synthetic fluorescent indicators 
(Cotruvo, Jr., Aron, Ramos-Torres, & Chang, 2015), or determining the subcellular localisation 
of Cu using synchrotron-based X-ray fluorescence microscopy (Grochowski et al., 2019). 
 
The biological effects of CuATSM on mouse hippocampus was not investigated in Chapter 4 
however, the large increase in Cu levels of other brain regions following treatment raises the 
possibility that CuATSM may also increase Cu levels in the hippocampus. This may have 
negative effect on hippocampal associated functions such as learning and memory (Dhikav & 
Anand, 2012), as memory impairment is a common neurological sign in Wilson’s disease 
patients (Hegde, Sinha, Rao, Taly, & Vasudev, 2010) and high serum Cu levels are correlated 
with low cognitive performance in children (Zhou et al., 2015) and adults (Salustri et al., 2010). 
Indeed, Cu supplementation treatment in male Wister rats (0.15 mg Cu/100 g body weight, 
daily IP injection for 90 days) increased Cu and Zn levels in the hippocampus (73% and 77% 
increase respectively), and was associated with impaired spatial memory and poorer 
neuromuscular coordination (Pal et al., 2013). The effects of CuATSM-But on hippocampal 
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metal levels was therefore investigated in this study to determine if hippocampal Cu 
accumulation occurs in either WT or Ctr1+/− mice. CuATSM-But treatment did not increase 
hippocampal Cu levels in WT mice but did increase hippocampal Cu levels in the Ctr1+/− mouse 
to similar levels as those in untreated WT mice. While this may suggest that CuATSM-But 
treatment would not have an effect on hippocampal function, a study measuring human serum 
Cu levels found it was the increase in free Cu rather than protein bound Cu that correlated with 
mental decline (Salustri et al., 2010). Thus, in addition to determining any functional effects 
on hippocampal associated memory and learning by utilising behavioural tests such as the 
Morris water maze (Pal et al., 2013), it may be appropriate to identify the cellular destination 
of Cu (labile or tightly bound to protein) that is delivered by CuATSM-But in future in vivo 
studies. 
 
Contrary to the lack of effects of CuATSM on regional Fe levels and not supporting hypothesis 
3.1, CuATSM-But treatment was associated with a reduction in cortical and hippocampal Fe 
levels in both mouse genotypes. It is feasible that this may result from the free carboxyl group 
of butyric acid interacting with Fe. This is because the carboxyl sidechain of glutamic acid has 
been found to play a role in sequestering Fe to the inner compartment of ferritin, the primary 
Fe storage protein (Pozzi et al., 2017). Furthermore, addition of a carboxyl group to a ruthenium 
anticancer compound increased its ability to chelate Fe in vitro (Kamatchi et al., 2017). Thus, 
CuATSM-But may have a dual function as a Cu delivery and Fe chelating agent, though why 
this only occurs in the cortex and hippocampus is not known. Striatal Fe levels were markedly 
increased in Ctr1+/−, but not WT, mice following CuATSM-But treatment, and this may be 
related to the sizeable increase in striatal Cu levels observed only in the Ctr1+/− mouse. It is 
possible that while delivering Cu to the Cu deficient striatum, CuATSM-But may sequester Fe 
from brain regions such as the cortex and hippocampus, resulting in the redistribution of Fe. 
As ICP-MS does not differentiate between metal ions that are free or bound to proteins or other 
molecules, the observed increase in striatal Fe in Ctr1+/− mice may represent an increase in 
either bioavailable Fe or Fe sequestered by CuATSM-But. This also suggests that regions 
exhibiting no change in total Fe levels following CuATSM-But treatment may have reduced 
levels of bioavailable Fe. In future work, metal chelation assays could be used to determine the 
Fe chelation ability of both CuATSM-But and the unmetallated ligand (H2ATSM-But), and 
further pharmacokinetic studies are needed to investigate the biodistribution and clearance rate 
of both CuATSM-But and H2ATSM-But. 
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CuATSM-But generally had few effects on brain Zn levels in WT mice, which is in contrast to 
the increase in WT cortical, striatal, and cerebellar Zn levels following CuATSM treatment in 
WT mice. This may be explained by the smaller increases in regional brain Cu levels following 
CuATSM-But which may not be sufficient to upregulate expression of MT-1/-2 as discussed 
in Section 4.4. In contrast, the large increase in Cu levels following CuATSM-But treatment 
in the striatum of Ctr1+/- mice may have stimulated an upregulation of striatal MT-1/-2 
expression in this region, resulting in an increased Zn pool bound to this protein. In future 
work, it would be of interest to quantify levels of metal-binding proteins such as ceruloplasmin 
and MT-1/-2 in both genotypes and following Cu supplementation treatment. 
 
Similar to treatment with CuATSM and in support of hypothesis 3.1, SN cell number and 
striatal dopamine levels were unaffected by CuATSM-But however, there was an unexpected 
decrease in DOPAC and HVA levels in both genotypes. While there are no studies that have 
linked high Fe concentrations with altered dopamine metabolism, there are a number of studies 
that have found reduced striatal Fe concentrations can lead to a reduction in DOPAC and HVA 
levels without altering dopamine levels (Matak et al., 2016; Pino et al., 2017). This may 
indicate that while total Fe levels may be elevated or unchanged in this study, the amount of 
bioavailable Fe may be reduced as a result of Fe being sequestered by the carboxyl functional 
group of CuATSM-But, however the role of Fe in the formation of DOPAC and HVA is 
currently not known.  
 
5.4.2 Validation of the MPTP lesioned Ctr1+/− mouse model 
Slight differences in the baseline measurements for the MPTP lesioned Ctr1+/− mouse were 
observed between this chapter and Chapter 4 however, the overall results are consistent in 
showing knockdown of Ctr1 leads to a reduction in brain Cu levels with minimal effects on 
the nigrostriatal pathway. As expected, MPTP induced marked damage to the nigrostriatal 
pathway but had few effects on brain metal levels. Thus, while CuATSM was not tested 
alongside CuATSM-But in this study, the reproducibility of the MPTP-lesioned Ctr1+/− mouse 
as a model for Cu deficiency and degeneration of the nigrostriatal pathway allows for 
reasonable comparisons to be made between the two compounds. 
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5.4.3 Effects of CuATSM-But in the MPTP lesioned mouse models 
In Section 4.4, it was hypothesised that CuATSM entry into the cell does not change with 
MPTP treatment, but the MPTP associated increase in cellular oxidative stress promoted the 
dissociation of Cu from the ligand resulting in higher amounts of Cu in these degenerating 
brain regions compared to non-degenerating regions. This appears to be accurate in the 
midbrain of Ctr1+/− mice, where the increase in Cu levels by CuATSM-But was enhanced by 
MPTP. Unexpectedly, the amount of Cu increase by CuATSM-But was not further increased 
in the MPTP associated degenerating striatum in Ctr1+/− mice or the degenerating midbrain and 
striatum in WT mice. As the dissociation of Cu from CuATSM is highly dependent on time 
spent inside the cell (Sirois et al., 2018), it is possible that the less lipophilic CuATSM-But has 
limited ability to leave the cell compared to the original compound. Hence, a greater proportion 
of CuATSM-But that enters the cell will lose its Cu under normal cellular conditions due to its 
extended time within the cell. Thus, while the rate of Cu dissociation from CuATSM-But may 
be greater following MPTP lesion, total cellular Cu levels would not differ to that in unlesioned 
mice treated with CuATSM-But as the amount of compound entering the cell would not differ. 
Additionally, Cu levels in the striatum and midbrain of MPTP lesioned Ctr1+/− mice did not 
differ to those in MPTP lesioned WT mice following CuATSM-But treatment. This suggests 
that Cu concentrations achieved by CuATSM-But in degenerating brain regions is not 
dependent on endogenous Cu levels and this may be a desirable trait as Cu levels may differ at 
different stages of PD. 
 
CuATSM-But did not increase Cu levels in the midbrain of lesioned WT mice to the same level 
as CuATSM treatment (51% vs 488% increase from respective baseline levels) however, in 
support of hypothesis 3.2, CuATSM-But was equally as effective in attenuating SN cell loss in 
these animals as CuATSM, with the protected cells likely to be viable as discussed in Section 
4.4. This suggests a modest increase in midbrain Cu levels is sufficient to prevent MPTP 
induced cell loss in the Cu normal brain. It is possible that the recommended dose of 72 mg/day 
CuATSM identified in phase 1 clinical trial (Evans et al., 2017) chosen to achieve patient 
plasma concentrations similar to those achieved by the 30 mg/kg dose shown to be effective in 
rodent studies (Hung et al., 2012), may elevate brain Cu to levels higher than a modest increase. 
However, no data is currently available for brain Cu levels in patients treated with CuATSM 
as Cu levels cannot be quantified in the living mammalian brain for technical reasons. Such 
data is likely important to determine for future therapeutic purposes, as the large increase in 
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Cu levels facilitated by CuATSM treatment in Cu deficient lesioned mice (1243% increase 
from baseline Ctr1+/− levels) failed to prevent the MPTP induced cell loss in the SN, while the 
smaller increase conferred by CuATSM-But treatment in the same model (149% increase from 
baseline Ctr1+/− levels) successfully prevented cell loss. The difference in neuroprotection of 
the two compounds is possibly due to the smaller increase in regional Cu levels conferred by 
CuATSM-But, which lowers the likelihood of Cu interacting with dopamine to generate 
potentially damaging oxidative species (Pham & Waite, 2014). Furthermore, the carboxyl side 
chain of CuATSM-But may have additional protective free radical scavenging abilities, as the 
addition of a carboxyl group to a ruthenium complex increased the compound's ability to 
scavenge free radicals such as  hydroxyl, nitric oxide, and superoxide radicals by donating a 
proton to stabilise the unpaired electrons (Kamatchi et al., 2017). While any potential 
antioxidant abilities of CuATSM-But requires further investigation, these results provide 
evidence that the smaller increase in Cu levels facilitated by CuATSM-But appears to be more 
effective in preventing cell loss in the Cu deficient SN compared to the larger increase produced 
by CuATSM. 
 
While more successful in preventing cell loss in Cu deficient SN than CuATSM, CuATSM-
But was similarly unable to prevent the loss or restore dopamine levels in the striatum, which 
did not support hypothesis 3.2. While it was suggested in Section 4.4 that the high Cu levels 
following CuATSM treatment may react with dopamine to cause sustained depletion of striatal 
dopamine levels, it is an unlikely reason in the current study where Cu levels were raised to 
physiological levels. A possible explanation is the butyric acid functional group of CuATSM-
But may have Fe chelating properties as described above. Fe is needed for the catalytic activity 
of tyrosine hydroxylase, the rate limiting enzyme for catecholamine synthesis (Ramsey, Hillas, 
& Fitzpatrick, 1996) and studies have shown that Fe deficiency reduces striatal dopamine and 
dopamine metabolite levels without altering tyrosine hydroxylase protein expression in vivo 
(Matak et al., 2016; Pino et al., 2017). Furthermore, Fe deficiency was found to prevent 
dopamine reuptake in vivo (Nelson, Erikson, Piñero, & Beard, 1997), further depleting 
intracellular dopamine levels and potentiating the autooxidation of dopamine (Umek, Geršak, 
Vintar, Šoštarič, & Mavri, 2018). Thus, the potential Fe chelating abilities of CuATSM-But 
may be hazardous to striatal dopamine physiology in the mouse models used in this study that 
exhibit normal brain Fe levels. In PD however, Fe levels are typically elevated in the SN 
(Ashraf, Clark, & So, 2018) and trials are currently underway to determine the efficacy of the 
Fe chelator deferiprone in the treatment of PD (ClinicalTrials.gov identifier: NCT02655315). 
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Therefore, the Cu delivery and possible Fe chelation ability of CuATSM-But may be promising 
as a future therapeutic for PD. 
 
5.4.4 Study limitations not discussed elsewhere 
The size of the half striatum has always been a limiting factor in the number of biochemical 
tests that can be performed. In this study, dopamine physiology was prioritised over metal 
concentrations and this was because the high sensitivity of ICP-MS (Bulska & Wagner, 2016) 
provided very small standard deviations in metal levels reported as reported in Chapter 4. As 
such, only a portion of each treatment group was analysed by ICP-MS (see Appendix 2 for 
group sizes) and so while the standard deviation is larger for striatal metal levels compared to 
other brain regions these results are likely accurate as the striatal metal levels reported in this 
study are similar to those reported in Section 4.3. 
 
5.4.5 Conclusion 
The current data demonstrates that addition of butyric acid to CuATSM at the R4 terminal 
amino position diminished the amount of Cu increase in the brain following treatment. This 
may result from the decreased lipophilicity of CuATSM-But that limits its passage through the 
blood brain barrier (Paterson et al., 2010). Regional brain Cu levels were elevated by 
CuATSM-But in Ctr1+/− mice to similar levels to those in untreated WT mice, while only 
marginally increasing Cu levels above physiological levels in the degenerating midbrain and 
striatum. This smaller increase in brain Cu was associated with attenuation of the MPTP 
induced loss of cell in the SN of both normal and Cu deficient mice, although striatal dopamine 
levels remained depleted. While other factors are likely involved that prevented restoration of 
striatal dopamine levels, the protection of SN cells in Ctr1+/− mice following CuATSM-But 
treatment, but not CuATSM treatment, suggests increasing midbrain Cu levels to physiological 
levels is a more effective treatment strategy than raising Cu to supraphysiological levels. This 
study provides preliminary evidence that modification of CuATSM through the addition of a 
functional group represents one approach to control the delivery of Cu to the brain by CuATSM 
and warrants further investigation for its potential use in humans. 
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6  AGE RELATED CHANGES TO 
IRON, COPPER, AND ZINC IONS 
IN THE MOUSE BRAIN 
6.1 Introduction 
CuATSM has been found to be beneficial and well tolerated in short term (20 days) studies in 
mouse models of PD (Chapter 4; Hung et al., 2012) and in phase 1 clinical trials for PD (6 
months) (Evans et al., 2017). Should CuATSM treatment move into clinical practice however, 
it is likely to be prescribed for a much longer-term given the average life expectancy of a PD 
patient following diagnosis is 12.4 years (Deloitte, 2015). Thus, the ~5 fold increase in regional 
brain Cu levels following CuATSM treatment observed in Chapter 4 raises concerns regarding 
the potential long-term use of this compound. As there are currently no technologies available 
to quantify brain Cu levels in the living mammalian brain, including in humans, determining 
the effects of long-term CuATSM treatment on the brain, and also the effects of prolonged 
levels of markedly increased Cu levels on the brain, are most appropriately tested in animal 
models.  
 
The C57Bl/6 mouse is the most commonly used animal in research (Johnson, 2012), and 
studies have shown that metal ion levels in the mouse brain change with age (Portbury et al., 
2017). Thus, to distinguish between Cu accumulation mediated by CuATSM treatment and 
normal age associated accumulation in mice, knowledge regarding the age associated changes 
in regional brain metal levels in healthy C57Bl/6 mice is required. However, current literature 
on the effects of aging on brain metal ion levels in mice are scarce and the data from different 
mouse strains/hybrids is limited to the whole brain (Maynard et al., 2006, 2002) or focused on 
a single metal ion in a specific brain region (Walker et al., 2016; Wang et al., 2010). To address 
this lack of knowledge, the current chapter aimed to quantify total Fe, Cu, and Zn levels in the 
healthy C57Bl/6 mouse brain across a range of ages to evaluate regional differences and age 
associated changes within and between brain regions across the mouse lifespan. Additionally, 
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to further characterise the Ctr1+/− mouse described in this thesis, the effects of Ctr1 knockdown 
on age associated brain metal changes were also investigated. 
 
6.2 Experimental procedures 
6.2.1 Animals 
Male and female C57Bl/6 (n = 53) and Ctr1+/− (n = 55) mice were obtained at a range of ages 
to represent the normal adult lifespan (Table 6.1) and maintained as described in Section 2.1. 
Brain tissue was collected as described in Section 2.3, with whole brains being micro-dissected 
into the large brain regions of the cortex, hippocampus, striatum, midbrain, and cerebellum, 
and stored at −70°C until metal analysis.  
 
Table 6.1 Mouse number at each age 
Age (months) C57Bl/6 Ctr1+/–  
3 5 5 
4 3 5 
5 7 7 
6 6 7 
7 3 3 
8 3 1 
9 7 5 
10 2 5 
11 2 2 
12 4 4 
13 2 2 
14 4 3 
15 1 1 
16 0 1 
18 4 4 
 
 
6.2.2 Measuring brain metal levels 
The candidate prepared and quantified metal levels in the cortex (35 mg), striatum (20 mg), 
hippocampus (25 mg), midbrain (20 mg), and cerebellum (35 mg) from all mice using ICP-MS 
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(Agilent Technologies 7900 ICP-MS, Agilent Technologies, Mulgrave, Australia) as described 
in Section 2.4.  
 
6.2.3 Statistics 
Outliers were identified and removed as described in Section 2.7 and are summarised in 
Appendix 3. A table of mean ± SEM of metal concentrations in all brain regions collected at 
each age can be found in Appendix 4. Linear regression analyses were performed to determine 
if age predicts regional brain Fe, Cu, or Zn levels in C57Bl/6 mice. To identify any interaction 
effect of brain region and age on each metal, a one-way analysis of covariance (ANCOVA) 
was performed. A statistically significant (p < 0.05) interaction between brain region and age 
indicated that age associated change in a specific metal differed between brain regions, while 
a non-significant interaction indicated the rate of change was similar. To quantify the difference 
in a metal’s concentration between brain regions across the C57Bl/6 mouse lifespan, pairwise 
comparisons were made at representative ages for immature (3 months), mature (6 months), 
middle (13 months), and old (17 months) mice as defined by Flurkey, Currer, & Harrison 
(2007). Furthermore, to investigate the effects of Ctr1 gene knockdown on the age associated 
changes in regional metal levels, a one-way ANCOVA was used to determine the interaction 
effect of genotype (C57Bl/6 or Ctr1+/− mice) and age on metal concentrations in each brain 
region. A significant interaction (p < 0.05) indicated that the rate of metal change with age was 
different between the genotypes, while a non-significant interaction indicated the rate of 
change was similar. To identify mouse genotype differences in regional brain metal 
concentrations throughout the animal’s lifetime, pairwise comparisons were made at 
representative ages for immature (3 months), mature (6 months), middle (13 months), and old 
(17 months) mice. The Bonferroni procedure was used to adjust the multiple comparisons in 
both one-way ANCOVA analyses. 
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6.3 Results 
6.3.1 Regional Fe levels through the lifespan of C57Bl/6 mouse 
Linear regression analyses found that age was positively correlated with Fe levels in all brain 
regions of C57Bl/6 mice (overall p < 0.001; Figure 6.1A-E), and a one-way ANCOVA 
identified a significant brain region and age interaction for Fe levels (p = 0.047; Table 6.2). Fe 
concentrations at specific representative ages were estimated from the linear regression 
equations and are reported in Table 6.3, with corresponding pairwise comparisons reported in 
Table 6.4 and visualised in Figure 6.1F. At 3 months, regional Fe levels were relatively 
homogenous in WT mice, with the region of lowest Fe, the midbrain, containing 16% lower 
levels than the region with the highest Fe, the cerebellum (p = 0.024). Cerebellar Fe levels did 
not significantly differ from those in the striatum at any age investigated, indicating an 
equivalent rate of age associated Fe accumulation between these regions. Similarly, while 
cerebellar Fe levels were significantly higher than those in the hippocampus (10%; p = 0.011), 
and midbrain (15%; p < 0.001) by 6 months, these differences remained relatively constant 
with aging. Conversely, Fe levels in the cerebellum were significantly higher than those in the 
cortex at 6 months (15%; p < 0.001) and this difference increased with age (28% at 13 months 
and 33% at 17 months; overall p < 0.001) indicating the age associated accumulation of Fe in 
the cortex is slower than the cerebellum. Indeed, the cortex exhibited a slightly slower rate of 
Fe accumulation compared to most brain regions, with the cortex exhibiting increasingly lower 
Fe levels compared  to the striatum (20% at 13 months and 25% at 17 months; overall p < 
0.001) and hippocampus (15% at 13 months and 19% at 17 months; overall p < 0.05). Overall, 
these results indicate that while modest differences in regional Fe levels are present at all ages, 
the overall rate of Fe accumulation with age is similar between all brain regions except the 
cortex. The general regional distribution of Fe at all ages from highest to lowest levels is 
cerebellum > striatum > hippocampus > midbrain > cortex. 
 
Table 6.2 Summary of one-way ANCOVA to determine the interaction effect of Brain 
region and Age on each metal in C57Bl/6 mice. 
Genotype Metal F-Statistic P-Value 
C57Bl/6 Iron F(4,224) = 2.45 0.047 * 
 Copper F(4,235) = 65.99 <0.001 * 
  Zinc F(4,238) = 2.91 0.022 * 
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Figure 6.1 Age associated changes in regional brain iron levels in C57Bl/6 mice. Linear regression analysis of age associated changes in Fe 
levels in the cortex (A), striatum (B), hippocampus (C), midbrain (D), and cerebellum (E). Additionally, a merged graph of all regional Fe 
regression analysis (F) was generated to visualise the ANCOVA and pairwise comparisons.
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Table 6.3 Estimated regional metal levels in the C57Bl/6 mouse 
    3 months 6 months 13 months 17 months 
Iron  
(µg/g dry 
weight) 
Cortex 61.40 ± 2.29 64.20 ± 1.63 70.73 ± 1.86 74.46 ± 2.87 
Striatum 63.58 ± 2.44 69.93 ± 1.74 84.75 ± 1.92 93.22 ± 2.96 
Hippocampus 63.10 ± 2.29 68.52 ± 1.61 81.17 ± 1.93 88.40 ± 2.99 
Midbrain 59.83 ± 2.27 64.44 ± 1.61 75.19 ± 1.98 81.33 ± 3.04 
Cerebellum 69.56 ± 2.21 75.93 ± 1.56 90.79 ± 1.94 99.29 ± 2.98 
Copper 
(µg/g dry 
weight) 
Cortex 16.85 ± 0.91 16.80 ± 0.64 16.69 ± 0.71 16.62 ± 1.10 
Striatum 23.22 ± 0.90 30.25 ± 0.64 46.63 ± 0.75 56.00 ± 1.15 
Hippocampus 20.15 ± 0.85 20.23 ± 0.60 20.42 ± 0.72 20.52 ± 1.10 
Midbrain 13.44 ± 0.89 14.00 ± 0.63 15.32 ± 0.75 16.08 ± 1.16 
Cerebellum 24.27 ± 0.85 27.23 ± 0.60 34.15 ± 0.72 38.10 ± 1.10 
Zinc 
(µg/g dry 
weight) 
Cortex 77.91 ± 2.35 76.93 ± 1.66 74.65 ± 1.83 73.34 ± 2.85 
Striatum 66.45 ± 2.28 64.77 ± 1.61 60.84 ± 1.92 58.60 ± 2.96 
Hippocampus 90.52 ± 2.18 88.86 ± 1.55 85.00 ± 1.83 82.79 ± 2.82 
Midbrain 47.06 ± 2.31 47.93 ± 1.64 49.98 ± 1.95 51.14 ± 3.00 
Cerebellum 58.95 ± 2.21 60.77 ± 1.59 65.02 ± 1.88 67.44 ± 2.86 
 
The estimated metal concentrations (µg/g of dry tissue) calculated from the linear regression equation in each brain region at representative ages 
for immature (3 months), mature (6 months), middle (13 months), and old (17 months) healthy C57Bl/6 mice and used for pairwise comparisons.  
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Table 6.4 Percent difference of metal levels between brain regions at representative ages in C57Bl/6 mice 
 
 
Summary of pairwise comparisons of a metal between brain regions at respective ages for immature (3 months), mature (6 months), middle (13 months), and 
old (17 months) healthy C57Bl/6 mice reported as percent difference. Green and red shaded values indicate a significant increase and decrease respectively. *p 
< 0.05, **p < 0.005, ***p < 0.001.
3 months 6 months 13 months 17 months 3 months 6 months 13 months 17 months 3 months 6 months 13 months 17 months
Striatum ↓ 4% ↓ 9% ↓ 20% *** ↓ 25% *** ↓ 38% *** ↓ 80% *** ↓ 179% *** ↓ 237% *** ↑ 15% * ↑ 16% *** ↑ 18% *** ↑ 20% **
Hippocampus ↓ 3% ↓ 7% ↓ 15% ** ↓ 19% * ↓ 20% ↓ 20% ** ↓ 22% ** ↓ 23% ↓ 16% ** ↓ 16% *** ↓ 14% ** ↓ 13%
Midbrain ↑ 3% 0% ↓ 6% ↓ 9% ↑ 20% ↑ 17% * ↑ 8% ↑ 3% ↑ 40% *** ↑ 38% *** ↑ 33% *** ↑ 30% ***
Cerebellum ↓ 13% ↓ 18% *** ↓ 28% *** ↓ 33% *** ↓ 44% *** ↓ 62% *** ↓ 105% *** ↓ 129% *** ↑ 24% *** ↑ 21% *** ↑ 13% ** ↑ 8%
Cortex ↑ 3% ↑ 8% ↑ 17% *** ↑ 20% *** ↑ 27% *** ↑ 44% *** ↑ 64% *** ↑ 70% *** ↓ 17% * ↓ 19% *** ↓ 23% *** ↓ 25% **
Hippocampus ↑ 1% ↑ 2% ↑ 4% ↑ 5% ↑ 13% ↑ 33% *** ↑ 56% *** ↑ 63% *** ↓ 36% *** ↓ 37% *** ↓ 40% *** ↓ 41% ***
Midbrain ↑ 6% ↑ 8% ↑ 11% * ↑ 13% ↑ 42% *** ↑ 54% *** ↑ 67% *** ↑ 71% *** ↑ 29% *** ↑ 26% *** ↑ 18% ** ↑ 13%
Cerebellum ↓ 9% ↓ 9% ↓ 7% ↓ 7% ↓ 4% ↑ 10% * ↑ 27% *** ↑ 32% *** ↑ 11% ↑ 6% ↓ 7% ↓ 15%
Cortex ↑ 3% ↑ 6% ↑ 13% ** ↑ 16% * ↑ 16% ↑ 17% ** ↑ 18% ** ↑ 19% ↑ 14% * ↑ 13% *** ↑ 12% ** ↑ 11%
Striatum ↓ 1% ↓ 2% ↓ 4% ↓ 5% ↓ 15% ↓ 50% *** ↓ 128% *** ↓ 173% *** ↑ 27% *** ↑ 27% *** ↑ 28% *** ↑ 29% ***
Midbrain ↑ 5% ↑ 6% ↑ 7% ↑ 8% ↑ 33% *** ↑ 31% *** ↑ 25% *** ↑ 22% ↑ 48% *** ↑ 46% *** ↑ 41% *** ↑ 38% ***
Cerebellum ↓ 10% ↓ 11% * ↓ 12% * ↓ 12% ↓ 20% * ↓ 35% *** ↓ 67% *** ↓ 86% *** ↑ 35% *** ↑ 32% *** ↑ 24% *** ↑ 19% **
Cortex ↓ 3% 0% ↑ 6% ↑ 8% ↓ 25% ↓ 20% * ↓ 9% ↓ 3% ↓ 66% *** ↓ 60% *** ↓ 49% *** ↓ 43% ***
Striatum ↓ 6% ↓ 9% ↓ 13% * ↓ 15% ↓ 73% *** ↓ 116% *** ↓ 204% *** ↓ 248% *** ↓ 41% *** ↓ 35% *** ↓ 22% ** ↓ 15%
Hippocampus ↓ 5% ↓ 6% ↓ 8% ↓ 9% ↓ 50% *** ↓ 44% *** ↓ 33%*** ↓ 28% ↓ 92% *** ↓ 85% *** ↓ 70% *** ↓ 62% ***
Cerebellum ↓ 16% * ↓ 18% *** ↓ 21% *** ↓ 22% *** ↓ 81% *** ↓ 95% *** ↓ 123% *** ↓ 137% *** ↓ 25% ** ↓ 27% *** ↓ 30% *** ↓ 32% **
Cortex ↑ 12% ↑ 15% *** ↑ 22% *** ↑ 25% *** ↑ 31% *** ↑ 38% *** ↑ 51% *** ↑ 56% *** ↓ 32% *** ↓ 27% *** ↓ 15% ** ↓ 9%
Striatum ↑ 9% ↑ 8% ↑ 7% ↑ 6% ↑ 4% ↓ 11% * ↓ 37% *** ↓ 47% *** ↓ 13% ↓ 7% ↑ 6% ↑ 13%
Hippocampus ↑ 9% ↑ 10% * ↑ 11% * ↑ 11% ↑ 17% * ↑ 26% *** ↑ 40% *** ↑ 46% *** ↓ 54% *** ↓ 46% *** ↓ 31% *** ↓ 23% **
Midbrain ↑ 14% * ↑ 15% *** ↑ 17% *** ↑ 18% *** ↑ 45% *** ↑ 49% *** ↑ 55% *** ↑ 58% *** ↑ 20% ↑ 21% *** ↑ 23% *** ↑ 24% **
ZincIron Copper
Cortex
Striatum
Hippocampus
Midbrain
Cerebellum
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6.3.2 Regional Cu levels through the lifespan of C57Bl/6 mouse 
A one-way ANCOVA identified a significant interaction between brain region and age in Cu 
levels (p < 0.001; Table 6.2). This reflects a regional difference in Cu accumulation with age, 
with linear regression analysis identifying Cu levels in the C57Bl/6 mouse striatum (p < 0.001), 
midbrain (p = 0.006), and cerebellum (p < 0.001) being positively correlated with age, while 
cortical and hippocampal Cu levels are not (Figure 6.2A-E). Estimated Cu concentrations from 
the linear regression equations at the representative ages are reported in Table 6.3, with 
corresponding pairwise comparisons reported in Table 6.4 and visualised in Figure 6.2F. At 
3 months of age, Cu levels were markedly different between brain regions, with the regions 
containing the highest Cu levels, the cerebellum and striatum, respectively exhibiting 45% and 
42% more Cu then the region with the lowest Cu levels, the midbrain (overall p < 0.001). The 
striatum exhibited the greatest rate of Cu accumulation with age such that by 6 months, striatal 
Cu levels were statistically greater than all other brain regions and this difference continued to 
increase through to 17 months, where striatal Cu levels were markedly higher than the cortex 
(70%; p < 0.001), hippocampus (63%; p < 0.001), midbrain (71%; p < 0.001), and cerebellum 
(32%; p < 0.001). The cerebellum exhibited the second greatest rate of Cu accumulation with 
age such that cerebellar Cu levels were statistically greater than the cortex, hippocampus, and 
midbrain by 3 months, and continued to increase through to 17 months where cerebellar Cu 
levels were markedly higher than those in the cortex (56%; p < 0.001), hippocampus (46%; p 
< 0.001), and midbrain (58%; p < 0.001). Until middle age, midbrain Cu levels were 
statistically lower than those in all other brain regions however, the modest increase in Cu 
levels with age resulted in midbrain Cu levels reaching similar levels to those in the cortex and 
hippocampus at older ages; although midbrain Cu levels remained well below striatal and 
cerebellar Cu levels. Cortical and hippocampal Cu levels remained constant at all ages. These 
data demonstrate that Cu accumulates only in specific brain regions with age and implicates 
either the importance of Cu in the normal functioning of these regions, or these regions 
sequester excess Cu with age. The general distribution of Cu at all ages from highest to lowest 
levels is striatum > cerebellum > hippocampus > cortex = midbrain. 
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Figure 6.2 Age associated changes in regional brain copper levels in C57Bl/6 mice. Linear regression analysis of age associated changes in Cu 
levels in the cortex (A), striatum (B), hippocampus (C), midbrain (D), and cerebellum (E). Additionally, a merged graph of all regional Cu 
regression analysis (F) was generated to visualise the ANCOVA and pairwise comparisons.
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6.3.3 Regional Zn levels through the lifespan of C57Bl/6 mouse 
Linear regression analysis found no relationship between Zn levels and age in most brain 
regions of the C57Bl/6 mouse except in the cerebellum, where a weak positive correlation was 
observed (p = 0.016; Figure 6.3A-E). This likely underlies the significant interaction between 
brain region and age following a one-way ANCOVA (p = 0.022; Table 6.2). The estimated Zn 
concentrations from the linear regression equations at the representative ages are reported in 
Table 6.3, with corresponding pairwise comparisons reported in Table 6.4 and visualised in 
Figure 6.3F. Zn levels were markedly different between brain regions by 3 months of age, 
with the highest levels observed in the hippocampus, followed by the cortex, striatum, 
cerebellum, and midbrain. The pairwise comparisons confirmed that the difference between 
regional Zn levels remained relatively constant up to 17 months of age for most brain regions, 
with the hippocampus containing greater Zn levels compared to the cortex (~13% higher; 
overall p < 0.05, though no statistical difference was found at 17 months), striatum (~28% 
higher; overall p < 0.001), and midbrain (~43% higher; overall p < 0.001) in all ages 
investigated. However, the difference between Zn levels in the hippocampus and cerebellum 
became smaller with age (35% more at 3 months, and 19% more at 17 months; overall p < 
0.005) due to the modest age associated increase in cerebellar Zn levels. Overall though, these 
data suggest that regional Zn levels do not markedly change with age and the general regional 
distribution of Zn at all ages from highest to lowest levels is hippocampus > cortex > striatum 
= cerebellum > midbrain. 
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Figure 6.3 Age associated changes in regional brain zinc levels in C57Bl/6 mice. Linear regression analysis of age associated changes in Zn 
levels in the cortex (A), striatum (B), hippocampus (C), midbrain (D), and cerebellum (E). Additionally, a merged graph of all regional Zn 
regression analysis (F) was generated to visualise the ANCOVA and pairwise comparisons.
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6.3.4 Effects of Ctr1 expression on regional metal levels with age 1 
A one-way ANCOVA determined a statistically significant interaction effect of genotype and 2 
age on Cu levels in the striatum (p < 0.001), midbrain (p = 0.005), and cerebellum (p < 0.001); 3 
but no interaction effect on Fe or Zn levels in any brain region (Table 6.5). The estimated metal 4 
concentrations from the linear regression equations (found in Appendix 5-7) at the 5 
representative ages for Ctr1+/− mice are reported in Table 6.6 and used for pairwise comparison 6 
with the metal concentrations in C57Bl/6 (Table 6.4), which are summarised in Table 6.7 and 7 
visualised in Figure 6.4. By 3 months, Ctr1+/− mice had statistically lower Cu levels then 8 
C57Bl/6 mice in the cortex (50%; p < 0.001), striatum (54%; p < 0.001), hippocampus (51%; 9 
p < 0.001), midbrain (39%; p < 0.001), and cerebellum (53%; p < 0.001). At all ages, cortical 10 
and hippocampal Cu levels remained constant between C57Bl/6 and Ctr1+/− mice. Conversely, 11 
the difference between C57Bl/6 and Ctr1+/− mice became increasingly larger with age in the 12 
striatum (59% at 6 months to 66% at 17 months; overall p < 0.001), midbrain (42% at 6 months 13 
to 52% at 17 months; overall p < 0.001), and cerebellum (56% at 6 months to 63% at 17 months; 14 
overall p < 0.001), indicating that the rate of Cu accumulation in these regions was greater in 15 
the C57Bl/6 mouse compared to the Ctr1+/− mouse. Pairwise comparison of respective Fe and 16 
Zn levels between the genotypes determined there was less than 2% and 9% difference between 17 
them at all ages in all brain regions. Together, these results indicate that knockdown of Ctr1 18 
results in a ~50% reduction in Cu levels in all brain regions that persists throughout the mouses 19 
lifespan. 20 
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Table 6.5 Summary of one-way ANCOVA to determine the interaction effect of Genotype 
and Age on each metal in various brain regions. 
Metal Brain region F-Statistic P-value 
Iron Cortex F(1,91) = 0.37 0.545 
 Striatum F(1,89) = 1.12 0.293 
 Hippocampus F(1,93) = 0.04 0.849 
 Midbrain F(1,89) = 1.61 0.208 
  Cerebellum F(1,98) = 0.51 0.477 
Copper Cortex F(1,92) = 0.05 0.833 
 Striatum F(1,90) = 59.11 <0.001 * 
 Hippocampus F(1,96) = 0.00 0.950 
 Midbrain F(1,93) = 8.33 0.005 * 
  Cerebellum F(1,101) = 37.97 <0.001 * 
Zinc Cortex F(1,97) = 1.15 0.287 
 Striatum F(1,92) = 0.58 0.448 
 Hippocampus F(1,100) = 0.49 0.487 
 Midbrain F(1,96) = 2.69 0.104 
  Cerebellum F(1,98) = 0.66 0.418 
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Table 6.6 Estimated regional metal levels in the Ctr1+/− mouse 
    3 months 6 months 13 months 17 months 
Iron  
(µg/g dry 
weight) 
Cortex 61.49 ± 2.59 63.77 ± 1.86 69.10 ± 2.21 72.14 ± 3.38 
Striatum 60.33 ± 2.53 68.57 ± 1.80 87.79 ± 2.19 98.78 ± 3.36 
Hippocampus 62.74 ± 2.49 68.45 ± 1.80 81.76 ± 2.16 89.36 ± 3.28 
Midbrain 62.82 ± 2.60 65.64 ± 1.83 72.23 ± 2.35 75.99 ± 3.62 
Cerebellum 73.33 ± 2.46 78.57 ± 1.72 90.79 ± 2.28 97.78 ± 3.52 
Copper 
(µg/g dry 
weight) 
Cortex 8.38 ± 0.35 8.36 ± 0.25 8.33 ± 0.30 8.31 ± 0.45 
Striatum 10.74 ± 0.35 12.54 ± 0.25 16.75 ± 0.30 19.16 ± 0.47 
Hippocampus 9.97 ± 0.33 10.03 ± 0.24 10.17 ± 0.29 10.26 ± 0.44 
Midbrain 8.15 ± 0.34 8.06 ± 0.25 7.87 ± 0.29 7.76 ± 0.44 
Cerebellum 11.51 ± 0.32 12.03 ± 0.23 13.26 ± 0.29 13.96 ± 0.44 
Zinc 
(µg/g dry 
weight) 
Cortex 72.75 ± 2.15 73.06 ± 1.54 73.80 ± 1.79 74.22 ± 2.74 
Striatum 58.79 ± 2.24 58.19 ± 1.59 56.79 ± 1.94 55.99 ± 2.98 
Hippocampus 93.9 ± 2.10 91.21 ± 1.51 84.94 ± 1.79 81.35 ± 2.72 
Midbrain 51.48 ± 2.10 50.19 ± 1.50 47.17 ± 1.80 45.44 ± 2.76 
Cerebellum 58.11 ± 2.10 59.09 ± 1.46 61.38 ± 1.94 62.68 ± 3.00 
 
The estimated metal concentrations (µg/g of dry tissue) calculated from the linear regression equation in each brain region at representative ages 
for immature (3 months), mature (6 months), middle (13 months), and old (17 months) healthy Ctr1+/− mice and used for pairwise comparisons.  
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Figure 6.4 Comparison of age associated changes in regional brain copper levels between wild-type and Ctr1+/− mice. Trend lines showing 2 
the age associated changes in copper levels between wild-type and Ctr1+/− mice in the cortex (A), striatum (B), hippocampus (C), midbrain (D), 3 
and cerebellum (E).  4 
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Table 6.7 Percent difference of metal levels between Ctr1+/− mice and C57Bl/6 mice in 
different brain regions. 
 
Summary of pairwise comparisons of a metal levels between various brain regions of the 
Ctr1+/− mouse and C57Bl/6 mouse at respective ages for immature (3 months), mature (6 
months), middle (13 months), and old (17 months) mice reported as percent differences. Red 
shaded values indicate a significant decrease. ***p < 0.001. 
 
Key points: 
• Modest differences in Fe levels are found between brain regions in the C57Bl/6 mouse 
at all ages, however the regional rate of Fe accumulation with age is similar except in 
the cortex 
• Cu is heterogeneously expressed in the C57Bl/6 mouse brain with only the striatum and 
cerebellum exhibiting a marked change in Cu levels with age  
• Zn distribution is heterogenous in the C57Bl/6 mouse brain but remained constant with 
age 
• Genetic knockdown of Ctr1 results in a lifelong reduction in brain Cu levels that 
appears to alter the age dependent rate of Cu accumulation in the striatum and 
cerebellum 
 
6.4 Discussion 
Aging is the most significant risk factor for a wide range of neurological conditions (Hou et 
al., 2019) and a role for metal dyshomeostasis in these conditions is becoming more apparent 
(Cicero et al., 2017). Novel therapeutics are being developed to target metal dyshomeostasis 
for the treatment of these neurological conditions (Sales et al., 2019; Weekley & He, 2017), 
however without an accurate way to measure brain metal levels in living human patients, these 
compounds must be tested in appropriate animal models. In order to improve our understanding 
3 months 6 months 13 months 17 months
Cortex ↓ 50% *** ↓ 50% *** ↓ 50% *** ↓ 50% ***
Striatum ↓ 54% *** ↓ 59% *** ↓ 64% *** ↓ 66% ***
Hippocampus ↓ 51% *** ↓ 50% *** ↓ 50% *** ↓ 50% ***
Midbrain ↓ 39% *** ↓ 42% *** ↓ 49% *** ↓ 52% ***
Cerebellum ↓ 53% *** ↓ 56% *** ↓ 61% *** ↓ 63% ***
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of the age related changes in metal levels in the mouse brain, this chapter reports the first 
detailed quantitative analysis of Fe, Cu, and Zn in five large regions of the brain across the 
lifespan of the most commonly cited mouse strain, the C57Bl/6 mouse (Johnson, 2012). 
 
Fe is the most abundant transition metal in the brain and is involved in a number of vital 
processes including neurotransmitter synthesis/metabolism, myelin synthesis, mitochondrial 
respiration, and oxygen transport (Ward et al., 2014). The dysregulation of Fe is associated 
with a number neurological conditions including PD, Alzheimer’s disease, multiple sclerosis, 
aceruloplasminemia, and Huntington’s disease (as reviewed in Ashraf, Clark, & So 2018, and 
Ward et al. 2014). Fe levels were found to be similar between the cortex, striatum, 
hippocampus, midbrain, and cerebellum of immature C57Bl/6 mice and this was consistent 
with reports using laser ablation-ICP-MS in 4 month old C57Bl/6 mice (Hare et al., 2012; 
Matusch et al., 2010; Paul et al., 2015). Brain Fe levels in the C57Bl/6 mouse typically increase 
with age, with Hahn et al. (2009) reporting a 33% increase in whole brain Fe levels between 4 
and 16 months using a chromagen-based spectrophotometric method; Portbury et al. (2017) 
reporting a 56% increase in whole brain between 3 and 24 months using LA-ICP-MS; and 
Walker et al. (2016) reporting an 82% and 200% increase in respective striatal and SN levels 
between 2 and 19 months using synchrotron radiation-based X-ray fluorescence. The current 
study is in agreement with these studies but demonstrates that the age associated accumulation 
of Fe occurs in all brain regions of the C57Bl/6 mouse and further demonstrates that the rate 
of Fe accumulation with age is similar between all brain regions, except the cortex, which was 
slower. Thus, Fe levels in the old C57Bl/6 mouse (17 months) were similar between all brain 
regions except the cortex, which exhibited statistically lower levels. This contrasts with the Fe 
levels in equivalently aged humans (aged ~50 years; Flurkey et al. 2007), where Fe levels were 
found to be significantly higher in the SN and putamen compared to other regions including 
the cortex, hippocampus, and cerebellum, where similar levels were observed (Davies et al., 
2013; Ramos et al., 2014b). Furthermore, these human studies determined that Fe levels in all 
brain regions tended to increase with age (between 50 and 90 years of age) and this is consistent 
with the age associated increase in Fe observed in the mice of this study (human equivalent 
ages of 20 to 60 years; Flurkey et al. 2007). Thus, while the regional distribution of Fe is 
different between humans and mice, the age associated accumulation of Fe in all brain regions 
is similar between the species. This indicates there may be a common biological process 
between humans and mice that causes Fe to accumulate in brain regions with age and suggests 
that the C57Bl/6 mouse strain may be an appropriate model to investigate this. 
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Zn is the second most abundant trace element in the brain, where it is a vital structural 
component for ~70% of all brain proteins (including the antioxidant SOD1), and plays an 
important role in regulating synaptic transmission and plasticity that influence cognition and 
memory (Portbury & Adlard, 2017). Dyshomeostasis of brain Zn levels is associated with a 
number of neurological disorders including Alzheimer’s disease, amyotrophic lateral sclerosis, 
depression, schizophrenia, and PD (reviewed in Portbury & Adlard (2017). Zn levels were 
found to be heterogeneously distributed between brain regions in the immature C57Bl/6 mouse 
brain, with the highest levels found in the hippocampus, and the lowest found in the midbrain 
and this was consistent with other studies investigating Zn levels in 4 month old C57Bl/6 mice 
using laser ablation-ICP-MS (Hare et al., 2012; Matusch et al., 2010). The effects of age on 
mouse brain Zn levels is conflicting, with Portbury et al. (2017) reporting a 190% increase in 
total brain Zn levels in C57Bl/6 mice between 3 and 24 months using laser ablation-ICP-MS; 
while other studies using ICP-MS reported no change in total brain Zn levels in either hybrid 
C57Bl6/SJL and C57Bl6/DBA mice between 3 and 18 months (Maynard et al., 2006, 2002), 
or C3H mice between 1 week to 24 months of age (Takahashi et al., 2001). In the current study, 
no marked changes in C57Bl/6 mouse Zn levels were observed between 3 and 17 months of 
age in any brain region except the cerebellum, where a modest increase in Zn levels was 
observed. However, the old mouse brain exhibited a similar distribution of Zn as the immature 
mouse brain, with the highest levels found in the hippocampus, followed by the cortex, 
cerebellum, striatum, and midbrain. This regional pattern of Zn distribution in the mouse brain 
was similar to that observed in equivalently aged (~50 years old) human brains (Ramos et al., 
2014a). In addition, this human study identified a tendency for Zn levels to increase with age 
in the hippocampus, striatum, and midbrain, while cerebellar and cortical Zn levels remained 
unchanged (between 50 and 90 years of age). The subsequent changes in regional Zn levels 
resulted in the distribution of Zn in the 90 year old human brain no longer coinciding with the 
distribution observed in the old C57Bl/6 mice. Thus, the C57Bl/6 mouse may not accurately 
mimic the age associated changes in regional Zn levels observed in the human brain. However, 
the C57Bl/6 mouse may be useful in modelling the Zn distribution in the human brain up to a 
mouse age of 18 months (human equivalent age of ~50 years). 
 
Cu is an essential trace element that, while expressed at lower levels than Fe or Zn in the brain, 
is an important cofactor and structural component for a number of enzymes involved in energy 
production, antioxidant defence, Fe homeostasis, and neurotransmitter synthesis (Scheiber et 
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al., 2014). The dyshomeostasis of Cu is associated with a number of neurological disorders 
including Menkes disease, Wilson’s disease, Alzheimer’s disease, and PD (as reviewed in 
Scheiber et al. (2014)). In this study, Cu concentrations varied between brain regions in the 
C57Bl/6 mouse, with markedly higher Cu levels observed in the striatum and cerebellum, while 
cortical, hippocampal, and midbrain expressed similar but lower Cu levels. These results are 
consistent with the reported similar levels of Cu in the cortex and midbrain observed in 4 month 
old C57Bl/6 mouse using laser ablation-ICP-MS (Hare et al., 2012; Matusch et al., 2010) 
however, contrasting with the current study, these studies both reported that striatal Cu levels 
did not differ to those in other brain regions. The different results for striatal Cu levels between 
the current and previous studies may have resulted from the inclusion of the subventricular 
zone (SVZ) and/or choroid plexus in the dissected whole striatum in this study. These regions 
play an important role in brain Cu homeostasis and have been found to contain high levels of 
Cu (Hare et al., 2012; Matusch et al., 2010; Scheiber et al., 2014). Additionally, Cu has been 
reported to accumulate in astrocyte in the SVZ of 129S1 mice and Sprague-Dawley rats 
between 3 weeks and 9 months of age (Pushkar et al., 2013). Future experiments could avoid 
such potential errors by using a more accurate brain isolation technique, such as micropunch 
dissection; or use laser ablation-ICP-MS, where brain metals are quantified directly on brain 
sections and so provide more accurate data on the regional distribution of metals in the brain.  
 
Whole brain Cu levels in the mouse have previously been reported to increase with age, with 
Massie et al. (1979) reporting a 45% increase in whole brain Cu levels in C57Bl/6 mice 
between 2 and 21 months using atomic absorption spectrometry; Portbury et al. (2017) 
reporting a 99% increase in whole brain Cu levels in C57Bl/6 mice between 3 and 24 months 
using laser ablation-ICP-MS; and Maynard et al. (2006, 2002) reporting a 46% and 34% 
increase in respective whole brain Cu levels between 3 and 18 month old hybrid C57Bl6/SJL 
and C57Bl6/DBA mice using ICP-MS. Another study using laser ablation-ICP-MS in BALB/C 
mice noted that while total brain Cu levels increased with age, striatal and cortical Cu content 
were reduced (Wang et al., 2010), suggesting that age associated changes in Cu levels may 
differ depending on brain region and mouse strain. In the current study, Cu levels in the cortex, 
hippocampus, and midbrain of C57Bl/6 mice were unchanged with age however, both the 
striatum and cerebellum exhibited a positive linear relationship between Cu levels and age, 
resulting in a marked increase in Cu levels between 3 and 17 months of age. It is feasible that 
the age associated increase in whole brain Cu levels reported in the aforementioned studies is 
driven by Cu accumulation in the striatum (or neighbouring regions as discussed above) and 
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cerebellum. The regional distribution of Cu in the old C57Bl/6 mice of this study were different 
to the distribution observed in equivalently aged (~50 years old) human brains, where Cu levels 
were highest in the SN and putamen, while other regions such as the cortex, hippocampus, and 
cerebellum exhibited similar but lower Cu levels (Davies et al., 2013; Ramos et al., 2014a). 
These human studies also identified that regional Cu levels did not markedly change with age 
(between 50 and 90 years of age) and this is similar to the constant levels of Cu observed in 
the cortex, hippocampus, and midbrain of C57Bl/6 mice with age, but contrasts to the marked 
increase observed in the striatum and cerebellum. Thus, the distribution of Cu and subsequent 
changes with age in the mouse brain appears to differ to that observed in the human brain. 
While further studies are needed to confirm these results, the current data suggests that future 
experiments aiming to determine the long-term effects of Cu modifying compounds in the 
C57Bl/6 mouse should take into consideration that Cu may accumulate in the striatum and 
cerebellum with age and not interpret these “normal” changes as effects of the compound. 
 
Low brain levels of Cu have been implicated in the aetiology of PD (Davies et al., 2014), and 
this has led to the development of a number of compounds that aim to restore brain Cu levels 
(Helsel & Franz, 2015). The MPTP lesioned Ctr1+/− mouse characterised in Chapter 4 is the 
first PD mouse model that exhibits concurrent Cu deficiency and degeneration of the 
nigrostriatal pathway and has demonstrated the importance of modelling Cu deficiency in the 
study of therapeutics which are likely to modify this aspect of PD pathophysiology (see 
Chapter 4 and 5). The use of this novel murine model in long-term studies of Cu modifying 
therapies will be valuable to evaluate the efficacy and potential toxicity of these compounds, 
particularly as potential clinical use is likely to be long-term. Another feature of PD reproduced 
by this model is the ~50% reduction in Ctr1 expression in the SN (Davies et al., 2014), however 
the role of Ctr1 in aging has yet to be explored. The current study demonstrated that brain Cu 
levels in Ctr1+/− mice were ~50% lower than those in WT C57Bl/6 mice, while Fe and Zn levels 
did not differ at any age in any brain regions. This provides further evidence that Ctr1 is a 
specific transporter of Cu and its expression is the major determinant of Cu levels in the mouse 
brain. It also suggests that once dysregulation of Ctr1 occurs, such as in PD (Davies et al., 
2014), the brain cannot compensate for the reduction in brain Cu levels, thus restoring 
expression of Ctr1 may be a viable target for future drug development. Furthermore, Ctr1+/− 
mouse exhibited a significantly lower rate of Cu accumulation with age compared to C57Bl/6 
mice in the striatum and cerebellum, suggesting that the expression of Ctr1 is involved in the 
age associated accumulation of Cu in the mouse. 
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This chapter provides a comprehensive report on the regional distribution and age related 
changes of Fe, Cu, and Zn trace elements in the C57Bl/6 mouse and demonstrates that the 
distribution of metals differs between young and old mouse brains. Thus, age should be 
factored into the design and interpretation of future murine studies that aim to investigate or 
manipulate brain metal pathways, particularly in studies that aim to investigate the long-term 
effects of metal modulating compounds. This could provide more accurate data on the efficacy 
of these compounds in animal models such that they may be more accurately translated into 
the human condition. 
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7 FINAL DISCUSSION AND 
CONCLUSIONS 
7.1 Introduction 
Cu is an important biometal that is involved in a range of processes related to brain 
development and maintenance of neuronal function (Lutsenko, Washington-Hughes, Ralle, & 
Schmidt, 2019). The lower Cu content observed in dopaminergic neurons of the PD SN has 
been hypothesised to be a key feature to explain why these cells are selectively lost during the 
disease process (Davies et al., 2014) however, little has been done to investigate this possible 
relationship further. Nevertheless, compounds that aim to increase brain Cu levels are in 
current clinical trials in patients with PD (ClinicalTrials.gov identifier: NCT03204929) in the 
hope that this approach will result in clinical benefits. Early data from this trial has been 
promising (Evans et al., 2017) but such early stage trials are short term and technical limitations 
mean that changes in the central nervous system resulting from treatment are difficult to 
directly quantify. As a result, research into metal delivery approaches have been heavily reliant 
on the use of animal models. However, a limitation of common models of PD is they do not 
model the SN Cu deficiency that may be a potential target for these compounds. To address 
this limitation, this thesis characterises a novel Cu deficient mouse model of PD and 
subsequently tests the effectiveness of Cu delivery compounds in this model. Furthermore, the 
age associated changes in regional brain metal levels in the C57Bl/6 mouse strain is reported 
to act as a reference guide for future mouse-based studies that aim to manipulate regional brain 
metal levels. 
 
7.2 Summary of findings and significance 
The PD SN exhibits a significant reduction in Cu levels that is correlated with expression of 
the Cu transporter Ctr1 (Davies et al., 2014). The Ctr1+/− mouse, which exhibits a reduction in 
brain Cu levels resulting from knockdown of the Ctr1 gene to a similar degree as that observed 
in PD (Lee et al., 2001), can therefore be combined with the dopaminergic neurotoxin MPTP 
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to generate a valid model of PD that exhibits both brain Cu deficiency and degeneration of the 
nigrostriatal pathway. 
 
To ensure that observed differences between Ctr1+/− and WT mice result from genetic 
manipulation rather than differences in MPTP toxicokinetics, Aim 1.1 of this thesis was to 
determine whether knockdown of Ctr1 influenced the metabolism of MPTP. The results of this 
study determined no difference in MPTP metabolism rate between WT and Ctr1+/− mice, hence 
differences observed between the genotypes in subsequent studies are most likely due to the 
effects of Cu deficiency rather than any intrinsic differences in MPTP metabolism that may 
alter lesion size. 
 
Aim 2.1 of this thesis investigated the effects of Ctr1 knockdown on brain metal levels, SN 
cell number, and striatal dopaminergic function. Compared to WT mice, Ctr1+/− mice exhibited 
a ~50% reduction in Cu levels in all brain regions, which is similar to the reduction in Cu levels 
observed in the degenerating brain regions of PD patients (Davies et al., 2014). This reduction 
in nigrostriatal Cu levels was not associated with changes in SN cell number or striatal 
dopamine physiology, suggesting that Cu linked cellular functions, such as the activity of 
cuproproteins, are not altered and a Cu deficiency of this magnitude alone is not sufficient to 
cause neurodegeneration. However, it should be noted that a more severe reduction in brain Cu 
levels as observed in the brindled mutant mouse model of Menkes disease (brain Cu content is 
2-4 fold lower than WT) resulted in the formation of abnormal cells in the cortex, hippocampus, 
and cerebellum that was associated with severe neurological symptoms including tremors, 
ataxia, and seizures (Lenartowicz et al., 2015); while complete knockout of Ctr1 is 
embryonically lethal in mice (Lee et al., 2001), thus demonstrating the essential role of Cu in 
normal development and neurological function in mice. 
 
To model the PD brain at the onset of clinical diagnosis, which is currently the earliest time a 
potential neuroprotective treatment could be commenced, an acute MPTP dosing regimen was 
used to induce significant cell loss in the SN and marked depletion of striatal dopamine levels 
(Jackson-Lewis & Przedborski, 2007). This model was used to investigate Aim 2.2, which was 
to determine whether Ctr1 knockdown would alter the sensitivity of the nigrostriatal pathway 
to MPTP. While Cu deficiency did not exacerbate the toxicity of MPTP, the resulting MPTP 
lesioned Ctr1+/− mouse exhibited both degeneration of the nigrostriatal pathway and, for the 
first time, brain Cu deficiency, which are key features of the same brain regions in PD. Thus, 
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this novel model represents an improvement to the current models of PD to which the efficacy 
of Cu delivery compounds can be tested for the treatment of PD. 
 
CuATSM has recently completed phase 1 trials in PD (Evans et al., 2017) and while CuATSM 
was found to improve motor symptoms and prevent SN cell loss in four different models of PD 
(Hung et al., 2012), the effects of therapeutic doses of CuATSM on regional brain metal levels 
had yet to be quantified in vivo. Thus, Aim 2.3 of this thesis was to quantify regional brain 
metal levels in healthy WT and Ctr1+/− mice following CuATSM treatment. Contrary to the 
reported selective accumulation of CuATSM in regions that exhibit mitochondrial dysfunction, 
such as the degenerating striatum of PD patients (Ikawa et al., 2011), the current study found 
that a 30 mg/kg/day CuATSM treatment over 20 days increased Cu levels in all brain regions 
of unlesioned WT and Ctr1+/− mice ~5 fold and ~4 fold above physiological levels respectively. 
While this increase in Cu levels was not associated with dysregulation of SN cell number or 
striatal dopamine physiology in either mouse strain in this study, similar elevations in brain Cu 
have been reported to promote neuronal inflammation that may become hazardous over time 
(Terwel et al., 2011). While caution must be used when extrapolating rodent-based research 
into potential affects in humans, it is possible that the recommended dose of 72 mg/day 
CuATSM established in phase 1 clinical trial in PD (Evans et al., 2017), chosen to achieve 
patient plasma concentrations similar to those achieved by the 30 mg/kg dose shown to be 
effective in rodent studies (Hung et al., 2012), may cause adverse effects with long-term use. 
Furthermore, while CuATSM treatment did not increase Ctr1+/− Cu content to the same level 
as treated WT mice, the proportional increase in Ctr1+/− mice was greater, suggesting that 
endogenous Cu levels may affect the regional accumulation of CuATSM in the brain and 
highlights the importance of testing Cu compounds in a Cu deficient model. 
 
To investigate the effects of Cu deficiency on the efficacy of CuATSM in MPTP lesioned mice, 
Aim 2.4 of this thesis was to compare brain metal levels, substantia nigra cell number, and 
striatal dopaminergic function between lesioned Ctr1+/− and WT mice treated with CuATSM. 
The resulting data demonstrated that, similar to when given to unlesioned animals, CuATSM 
increased regional Cu levels to supraphysiological levels in all brain regions however, the 
elevation in Cu levels was enhanced in degenerating brain regions such as the midbrain and 
striatum in both mouse strains. While CuATSM treatment was effective in preventing SN cell 
loss in WT mice, it was less effective in attenuating the MPTP associated cell loss in the Cu 
deficient Ctr1+/− mouse. These results suggest that the Cu deficiency in Ctr1+/− mice appears to 
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alter some, as a yet to be defined physiological pathway in this brain region that reduces the 
apparent neuroprotective effects of CuATSM. As the SN in PD exhibits a similar degree of Cu 
deficiency, these findings demonstrate the importance of modelling the dysregulated system 
that a compound is targeting i.e. brain Cu levels and potential Cu associated pathways. 
Interestingly, CuATSM did not promote recovery of striatal dopamine function in either MPTP 
lesioned mouse models, which may indicate that the surviving cells are senescent. However, 
only low doses of MPTP (2 mg/kg) have been found to reduce tyrosine hydroxylase expression 
without causing neuronal loss (Alam, Edler, Burchfield, & Richardson, 2017), while doses 
similar to the one used in this study are well established to cause marked reduction in 
dopaminergic cell number and tyrosine hydroxylase protein (Kolacheva et al., 2014; Kolacheva 
& Ugrumov, 2018) and mRNA (Kozina et al., 2014; Xu et al., 2005) levels. Furthermore, while 
not measured in this study, CuATSM has been found to prevent the loss of tyrosine hydroxylase 
protein and mRNA levels in the SN of MPTP lesioned WT mice (Hung et al., 2012) and this 
may be due to the promoted expression of a number of genes involved in dopamine synthesis 
and general neuronal health (Cheng et al., 2016). Thus, the surviving SN cells following 
CuATSM treatment in MPTP lesioned WT mice are likely to be viable cells that have yet to 
sufficiently recover to produce dopamine, or other undefined mechanisms, such as down-
regulating of tyrosine hydroxylase, are preventing the restoration of dopamine levels in this 
model. It is possible that excess Cu following CuATSM treatment is exported from the striatum 
into the extracellular space, where dopamine levels are elevated due to MPTP promoted release 
(Choi et al., 2015), resulting  in the facilitated autoxidation of dopamine to further deplete 
dopamine levels and elevate cellular oxidative stress (Pham & Waite, 2014). This could 
represent a particularly hazardous relationship, as it suggests that CuATSM could potentially 
reduce the efficacy of levodopa treatment, the gold standard treatment for PD symptoms that 
acts to increase brain dopamine levels. Thus, it is apparent that a number of fundamental 
biological questions regarding the potential therapeutic use of CuATSM in PD have yet to be 
answered which, in the absence of accurate methods to measure brain Cu levels in living 
patients, can only be answered through testing in appropriate animal models. The results from 
this study provide evidence to suggest that endogenous Cu levels alters the efficacy of Cu based 
therapeutics and so validate the testing of such compound in the MPTP lesioned Ctr1+/− mouse, 
which appears to accurately replicate the degenerating Cu deficient SN observed in PD. The 
use of this model in future studies may provide more reliable results regarding the potential 
neuroprotective efficacy of Cu compounds for the treatment of PD and so improve the 
translational pipeline from basic research to clinically approved treatment. 
 111 
 
Aim 3.1 and 3.2 of this thesis was to determine if addition of a butyric acid functional group to 
CuATSM to form the less lipophilic compound CuATSM-But would alter the pharmacological 
properties of the original compound to improve its efficacy as a therapeutic for PD. In this 
study, CuATSM-But increased brain Cu levels by a much smaller extent than CuATSM in 
unlesioned WT mice, suggesting a lower risk for adverse Cu associated effects in healthy brain 
regions using this compound. Furthermore, CuATSM-But treatment increased regional brain 
Cu levels in the Cu deficient Ctr1+/− mouse to similar levels as those in untreated WT mice, 
thus restoring Ctr1+/− Cu levels to normal physiological levels. Contrary to the enhanced 
increase in Cu levels following CuATSM treatment in the degenerating midbrain of both WT 
and Ctr1+/− mice, CuATSM-But did not further increase midbrain Cu levels in lesioned WT 
mice; and only further increased midbrain Cu levels in lesioned Ctr1+/− mice to a similar level 
as CuATSM-But treated lesioned WT mice. This suggests that the maximal Cu concentrations 
achieved by CuATSM-But treatment is independent of endogenous Cu levels and this may be 
a desirable trait as Cu levels may differ at different stages of PD. Furthermore, CuATSM-But 
treatment was associated with attenuation of SN cell loss in both lesioned WT and Ctr1+/− mice, 
indicating that increasing brain Cu levels to physiological levels (or slightly above) prevents 
MPTP mediated cell loss. While not investigated in this study, the butyric acid functional group 
has been found to have free radical scavenging abilities (Kamatchi et al., 2017), hence the 
butyric acid side chain of CuATSM-But may aid in the neuroprotective effects observed. 
Interestingly, while CuATSM-But prevented the MPTP mediated loss of SN cells, it did not 
restore striatal dopamine levels in either mouse strain. While the high Cu levels suggested 
previously is unlikely the reason for sustained depletion of striatal dopamine levels in this 
study, a possible explanation is that the butyric acid functional group may have Fe chelation 
abilities and so reduce bioavailable Fe levels (Kamatchi et al., 2017; Pozzi et al., 2017). This 
could prevent the synthesis and recycling of neuronal dopamine by reducing the catalytic 
activity of tyrosine hydroxylase (Matak et al., 2016; Pino et al., 2017) and preventing dopamine 
reuptake into the neurons (Nelson et al., 1997), resulting in sustained depletion of dopamine. 
Interestingly, while the suggested Fe chelation ability of CuATSM-But may have negative 
effects in this Fe normal mouse model, this trait may be beneficial in PD where Fe levels are 
elevated in the SN (Ashraf et al., 2018). In fact, trials are currently underway to determine the 
efficacy of the Fe chelator deferiprone in the treatment of PD (ClinicalTrials.gov identifier: 
NCT02655315). Together, these data suggest that modification of CuATSM through the 
addition of various functional groups, such as butyric acid, may allow diversification of 
 112 
CuATSM function beyond purely increasing brain Cu levels. An alternative route to this, is to 
add functional groups that increase the specificity of CuATSM to a particular tissue as 
demonstrated in imaging studies that added benzothiazole and styrylpyridine to CuATSM for 
targeted binding to Ab plaques in Alzheimer’s disease (Hickey et al., 2013). This may be a 
promising next step in the development of CuATSM as a therapeutic for PD as the Cu 
deficiency observed in this condition is restricted to degenerating brain regions. 
 
Given the current absence of methods to quantify brain metal content in living human patients, 
researchers are reliant on animal models, where postmortem analysis are possible at designated 
timepoints following treatment, to determine the effects of metal modifying compounds. This 
is especially important for determining the long-term effects and potential adverse effects of 
metal compounds that may be taken by patients for several years. To ensure that the effects of 
a metal modulating compound on regional brain metal levels in a mouse model are not 
confounded by natural age associated changes, it is important to determine what “normal” 
levels of regional brain metal levels are throughout the mouse lifespan. However, current 
literature on the effects of age on brain metal levels in various mouse strains are limited to 
either the whole brain or to select brain regions. Thus, Aim 4.1 of this thesis was to quantify 
Fe, Cu, and Zn levels in the large brain regions of the cortex, striatum, hippocampus, midbrain, 
and cerebellum from infancy to old age in the C57Bl/6 mouse, the most commonly cited animal 
in research (Johnson, 2012). It was demonstrated that Fe levels are relatively homogenous 
across the investigated brain regions in young adult animals, and all regions exhibit a similar 
rate of increased Fe concentrations with age. In contrast, Cu levels were heterogeneously 
distributed in young adult animals and only the striatum and cerebellum exhibited marked 
accumulation of Cu with age. Zn levels were heterogenous between the investigated brain 
regions in young adult animals, and in contrast to Fe and Cu, Zn levels remained constant with 
age. Additionally, this study also reports for the first time the effects of aging on brain metal 
levels in the Ctr1+/− mouse (Aim 4.2), demonstrating that knockdown of Ctr1 is associated with 
a lifelong reduction in Cu levels in all brain regions and a decreased rate of Cu accumulation 
with age in the striatum and cerebellum. These results provide further evidence that metal 
levels in the brain are different between young and old mice and demonstrates the importance 
of considering age as a factor in the design and interpretation of any mouse based studies that 
aim to investigate the contribution of metals in basic disease pathology or efficacy of metal 
modulating compounds. The data reported represents a valuable resource that can be used as a 
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reference guide for future metal-based research to help reduce the variability between 
studies/labs and thus improve the validity of results. 
 
7.3 Limitations and future directions 
While this study is the first to successfully model a Ctr1 mediated Cu deficiency similar to 
what is observed in human PD, the global Cu deficiency observed in this model does not 
replicate the specific regional Cu deficiency observed in PD (Davies et al., 2014). Furthermore, 
Ctr1+/−  mice appear to exhibit a Cu deficiency from birth (Lee et al., 2001), while it is presumed 
that PD patients do not exhibit a Cu deficiency until later in life (Davies et al., 2014; Dexter et 
al., 1991). It is possible then, that Ctr1+/− mouse developed pathways to compensate for their 
Cu deficiency and so may not be representative of the surviving dopaminergic neurons in PD. 
A more accurate model of PD associated changes in Cu would involve generation of a model 
where the Cu deficiency is restricted to the nigrostriatal pathway and is induced during 
adulthood. However, the development of such a model would only be appropriate after 
determining the importance of Cu in the vulnerability of the nigrostriatal pathway in PD.  
 
In Chapter 4, it was suggested that the nigrostriatal pathway in Ctr1+/− mice was equally 
sensitive to the toxic effects of MPTP as WT mice, as SN cell number and striatal dopamine 
levels were no different between the two genotypes, and this was not due to a difference in 
MPTP toxicokinetics (see Chapter 3). Given that this experiment used only one dose of MPTP, 
an experiment using different doses of MPTP (but lower than the one used in this study) to 
compare the rate of dopaminergic neuronal loss between Cu normal and Cu deficient cell 
culture and/or animal models would provide more robust data to test this conclusion. Such an 
experiment might also provide insight into the potential effects of a regional Cu deficiency on 
nigrostriatal vulnerability. Should Cu deficiency in the nigrostriatal pathway be strongly 
associated with neuronal vulnerability and death, this feature may suggest Cu deficiency as an 
early marker of the development and/or progression of PD and support the development of 
brain Cu imaging techniques in living patients.  
 
A common criticism of the acute MPTP regimen used in Chapter 4 and 5 is that this regimen 
induces too rapid a degeneration of the nigrostriatal pathway that may not allow the surviving 
neurons to express the same adaptive mechanisms that would otherwise develop following a 
slower and more progressive degenerative insult as seen in PD. As such, assessment of the 
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potential neuroprotective effects of CuATSM may be better tested in models such as the 
chronic MPTP plus probenecid mouse model, which more accurately replicates the progressive 
degeneration of the nigrostriatal pathway and motor deficits of PD (Meredith, Totterdell, 
Potashkin, & Surmeier, 2008). However, the increased handling of the toxin, and an extended 
period of its presence in animals, drastically increases the risk of misadventure for researchers. 
These concerns as well as higher maintenance costs required for specialised holding areas and 
need for a larger quantity of toxin may not be warranted to obtain preliminary data on the 
efficacy of therapeutic compounds, as is the case for this study, where CuATSM and CuATSM-
But are tested for the first time in a Cu deficient animal. Alternatively, future studies could also 
cross the Ctr1+/− mouse with existing genetic mouse models of PD, including those with 
mutations in  a-synuclein, Parkin, PINK1, or DJ-1 (Jagmag, Tripathi, Shukla, Maiti, & 
Khurana, 2016), to investigate whether these combined mutations would lead to a more natural 
development PD physiology, symptoms, or progression. Such models may also be useful to 
determine if compounds such as CuATSM have disease modifying effects. 
 
For the investigations of brain metal levels using ICP-MS throughout this thesis, the method 
for brain region isolation described in Section 2.4 may have resulted in isolated brain regions 
containing small amounts of their neighbouring regions. This may have influenced the results 
obtained from ICP-MS, the most affected region being the striatum, which may contain the 
choroid plexus or subventricular zone (as discussed in Section 6.4). The use of micropunch 
dissection technique for individual brain regions may reduce the incorporation of tissue outside 
the region of interest, however this may also further reduce collected tissue size, which as 
discussed in Section 5.4, may limit the number of biological tests that can be performed on the 
tissue. A potential solution is the use of laser ablation-ICP-MS where brain metal levels are 
quantified directly on brain sections and so provide more accurate data on the regional 
distribution of metals in the brain. However, inconsistencies with calibration standards and 
signal normalisation parameters make it difficult to validate the quantitative results from this 
technique (Pozebon, Scheffler, Dressler, & Nunes, 2014). Nevertheless, the results from this 
study indicate that both knockdown of Ctr1 and the Cu compounds used predominantly alter 
Cu levels in the mouse brain, thus future investigations will require more sophisticated 
techniques to determine the intracellular Cu handling and cellular destination of exogenous Cu. 
This could be achieved by quantifying labile Cu pools through the use synthetic fluorescent 
indicators (Cotruvo et al., 2015); determining subcellular localisation of Cu using synchrotron-
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based X-ray fluorescence microscopy (Grochowski et al., 2019); and determining the status of 
cellular cuproprotein physiology including protein expression (western blots), enzymatic 
activity (various activity assays), and metalation status (size exclusion chromatography 
coupled with ICP-MS (Luo, Ronk, Joubert, Semin, & Nashed-Samuel, 2019), or other mass 
spectrometry methods (Irvine & Stillman, 2017)). 
 
Results presented in Section 4.3 suggest that CuATSM is not neuroprotective in the MPTP 
lesioned Ctr1+/− mouse, and this was hypothesised to be because of a greater proportional 
increase in midbrain Cu levels that enhanced levels of cellular oxidative stress. To investigate 
this hypothesis, quantitative measurements of reactive species in CuATSM treated MPTP 
lesioned Ctr1+/− and WT mice are needed. This could be achieved through indirect 
measurements of the by-products of lipids, proteins, or nucleic acids oxidation; or directly by 
spectrofluorimetry and flow cytometry (various techniques are reviewed extensively in Rani, 
Asthana, Vadhera, Yadav, & Atale, (2015)). Additionally, it was suggested that elevated Cu 
levels could induce neuronal inflammation that may facilitate the degeneration of the 
nigrostriatal pathway over time. Thus, it would be beneficial to investigate the changes in 
inflammatory markers following CuATSM treatment through immunohistochemistry or 
measurements of various cytokines (targets reviewed in Sochocka, Diniz, & Leszek, (2017). 
Positive data from this experiment may warrant monitoring of inflammatory markers in future 
CuATSM clinical trials in PD through various biomarkers and imaging techniques (as reviewed 
in Stephenson, Nutma, van der Valk, & Amor, (2018)). As the duration of any future treatment 
in PD patients is likely to last several years, a significant limitation of the available data 
regarding the effects of CuATSM as a potential therapeutic for PD is that no studies have 
investigated the long-term effects of CuATSM in vivo. A long-term study in a Cu deficient 
animal model of PD using the recommended dose of CuATSM as determined in phase 1 
clinical trial (Evans et al., 2017) would provide invaluable information regarding the potential 
adverse effects of prolonged use of CuATSM including whether treatment results in 
progressive increase in brain Cu levels; and whether prolonged elevations in brain Cu levels 
promotes oxidative or inflammatory stress that contributes to neurodegeneration. The results 
from such an experiment could potentially improve the design of future CuATSM clinical trials 
by allowing researcher to prepare and implement appropriate monitoring and interventions if 
required. Additionally, as high Cu levels have been found to deplete striatal dopamine levels 
in vivo (Yu et al., 2008), it is imperative to investigate whether CuATSM treatment may modify 
the efficacy of levodopa co-treatment for symptom management. 
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The neuroprotective effects of CuATSM-But in MPTP lesioned Ctr1+/− mice was hypothesised 
to be due to the smaller extent of Cu increase in the brain compared to the same dose of 
CuATSM (see section 5.4). To confirm that the extent of Cu increase is the determining factor 
for this apparent neuroprotective effect in MPTP lesioned Ctr1+/− mice, a dose titration 
experiment for CuATSM should be performed in both in vitro and in vivo models of Cu 
deficiency, and this will aid in determining a recommended dose of CuATSM for use in future 
clinical trials. Furthermore, it was suggested that the carboxylic acid functional group of 
CuATSM-But may have contributed to the protection of SN cells by acting as an antioxidant, 
while exacerbating the depletion of striatal dopamine by chelating Fe in the MPTP lesioned 
Ctr1+/− mouse. These functions would need to be confirmed through various antioxidant and 
metal chelation assays (methods reviewed in Shahidi & Zhong, (2015)). However, if the results 
from these experiments demonstrate that CuATSM-But does have antioxidant and Fe chelation 
abilities, then this would warrant further investigation of CuATSM-But as a therapeutic in PD 
as, in addition to exhibiting Cu deficiency, the PD SN also exhibits Fe accumulation in the 
nigrostriatal pathway and elevated levels of oxidative stress (Ashraf et al., 2018). 
 
A potential limitation of the results in Chapter 4 are the small and varied sample sizes in each 
treatment group as a result of unexpected deaths during MPTP lesioning and data points 
identified as statistical outliers that were removed prior to analysis. However, post hoc power 
analysis using G*power program (Faul et al., 2007) revealed large effect sizes between 
respective treatment groups compared to untreated WT mice such that these experiments were 
strongly powered to detect differences i.e. 89% power (a = 0.05, Cohen’s d = 1.58) for 
midbrain Cu levels between untreated WT (n = 10) and untreated Ctr1+/− (n = 6) mice; 97% 
power  (a = 0.05, Cohen’s d = 1.98) for striatal dopamine levels between untreated WT (n = 
7) and MPTP WT (n = 7) mice; and 87% power  (a = 0.05, Cohen’s d = 1.82) for SN cell 
number between untreated WT (n = 5) and MPTP WT (n = 6) mice. This suggests that despite 
the small group sizes, the data reported in Chapter 4 is robust. These results were subsequently 
used to plan the experimental group sizes in Chapter 5. 
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7.4 Conclusions 
This thesis characterised for the first time a novel MPTP lesioned Ctr1+/− mouse model that 
exhibits a Ctr1 associated decrease in midbrain Cu levels and degeneration of the nigrostriatal 
pathway. This model can be used to more accurately test the efficacy of Cu delivery compounds 
in the treatment of PD, and may be useful in investigating the potential role of Cu deficiency 
on nigrostriatal vulnerability in the development/progression of PD. This thesis also provides 
the first evidence that CuATSM does not selectively increase Cu levels in degenerating brain 
regions rather, CuATSM increases Cu to supraphysiological levels in all brain regions and this 
increase is enhanced in regions that exhibit degeneration. Furthermore, the action of CuATSM 
appears to be affected by Cu deficiency as the relative increase in Cu was greater in Ctr1+/− 
mice compared to WT mice however, too large a fold increase in Cu levels appears to diminish 
the neuroprotective effects of CuATSM in the Cu deficient Ctr1+/− mouse. Alternatively, the 
restoration of Cu to physiological levels following CuATSM-But treatment was found to be 
neuroprotective in Ctr1+/− mice, suggesting this strategy to be more effective than raising Cu to 
supraphysiological levels. However further studies are needed to confirm this. Finally, to 
further our understanding of aging on mouse brain metallobiology, this thesis reports the metal 
levels of several large brain regions in the frequently cited C57Bl/6 mouse model at various 
stages of maturation. Ultimately, this work provides data to aid in the design and interpretation 
of future metal related murine studies in the hopes of improving the validity and reliability of 
basic research in mouse models of PD for better translation into the human condition. 
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APPENDICES 
Appendix 1 Treatment group sizes after removal of outliers for Chapter 4 
 
 
Boxplots were used to identify values greater than 1.5 standard deviations from the edge of 
the box for each treatment group. These values were considered outliers and removed from 
the data set prior to final analysis. The final groups sizes for each treatment group analysed in 
Chapter 4 are presented, with the number of outliers removed in parenthesis. Abbreviations: 
Ctr1+/−: Ctr1 heterozygous; CuATSM: Cu2+ bis(thiosemicarbazone) complex; DOPAC: 3,4-
Dihydroxyphenylacetic acid; HVA: Homovanillic acid; MPTP: 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; SN: Substantia nigra pars compacta; WT: Wild-type. 
Variable Brain region WT Ctr1+/− WT Ctr1+/− WT Ctr1+/− WT Ctr1+/−
Cortex 9 (1) 10 (0) 10 (0) 8 (1) 10 (0) 10 (0) 10 (2) 11 (2)
Striatum 10 (0) 10 (0) 9 (1) 9 (0) 9 (1) 10 (0) 12 (0) 13 (0)
Midbrain 10 (0) 9 (1) 10 (0) 8 (1) 9 (1) 5 (5) 11 (1) 12 (1)
Cerebellum 10 (0) 10 (0) 10 (0) 9 (0) 9 (1) 9 (1) 11 (1) 13 (0)
Cortex 9 (1) 10 (0) 9 (1) 8 (1) 8 (2) 7 (3) 11 (1) 12 (1)
Striatum 8 (2) 9 (1) 8 (2) 7 (2) 8 (2) 8 (2) 11 (1) 12 (1)
Midbrain 10 (0) 6 (4) 9 (1) 4 (5) 7 (3) 5 (5) 9 (3) 11 (2)
Cerebellum 10 (0) 10 (0) 8 (2) 6 (3) 8 (2) 8 (2) 11 (1) 13 (0)
Cortex 8 (2) 10 (0) 8 (2) 9 (0) 10 (0) 10 (0) 12 (0) 9 (4)
Striatum 10 (0) 10 (0) 10 (0) 8 (1) 9 (1) 7 (3) 11 (1) 13 (0)
Midbrain 9 (1) 10 (0) 8 (2) 8 (1) 9 (1) 8 (2) 11 (1) 11 (2)
Cerebellum 9 (1) 10 (0) 8 (2) 9 (0) 9 (1) 10 (0) 11 (1) 12 (1)
Dopamine Striatum 7 (1) 9 (0) 7 (0) 7 (1) 8 (1) 10 (0) 10 (0) 9 (0)
DOPAC 7 (1) 8 (1) 6 (1) 6 (2) 6 (3) 9 (1) 9 (1) 9 (0)
HVA 6 (2) 9 (0) 7 (0) 7 (1) 8 (1) 10 (0) 10 (0) 8 (1)
Dopamine 
Turnover 5 (3) 8 (1) 5 (2) 4 (4) 7 (2) 9 (1) 7 (3) 8 (1)
Estimated 
Cell Count SN 5 (0) 5 (0) 6 (0) 5 (0) 2 (0) 2 (0) 5 (0) 5 (0)
Zinc
Untreated MPTP CuATSM MPTP+CuATSM
Iron
Copper
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Appendix 2 Treatment group sizes after removal of outliers for Chapter 5 
 
 
Boxplots were used to identify values greater than 1.5 standard deviations from the edge of the 
box for each treatment group. These values were considered outliers and removed from the 
data set prior to final analysis. The final groups sizes for each treatment group analysed in 
Chapter 5 are presented, with the number of outliers removed in parenthesis. Abbreviations: 
Ctr1+/−: Ctr1 heterozygous; CuATSM-But: Cu2+ bis(thiosemicarbazone)-4’-butyric acid 
complex; DOPAC: 3,4-Dihydroxyphenylacetic acid; HVA: Homovanillic acid; MPTP: 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SN: Substantia nigra pars compacta; WT: Wild-
type. 
Variable Brain region WT Ctr1+/− WT Ctr1+/− WT Ctr1+/− WT Ctr1+/−
Cortex 13 (0) 10 (1) 7 (2) 9 (3) 10 (2) 12 (2) 7 (4) 10 (2)
Striatum 4 (0) 3 (0) 3 (0) 6 (0) 5 (0) 5 (0) 3 (0) 3 (3)
Hippocampus 13 (0) 10 (1) 8 (1) 10 (2) 12 (0) 13 (1) 10 (1) 11 (1)
Midbrain 12 (1) 9 (2) 9 (0) 12 (0) 12 (0) 11 (3) 11 (0) 11 (1)
Cerebellum 8 (5) 9 (2) 9 (0) 11 (1) 11 (1) 10 (4) 11 (0) 11 (1)
Cortex 12 (1) 10 (1) 8 (1) 10 (2) 8 (4) 11 (3) 11 (0) 7 (5)
Striatum 4 (0) 3 (0) 3 (0) 6 (0) 4 (1) 4 (1) 3 (0) 6 (0)
Hippocampus 10 (3) 10 (1) 8 (1) 9 (3) 12 (0) 12 (2) 11 (0) 11 (1)
Midbrain 9 (4) 8 (3) 9 (0) 9 (3) 12 (0) 9 (5) 8 (3) 12 (0)
Cerebellum 10 (3) 8 (3) 9 (0) 12 (0) 11 (1) 11 (3) 11 (0) 9 (3)
Cortex 13 (0) 8 (3) 8 (1) 10 (2) 10 (2) 12 (2) 10 (1) 10 (2)
Striatum 4 (0) 3 (0) 3 (0) 6 (0) 4 (1) 5 (0) 3 (0) 5 (1)
Hippocampus 13 (0) 10 (1) 8 (1) 9 (3) 12 (0) 12 (2) 11 (0) 11 (1)
Midbrain 12 (1) 11 (0) 9 (0) 11 (1) 10 (2) 12 (2) 8 (3) 12 (0)
Cerebellum 11 (2) 9 (2) 9 (0) 9 (3) 11 (1) 13 (1) 11 (0) 11 (1)
Dopamine Striatum 10 (3) 7 (4) 7 (2) 12 (0) 9 (3) 12 (2) 11 (0) 12 (0)
DOPAC 12 (1) 10 (1) 7 (2) 12 (0) 12 (0) 9 (5) 11 (0) 11 (1)
HVA 12 (1) 10 (1) 6 (3) 12 (0) 12 (0) 11 (3) 10 (1) 11 (1)
Dopamine 
Turnover 10 (3) 7 (4) 6 (3) 10 (2) 9 (3) 10 (4) 10 (1) 11 (1)
Estimated 
Cell Count SN 5 (0) 5 (0) 5 (0) 5 (0) 2 (0) 2 (0) 5 (0) 5 (0)
Zinc
Untreated MPTP CuATSM-But MPTP+CuATSM-But
Iron
Copper
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Age (months) Iron Copper Zinc Iron Copper Zinc
Cortex 3 3 (2) 3 (2) 3 (2) 4 (1) 4 (1) 4 (1)
4 3 (0) 3 (0) 3 (0) 4 (1) 4 (1) 5 (0)
5 7 (0) 6 (1) 6 (1) 6 (1) 6 (1) 6 (1)
6 6 (0) 6 (0) 6 (0) 6 (1) 6 (1) 6 (1)
7 3 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
8 2 (1) 3 (0) 3 (0) 1 (0) 1 (0) 1 (0)
9 7 (0) 6 (1) 7 (0) 5 (0) 5 (0) 5 (0)
10 2 (0) 2 (0) 2 (0) 5 (0) 5 (0) 5 (0)
11 1 (1) 2 (0) 2 (0) 1 (1) 1 (1) 2 (0)
12 3 (1) 4 (0) 4 (0) 3 (1) 3 (1) 4 (0)
13 2 (0) 2 (0) 2 (0) 1 (1) 1 (1) 1 (1)
14 4 (0) 4 (0) 4 (0) 2 (1) 2 (1) 3 (0)
15 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0)
16 1 (0) 1 (0) 1 (0)
17
18 4 (0) 4 (0) 4 (0) 4 (0) 4 (0) 4 (0)
Striatum 3 4 (1) 5 (0) 5 (0) 4 (1) 4 (1) 4 (1)
4 2 (1) 2 (1) 2 (1) 5 (0) 4 (1) 5 (0)
5 5 (2) 5 (2) 6 (1) 7 (0) 7 (0) 6 (1)
6 5 (1) 6 (0) 6 (0) 6 (1) 5 (2) 5 (2)
7 2 (1) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
8 2 (1) 3 (0) 3 (0) 0 (1) 0 (1) 0 (1)
9 6 (1) 6 (1) 7 (0) 5 (0) 5 (0) 5 (0)
10 2 (0) 1 (1) 2 (0) 4 (1) 5 (0) 4 (1)
11 2 (0) 2 (0) 2 (0) 2 (0) 2 (0) 2 (0)
12 4 (0) 4 (0) 4 (0) 4 (0) 4 (0) 4 (0)
13 2 (0) 2 (0) 2 (0) 2 (0) 2 (0) 2 (0)
14 1 (2) 1 (2) 1 (2) 3 (0) 3 (0) 3 (0)
15 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0)
16 1 (0) 0 (1) 0 (1)
17
18 4 (0) 4 (0) 4 (0) 3 (1) 3 (1) 3 (1)
Hippocampus 3 5 (0) 5 (0) 5 (0) 5 (0) 5 (0) 5 (0)
4 3 (0) 3 (0) 3 (0) 4 (1) 5 (0) 5 (0)
5 5 (2) 7 (0) 7 (0) 7 (0) 7 (0) 7 (0)
6 5 (1) 6 (0) 6 (0) 6 (1) 6 (1) 5 (2)
7 3 (0) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
8 3 (0) 3 (0) 3 (0) 1 (0) 1 (0) 1 (0)
9 7 (0) 6 (1) 7 (0) 4 (1) 4 (1) 4 (1)
10 2 (0) 2 (0) 2 (0) 4 (1) 4 (1) 5 (0)
11 2 (0) 2 (0) 2 (0) 2 (0) 2 (0) 2 (0)
12 3 (1) 3 (1) 4 (0) 3 (1) 3 (1) 3 (1)
13 2 (0) 2 (0) 2 (0) 1 (1) 1 (1) 2 (0)
14 4 (0) 4 (0) 4 (0) 3 (0) 3 (0) 3 (0)
15 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0)
16 1 (0) 1 (0) 1 (0)
17
18 3 (1) 4 (0) 4 (0) 4 (0) 4 (0) 4 (0)
Midbrain 3 5 (0) 5 (0) 5 (0) 3 (2) 4 (1) 4 (1)
4 3 (0) 3 (0) 3 (0) 5 (0) 3 (2) 5 (0)
5 6 (1) 5 (2) 6 (1) 7 (0) 7 (0) 7 (0)
6 6 (0) 6 (0) 5 (1) 7 (0) 7 (0) 7 (0)
7 1 (2) 3 (0) 2 (1) 2 (1) 3 (0) 3 (0)
8 3 (0) 3 (0) 3 (0) 1 (0) 1 (0) 1 (0)
9 5 (2) 5 (2) 5 (2) 4 (1) 4 (1) 5 (0)
10 2 (0) 2 (0) 2 (0) 5 (0) 5 (0) 5 (0)
11 2 (0) 2 (0) 2 (0) 2 (0) 2 (0) 2 (0)
12 4 (0) 4 (0) 4 (0) 3 (1) 4 (0) 4 (0)
13 2 (0) 2 (0) 2 (0) 2 (0) 1 (1) 2 (0)
14 3 (1) 4 (0) 4 (0) 2 (0) 2 (0) 2 (0)
15 1 (0) 1 (0) 1 (0) 0 (1) 1 (0) 1 (0)
16 1 (0) 1 (0) 1 (0)
17
18 3 (1) 3 (1) 3 (1) 3 (1) 4 (0) 4 (0)
Cerebellum 3 5 (0) 5 (0) 5 (0) 5 (0) 5 (0) 5 (0)
4 3 (0) 3 (0) 3 (0) 5 (0) 5 (0) 5 (0)
5 7 (0) 7 (0) 7 (0) 7 (0) 7 (0) 7 (0)
6 6 (0) 6 (0) 6 (0) 7 (0) 7 (0) 7 (0)
7 2 (1) 3 (0) 3 (0) 3 (0) 3 (0) 3 (0)
8 2 (1) 2 (1) 1 (2) 1 (0) 1 (0) 1 (0)
9 7 (0) 7 (0) 6 (1) 5 (0) 5 (0) 5 (0)
10 2 (0) 2 (0) 2 (0) 5 (0) 5 (0) 5 (0)
11 2 (0) 2 (0) 2 (0) 2 (0) 2 (0) 2 (0)
12 3 (1) 3 (1) 3 (1) 4 (0) 4 (0) 4 (0)
13 2 (0) 2 (0) 2 (0) 2 (0) 2 (0) 2 (0)
14 4 (0) 4 (0) 4 (0) 3 (0) 3 (0) 3 (0)
15 1 (0) 1 (0) 1 (0) 1 (0) 1 (0) 1 (0)
16 1 (0) 1 (0) 1 (0)
17
18 3 (1) 4 (0) 4 (0) 2 (2) 3 (1) 2 (2)
C57Bl/6 Ctr1+/−
  
Appendix 3 Mouse number at each age after removal of outliers for Chapter 6 
Boxplots were used to identify values 
greater than 1.5 standard deviations from 
the edge of the box in each age. These 
values were considered outliers and 
removed from the data set prior to final 
analysis. The final groups sizes for each 
Age analysed in Chapter 6 are presented, 
with the number of outliers removed in 
parenthesis 
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Appendix 4 Metal concentrations in different brain regions of the C57Bl/6 and Ctr1+/− mouse with age 
 
Age 
(months)
Iron
(µg/g dry weight)
Copper
(µg/g dry weight)
Zinc
(µg/g dry weight)
Iron
(µg/g dry weight)
Copper
(µg/g dry weight)
Zinc
(µg/g dry weight)
Cortex 3 66.19 ± 0.70 17.64 ± 0.83 76.21 ± 5.43 62.10 ± 1.40 8.88 ± 0.16 71.82 ± 2.49
4 62.80 ± 1.68 17.21 ± 0.73 79.40 ± 4.25 61.17 ± 2.07 8.44 ± 0.20 72.15 ± 5.03
5 61.70 ± 1.66 16.12 ± 0.48 75.72 ± 2.27 61.45 ± 2.79 8.04 ± 0.34 73.86 ± 2.51
6 63.31 ± 2.92 16.76 ± 0.80 76.46 ± 3.90 66.76 ± 2.92 8.39 ± 0.28 71.57 ± 4.51
7 62.20 ± 4.29 16.34 ± 0.90 71.96 ± 6.47 64.67 ± 4.40 8.31 ± 0.29 81.49 ± 2.40
8 72.28 ± 1.06 16.97 ± 1.16 86.15 ± 8.78 60.12 8.43 69.64
9 63.67 ± 2.48 16.11 ± 0.78 77.33 ± 3.00 63.33 ± 1.31 8.47 ± 0.38 72.95 ± 3.37
10 68.15 ± 2.19 16.32 ± 0.85 71.23 ± 3.29 69.45 ± 1.14 7.94 ± 0.14 71.13 ± 2.41
11 86.73 18.29 ± 1.27 78.33 ± 5.95 66.18 8.57 77.98 ± 5.40
12 73.31 ± 4.31 18.13 ± 0.78 74.92 ± 3.85 69.09 ± 2.05 8.06 ± 0.04 71.66 ± 3.75
13 67.11 ± 7.78 17.41 ± 1.04 67.96 ± 3.07 67.18 9.45 60.95
14 72.47 ± 6.11 16.19 ± 0.91 75.45 ± 8.85 68.26 ± 1.83 8.17 ± 0.68 78.49 ± 8.30
15 67.02 16.75 74.59 72.72 7.87 66.95
16 74.75 9.00 91.43
17
18 75.58 ± 3.12 16.07 ± 0.78 72.39 ± 3.57 72.22 ± 1.57 8.44 ± 0.22 72.20 ± 2.65
Striatum 3 62.24 ± 5.18 22.9 ± 1.28 63.11 ± 4.83 56.53 ± 3.57 10.46 ± 0.60 58.73 ± 4.81
4 73.11 ± 0.03 28.58 ± 0.97 72.07 ± 1.58 59.51 ± 6.23 11.46 ± 0.61 53.74 ± 2.95
5 66.15 ± 3.24 23.51 ± 1.20 68.01 ± 4.98 68.57 ± 4.00 11.39 ± 0.64 62.30 ± 3.86
6 70.52 ± 1.91 33.20 ± 2.86 65.79 ± 4.49 70.26 ± 5.73 13.48 ± 0.74 59.98 ± 3.40
7 66.85 ± 0.37 29.10 ± 1.15 50.96 ± 4.93 59.95 ± 1.96 11.91 ± 0.96 52.82 ± 2.02
8 73.34 ± 0.24 40.50 ± 3.17 68.13 ± 5.22
9 75.41 ± 3.32 38.06 ± 2.43 62.18 ± 4.45 75.02 ± 3.62 13.45 ± 0.44 53.25 ± 3.95
10 72.75 ± 9.65 40.72 66.17 ± 10.93 78.84 ± 4.18 15.02 ± 1.46 56.86 ± 3.15
11 100.62 ± 2.64 43.44 ± 6.63 72.51 ± 1.92 106.99 ± 7.87 18.73 ± 0.48 71.78 ± 4.26
12 76.64 ± 4.72 40.25 ± 1.34 58.84 ± 2.24 95.62 ± 10.08 18.49 ± 1.33 65.06 ± 6.96
13 85.17 ± 7.81 48.92 ± 0.52 57.73 ± 6.88 77.88 ± 2.07 15.15 ± 2.43 46.34 ± 1.00
14 96.83 ± 13.26 49.38 ± 4.27 69.33 ± 7.98 88.46 ± 7.06 16.89 ± 0.97 59.79 ± 5.59
15 86.27 37.51 48.94 110.86 18.60 50.36
16 124.72
17
18 92.87 ± 3.29 60.66 ± 6.25 56.91 ± 4.46 80.78 ± 11.10 18.35 ± 1.87 51.54 ± 1.55
Hippocampus 3 55.07 ± 2.71 18.96 ± 0.70 85.38 ± 2.77 59.05 ± 4.05 9.15 ± 0.48 91.07 ± 5.59
4 65.59 ± 7.90 19.16 ± 3.29 95.62 ± 12.26 64.46 ± 2.48 10.67 ± 0.74 90.65 ± 2.92
5 69.40 ± 2.33 20.97 ± 0.75 89.17 ± 6.19 67.69 ± 2.73 10.13 ± 0.29 96.35 ± 2.90
6 63.83 ± 2.81 19.62 ± 0.77 91.08 ± 3.49 67.93 ± 3.84 10.9 ± 0.13 98.50 ± 4.06
7 63.73 ± 1.70 18.45 ± 0.29 86.10 ± 5.41 66.73 ± 4.79 9.78 ± 0.62 83.51 ± 1.89
8 85.25 ± 10.46 20.46 ± 1.16 92.49 ± 0.33 68.23 9.72 79.33
9 77.04 ± 3.75 23.50 ± 0.86 85.97 ± 4.58 77.35 ± 6.79 10.36 ± 0.66 87.54 ± 7.03
10 63.92 ± 4.02 19.20 ± 0.93 77.88 ± 4.40 82.34 ± 12.28 8.80 ± 0.90 89.43 ± 7.43
11 97.87 ± 1.69 21.12 ± 3.37 102.64 ± 14.38 80.77 ± 0.19 10.88 ± 0.16 90.60 ± 7.99
12 79.94 ± 3.71 20.15 ± 2.29 85.40 ± 7.26 75.13 ± 0.74 9.09 ± 0.59 71.92 ± 2.07
13 92.20 ± 1.52 23.96 ± 4.39 85.80 ± 4.28 107.27 10.58 90.61 ± 10.74
14 81.62 ± 2.26 18.16 ± 0.48 82.02 ± 3.90 83.95 ± 6.48 10.15 ± 0.36 83.74 ± 5.520
15 77.36 20.72 71.71 71.92 9.76 76.72
16 96.57 11.23 85.58
17
18 79.36 ± 0.36 19.62 ± 0.28 83.15 ± 3.38 85.73 ± 2.77 10.66 ± 0.44 83.45 ± 3.91
Midbrain 3 60.82 ± 4.46 14.59 ± 1.13 48.94 ± 4.79 53.96 ± 1.37 7.26 ± 0.64 52.06 ± 5.82
4 60.97 ± 4.98 13.64 ± 0.81 46.65 ± 6.30 56.27 ± 5.15 7.97 ± 0.93 48.18 ± 5.50
5 60.91 ± 5.54 12.87 ± 0.76 43.15 ± 4.00 70.20 ± 5.18 8.53 ± 0.47 58.27 ± 3.95
6 63.00 ± 2.73 13.57 ± 0.48 49.82 ± 4.79 66.73 ± 3.03 7.87 ± 0.60 50.09 ± 3.26
7 58.37 13.38 ± 1.46 42.58 ± 0.53 72.58 ± 6.67 8.5 ± 1.09 46.63 ± 5.74
8 67.73 ± 2.78 13.64 ± 0.14 47.24 ± 3.50 58.23 7.57 38.40
9 75.54 ± 3.88 14.25 ± 0.78 52.51 ± 3.46 68.66 ± 2.67 8.28 ± 0.15 42.85 ± 3.62
10 64.57 ± 1.02 14.38 ± 0.09 51.28 ± 0.15 79.8 ± 4.91 8.35 ± 0.37 51.85 ± 3.92
11 78.95 ± 0.90 14.97 ± 1.62 54.93 ± 4.83 64.98 ± 0.61 6.89 ± 0.69 38.96 ± 4.04
12 73.88 ± 5.81 17.89 ± 1.03 47.40 ± 2.50 63.44 ± 1.45 8.18 ± 0.47 43.01 ± 4.39
13 75.77 ± 1.38 16.75 ± 1.51 50.09 ± 4.51 75.82 ± 9.01 8.48 50.68 ± 6.97
14 74.99 ± 0.63 15.16 ± 1.11 53.91 ± 4.63 79.11 ± 8.30 8.10 ± 1.07 41.17 ± 1.44
15 77.32 15.18 51.79 8.88 66.66
16 75.64 6.77 51.48
17
18 80.79 ± 3.62 15.06 ± 0.37 46.25 ± 2.71 69.26 ± 3.06 7.23 ± 0.35 46.83 ± 8.08
Cerebellum 3 68.25 ± 4.58 23.89 ± 1.43 64.22 ± 3.60 69.39 ± 4.00 10.65 ± 0.51 59.42 ± 2.52
4 70.20 ± 4.03 24.79 ± 3.29 58.98 ± 3.59 69.38 ± 2.34 11.15 ± 0.65 55.27 ± 3.45
5 70.39 ± 2.73 25.4 ± 0.34 58.38 ± 2.29 75.66 ± 4.43 12.03 ± 0.56 58.48 ± 3.35
6 74.92 ± 6.82 26.5 ± 1.21 57.77 ± 2.05 83.99 ± 4.46 11.84 ± 0.40 59.08 ± 2.53
7 76.85 ± 0.46 25.8 ± 0.67 59.45 ± 1.71 81.33 ± 6.45 13.21 ± 0.31 62.52 ± 1.29
8 87.20 ± 2.65 28.16 ± 1.33 66.89 77.90 13.53 59.26
9 87.90 ± 3.65 34.33 ± 1.62 62.96 ± 1.02 85.03 ± 4.25 14.23 ± 0.73 63.59 ± 2.76
10 85.76 ± 6.35 28.54 ± 1.57 61.57 ± 1.18 92.06 ± 7.65 12.28 ± 0.79 61.13 ± 3.10
11 98.52 ± 10.89 36.19 ± 0.82 66.77 ± 5.04 98.44 ± 7.60 14.41 ± 0.86 60.35 ± 0.47
12 86.14 ± 3.84 35.48 ± 2.06 65.18 ± 3.47 89.88 ± 5.52 12.68 ± 0.38 60.53 ± 4.06
13 81.98 ± 9.83 36.19 ± 0.8 61.71 ± 8.51 86.75 ± 6.71 14.10 ± 2.87 60.13 ± 0.30
14 97.06 ± 9.68 32.79 ± 1.54 68.65 ± 7.75 83.00 ± 1.36 12.01 ± 0.77 53.51 ± 3.94
15 79.55 29.36 51.50 93.61 12.02 57.30
16 105.00 15.12 65.17
17
18 97.22 ± 5.66 38.19 ± 2.74 70.21 ± 5.67 91.32 ± 4.16 13.58 ± 1.20 55.53 ± 0.3
C57Bl/6 Ctr1+/−
The concentrations of 
metals at various ages 
quantified using ICP-MS 
for each brain region and 
normalised to lyophilised 
tissue weight in C57Bl/6 
and Ctr1+/− mice. Data 
reported as mean ± SEM. 
Abbreviations: Ctr1+/−: 
Ctr1 heterozygous; ICP-
MS: Inductively coupled 
plasma-mass spectrometry 
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Appendix 5 Age associated changes in regional brain iron levels in Ctr1+/− mice. Linear regression analysis of age associated changes in Fe 
levels in the cortex (A), striatum (B), hippocampus (C), midbrain (D), and cerebellum (E). Additionally, a merged graph of all regional Fe 
regression analysis (F) was generated to demonstrate the differences in regional brain metal levels with age. 
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Appendix 6 Age associated changes in regional brain copper levels in Ctr1+/− mice. Linear regression analysis of age associated changes in Cu 
levels in the cortex (A), striatum (B), hippocampus (C), midbrain (D), and cerebellum (E). Additionally, a merged graph of all regional Cu 
regression analysis (F) was generated to demonstrate the differences in regional brain metal levels with age. 
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Appendix 7 Age associated changes in regional brain zinc levels in Ctr1+/− mice. Linear regression analysis of age associated changes in Zn 
levels in the cortex (A), striatum (B), hippocampus (C), midbrain (D), and cerebellum (E). Additionally, a merged graph of all regional Zn 
regression analysis (F) was generated to demonstrate the differences in regional brain metal levels with age. 
 125 
REFERENCES 
Abou Zeid, C., & Kaler, S. G. (2019). Normal Human Copper Metabolism. In K. H. Weiss & 
M. B. T.-W. D. Schilsky (Eds.), Wilson Disease (pp. 17–22). 
Alam, G., Edler, M., Burchfield, S., & Richardson, J. R. (2017). Single low doses of MPTP 
decrease tyrosine hydroxylase expression in the absence of overt neuron loss. 
NeuroToxicology, 60, 99–106. 
Alcaro, A., Huber, R., & Panksepp, J. (2007). Behavioral functions of the mesolimbic 
dopaminergic system: An affective neuroethological perspective. Brain Research 
Reviews, 56(2), 283–321. 
Aliaga, M. E., Carrasco-Pozo, C., López-Alarcón, C., Olea-Azar, C., & Speisky, H. (2011). 
Superoxide-dependent reduction of free Fe3+ and release of Fe2+ from ferritin by the 
physiologically-occurring Cu(I)–glutathione complex. Bioorganic & Medicinal 
Chemistry, 19(1), 534–541. 
Aliaga, M. E., López-Alarcón, C., Barriga, G., Olea-Azar, C., & Speisky, H. (2010). Redox-
active complexes formed during the interaction between glutathione and mercury and/or 
copper ions. Journal of Inorganic Biochemistry, 104(10), 1084–1090. 
Alibardi, L. (2017). Immunocytochemical localization of sulfhydryl oxidase in mammalian 
epidermis suggests that the enzyme cross-links keratins in the granular and transitional 
corneous layers. Acta Zoologica, 98(1), 32–37. 
Armstrong, R. A. (2014). When to use the Bonferroni correction. Ophthalmic and 
Physiological Optics, 34(5), 502–508. 
Ashraf, A., Clark, M., & So, P. W. (2018). The aging of iron man. Frontiers in Aging 
Neuroscience, 10(MAR), 1–23. 
Ayton, S., George, J. L., Adlard, P. A., Bush, A. I., Cherny, R. A., & Finkelstein, D. I. 
(2013). The effect of dopamine on MPTP-induced rotarod disability. Neuroscience 
Letters, 543, 105–109. 
Ayton, S., Lei, P., Duce, J. A., Wong, B. X. W., Sedjahtera, A., Adlard, P. A., … Finkelstein, 
D. I. (2013). Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. 
Annals of Neurology, 73(4), 554–559. 
 126 
Bandmann, O., Weiss, K. H., & Kaler, S. G. (2015). Wilson’s disease and other neurological 
copper disorders. The Lancet Neurology, 14(1), 103–113. 
Battaglia, G., Busceti, C. L., Molinaro, G., Biagioni, F., Traficante, A., Nicoletti, F., & 
Bruno, V. (2006). Pharmacological activation of mGlu4 metabotropic glutamate 
receptors reduces nigrostriatal degeneration in mice treated with 1-Methyl-4-Phenyl-
1,2,3,6-Tetrahydropyridine. Journal of Neuroscience, 26(27), 7222–7229. 
Bjorklund, G., Stejskal, V., Urbina, M. A., Dadar, M., Chirumbolo, S., & Mutter, J. (2018). 
Metals and Parkinson’s Disease: Mechanisms and Biochemical Processes. Current 
Medicinal Chemistry, 25(19), 2198–2214. 
Blandini, F., & Armentero, M.-T. (2012). Animal models of Parkinson’s disease. FEBS 
Journal, 279(7), 1156–1166. 
Blesa, J., Phani, S., Jackson-Lewis, V., & Przedborski, S. (2012). Classic and New Animal 
Models of Parkinson’s Disease. Journal of Biomedicine and Biotechnology, 2012, 1–10. 
Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015). Oxidative 
stress and Parkinson’s disease. Frontiers in Neuroanatomy, 9(July), 91. 
Bonnitcha, P. D., Bayly, S. R., Theobald, M. B. M., Betts, H. M., Lewis, J. S., & Dilworth, J. 
R. (2010). Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) – Potential 
combination agents for the PET imaging of hypoxia. Journal of Inorganic Biochemistry, 
104(2), 126–135. 
Bousquet-Moore, D., Mains, R. E., & Eipper, B. A. (2010). Peptidylgycine α-amidating 
monooxygenase and copper: A gene-nutrient interaction critical to nervous system 
function. Journal of Neuroscience Research, 88(12), 2535–2545. 
Brown, D. R. (2004). Role of the prion protein in copper turnover in astrocytes. Neurobiology 
of Disease, 15(3), 534–543. 
Buiakova, O. I., Xu, J., Lutsenko, S., Zeitlin, S., Das, K., Das, S., … Gilliam, T. C. (1999). 
Null mutation of the murine ATP7B (Wilson Disease) gene results in intracellular 
copper accumulation and late-onset hepatic nodular transformation. Human Molecular 
Genetics, 8(9), 1665–1671. 
Bulcke, F., & Dringen, R. (2016). Handling of Copper and Copper Oxide Nanoparticles by 
Astrocytes. Neurochemical Research, 41(1), 33–43. 
Bulcke, F., Dringen, R., & Scheiber, I. F. (2017). Neurotoxicity of Copper (M. Aschner & L. 
G. Costa, Eds.). 
Bulska, E., & Wagner, B. (2016). Quantitative aspects of inductively coupled plasma mass 
spectrometry. Philosophical Transactions. Series A, Mathematical, Physical, and 
Engineering Sciences, 374(2079), 20150369. 
Buncic, G., Hickey, J. L., Schieber, C., White, J. M., Crouch, P. J., White, A. R., … 
Donnelly, P. S. (2011). Water-soluble Bis(thiosemicarbazonato)copper(II) Complexes. 
Australian Journal of Chemistry, 64(3), 244. 
Calvo, J., Jung, H., & Meloni, G. (2017). Copper metallothioneins. IUBMB Life, 69(4), 236–
245. 
Castro-Hernández, J., Adlard, P. A., & Finkelstein, D. I. (2017). Pramipexole restores 
depressed transmission in the ventral hippocampus following MPTP-lesion. Scientific 
Reports, 7(1), 44426. 
Chen, C., Yin, M., Hsu, C., & Liu, T. (2007). Antioxidative and anti-inflammatory effects of 
 127 
four cysteine-containing agents in striatum of MPTP-treated mice. Nutrition, 23(7), 
589–597. 
Chen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & 
Johnson, J. A. (2009). Nrf2-mediated neuroprotection in the MPTP mouse model of 
Parkinson’s disease: Critical role for the astrocyte. Proceedings of the National 
Academy of Sciences, 106(8), 2933–2938. 
Chen, P., Miah, M. R., & Aschner, M. (2016). Metals and Neurodegeneration. 
F1000Research, 5, 366. 
Cheng, L., Quek, C. Y. J., Hung, L. W., Sharples, R. A., Sherratt, N. A., Barnham, K. J., & 
Hill, A. F. (2016). Gene dysregulation is restored in the Parkinson’s disease MPTP 
neurotoxic mice model upon treatment of the therapeutic drug CuII(atsm). Scientific 
Reports, 6(1), 22398. 
Chinta, S. J., Woods, G., Rane, A., Demaria, M., Campisi, J., & Andersen, J. K. (2015). 
Cellular senescence and the aging brain. Experimental Gerontology, 68, 3–7. 
Choi, D.-K. (2005). Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates 
Features of Parkinson’s Disease in Mice. Journal of Neuroscience, 25(28), 6594–6600. 
Choi, S. J., Panhelainen, A., Schmitz, Y., Larsen, K. E., Kanter, E., Wu, M., … Mosharov, E. 
V. (2015). Changes in Neuronal Dopamine Homeostasis following 1-Methyl-4-
phenylpyridinium (MPP + ) Exposure. Journal of Biological Chemistry, 290(11), 6799–
6809. 
Cicero, C. E., Mostile, G., Vasta, R., Rapisarda, V., Signorelli, S. S., Ferrante, M., … 
Nicoletti, A. (2017). Metals and neurodegenerative diseases. A systematic review. 
Environmental Research, 159(August), 82–94. 
Colombié, M., Gouard, S., Frindel, M., Vidal, A., Chérel, M., Kraeber-Bodéré, F., … 
Bourgeois, M. (2015). Focus on the Controversial Aspects of 64Cu-ATSM in Tumoral 
Hypoxia Mapping by PET Imaging   . Frontiers in Medicine  , Vol. 2, p. 58. Retrieved 
from https://www.frontiersin.org/article/10.3389/fmed.2015.00058 
Cotruvo, Jr., J. A., Aron, A. T., Ramos-Torres, K. M., & Chang, C. J. (2015). Synthetic 
fluorescent probes for studying copper in biological systems. Chemical Society Reviews, 
44(13), 4400–4414. 
Cowley, A. R., Dilworth, J. R., Donnelly, P. S., Heslop, J. M., & Ratcliffe, S. J. (2007). 
Bifunctional chelators for copper radiopharmaceuticals: the synthesis of [Cu(ATSM)–
amino acid] and [Cu(ATSM)–octreotide] conjugates. Dalton Trans., (2), 209–217. 
Crapo, J. D., Oury, T., Rabouille, C., Slot, J. W., & Chang, L. Y. (1992). Copper,zinc 
superoxide dismutase is primarily a cytosolic protein in human cells. Proceedings of the 
National Academy of Sciences, 89(21), 10405–10409. 
Cui, M., Aras, R., Christian, W. V., Rappold, P. M., Hatwar, M., Panza, J., … Tieu, K. 
(2009). The organic cation transporter-3 is a pivotal modulator of neurodegeneration in 
the nigrostriatal dopaminergic pathway. Proceedings of the National Academy of 
Sciences, 106(19), 8043–8048. 
Culotta, V. C., Klomp, L. W. J., Strain, J., Casareno, R. L. B., Krems, B., & Gitlin, J. D. 
(1997). The Copper Chaperone for Superoxide Dismutase. Journal of Biological 
Chemistry, 272(38), 23469–23472. 
Davies, K. M., Bohic, S., Carmona, A., Ortega, R., Cottam, V., Hare, D. J., … Double, K. L. 
(2014). Copper pathology in vulnerable brain regions in Parkinson’s disease. 
 128 
Neurobiology of Aging, 35(4), 858–866. 
Davies, K. M., Hare, D. J., Cottam, V., Chen, N., Hilgers, L., Halliday, G., … Double, K. L. 
(2013). Localization of copper and copper transporters in the human brain. Metallomics, 
5(1), 43–51. 
Davies, K. M., Mercer, J. F. B., Chen, N., & Double, K. L. (2016). Copper dyshomoeostasis 
in Parkinson’s disease: implications for pathogenesis and indications for novel 
therapeutics. Clinical Science, 130(8), 565–574. 
Dearling, J. L. J., & Packard, A. B. (2010). Some thoughts on the mechanism of cellular 
trapping of Cu(II)-ATSM. Nuclear Medicine and Biology, 37(3), 237–243. 
Dearling, J. L., Lewis, J. S., Mullen, G. E., Welch, M. J., & Blower, P. J. (2002). Copper 
bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity 
relationships. JBIC Journal of Biological Inorganic Chemistry, 7(3), 249–259. 
Deloitte. (2015). Living with Parkinson ’ s Disease An updated economic. (August). 
DeMaagd, G., & Philip, A. (2015). Parkinson’s Disease and Its Management: Part 1: Disease 
Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. P & T : A 
Peer-Reviewed Journal for Formulary Management, 40(8), 504–532. Retrieved from 
https://www.ncbi.nlm.nih.gov/pubmed/26236139 
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., … Bordet, R. 
(2014). Targeting chelatable Iron as a therapeutic modality in Parkinson’s disease. 
Antioxidants & Redox Signaling, 21(2), 195–210. 
Dexter, D. T., Carayon, A., Javoy-Agid, F., Agid, Y., Wells, F. R., Daniel, S. E., … Marsden, 
C. D. (1991). Alterations in the levels of ironm ferritin and other trace metals in 
Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. 
Brain, 114(4), 1953–1975. 
Dhikav, V., & Anand, K. (2012). Hippocampus in health and disease: An overview. Annals 
of Indian Academy of Neurology, 15(4), 239. 
Djoko, K. Y., Goytia, M. M., Donnelly, P. S., Schembri, M. A., Shafer, W. M., & McEwan, 
A. G. (2015). Copper(II)-Bis(Thiosemicarbazonato) Complexes as Antibacterial Agents: 
Insights into Their Mode of Action and Potential as Therapeutics. Antimicrobial Agents 
and Chemotherapy, 59(10), 6444–6453. 
Donnelly, P. S., Liddell, J. R., Lim, S., Paterson, B. M., Cater, M. A., Savva, M. S., … 
Crouch, P. J. (2012). An impaired mitochondrial electron transport chain increases 
retention of the hypoxia imaging agent diacetylbis(4-
methylthiosemicarbazonato)copperII. Proceedings of the National Academy of Sciences, 
109(1), 47–52. 
Dutta, S., & Sengupta, P. (2016). Men and mice: Relating their ages. Life Sciences, 152, 244–
248. 
Duty, S., & Jenner, P. (2011). Animal models of Parkinson’s disease: A source of novel 
treatments and clues to the cause of the disease. British Journal of Pharmacology, 
164(4), 1357–1391. 
Eilam, R., Peter, Y., Elson, A., Rotman, G., Shiloh, Y., Groner, Y., & Segal, M. (1998). 
Selective loss of dopaminergic nigro-striatal neurons in brains of Atm-deficient mice. 
Proceedings of the National Academy of Sciences, 95(21), 12653–12656. 
Evans, A., Rowe, D., Lee, W., & Rosenfeld, C. (2017). Preliminary evidence of CuATSM 
treatment benefit in Parkinson’s disease (P082). XXIV World Congress on Parkinson’s 
 129 
Disease and Related Disorders, 119–120. Retrieved from urn:nbn:de:101:1-
2019052912131149587864 
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible statistical 
power analysis program for the social, behavioral, and biomedical sciences. Behavior 
Research Methods, 39(2), 175–191. 
Fearnley, J. M., & Lees, A. J. (1991). Ageing and Parkinson’s Disease: substantia nigra 
regional selectivity. Brain, 114(5), 2283–2301. 
Festa, R. A., & Thiele, D. J. (2011). Copper: An essential metal in biology. Current Biology, 
21(21), R877–R883. 
Flurkey, K., Mcurrer, J., & Harrison, D. (2007). Mouse Models in Aging Research. In J. G. 
Fox, M. T. Davisson, F. W. Quimby, S. W. Barthold, C. E. Newcomer, & A. L. B. T.-T. 
M. in B. R. (Second E. Smith (Eds.), The Mouse in Biomedical Research (pp. 637–672). 
Franco-Iborra, S., Vila, M., & Perier, C. (2015). The Parkinson Disease Mitochondrial 
Hypothesis: Where Are We at? The Neuroscientist, 22(3), 266–277. 
Franke, S. K., van Kesteren, R. E., Wubben, J. A. M., Hofman, S., Paliukhovich, I., van der 
Schors, R. C., … Philippens, I. H. C. H. M. (2016). Progression and recovery of 
Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without 
persistent molecular and cellular damage. Neuroscience, 312(October), 247–259. 
Freitas, M., Hess, C., & Fox, S. (2017). Motor Complications of Dopaminergic Medications 
in Parkinson’s Disease. Seminars in Neurology, 37(02), 147–157. 
Frigerio, R., Fujishiro, H., Ahn, T.-B., Josephs, K. A., Maraganore, D. M., DelleDonne, A., 
… Ahlskog, J. E. (2011). Incidental Lewy body disease: do some cases represent a 
preclinical stage of dementia with Lewy bodies? Neurobiology of Aging, 32(5), 857–
863. 
Fu, Y., Yuan, Y., Halliday, G., Rusznák, Z., Watson, C., & Paxinos, G. (2012). A 
cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the 
substantia nigra, ventral tegmental area, and retrorubral field in the mouse. Brain 
Structure and Function, 217(2), 591–612. 
Fujibayashi, Y., Taniuchi, H., Yonekura, Y., Ohtani, H., Konishi, J., & Yokoyama, A. 
(1997). Copper-62-ATSM: a new hypoxia imaging agent with high membrane 
permeability and low redox potential. Journal of Nuclear Medicine : Official 
Publication, Society of Nuclear Medicine, 38(7), 1155–1160. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/9225812 
García-Cabezas, M. Á., John, Y. J., Barbas, H., & Zikopoulos, B. (2016). Distinction of 
Neurons, Glia and Endothelial Cells in the Cerebral Cortex: An Algorithm Based on 
Cytological Features. Frontiers in Neuroanatomy, 10, 107. 
Genoud, S., Senior, A. M., Hare, D. J., & Double, K. L. (2019). Meta-analysis of copper and 
iron in Parkinson’s disease brain and biofluids. Movement Disorders : Official Journal 
of the Movement Disorder Society. 
Giordano, S., Lee, J., Darley-Usmar, V. M., & Zhang, J. (2012). Distinct Effects of 
Rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on Cellular 
Bioenergetics and Cell Death. PLoS ONE, 7(9), e44610. 
Gonzalez-Cuyar, L. F., Perry, G., Miyajima, H., Atwood, C. S., Riveros-Angel, M., Lyons, P. 
F., … Castellani, R. J. (2008). Redox active iron accumulation in aceruloplasminemia. 
Neuropathology, 28(5), 466–471. 
 130 
Gotsbacher, M. P., Telfer, T. J., Witting, P. K., Double, K. L., Finkelstein, D. I., & Codd, R. 
(2017). Analogues of desferrioxamine B designed to attenuate iron-mediated 
neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of 
Parkinson’s disease. Metallomics, 9(7), 852–864. 
Grochowski, C., Blicharska, E., Krukow, P., Jonak, K., Maciejewski, M., Szczepanek, D., … 
Maciejewski, R. (2019). Analysis of Trace Elements in Human Brain: Its Aim, Methods, 
and Concentration Levels. Frontiers in Chemistry, 7, 115. 
Grosch, J., Winkler, J., & Kohl, Z. (2016). Early Degeneration of Both Dopaminergic and 
Serotonergic Axons – A Common Mechanism in Parkinson’s Disease   . Frontiers in 
Cellular Neuroscience  , Vol. 10, p. 293. Retrieved from 
https://www.frontiersin.org/article/10.3389/fncel.2016.00293 
Hahn, P., Song, Y., Ying, G. shuang, He, X., Beard, J., & Dunaief, J. L. (2009). Age-
dependent and gender-specific changes in mouse tissue iron by strain. Experimental 
Gerontology, 44(9), 594–600. 
Hamre, K., Tharp, R., Poon, K., Xiong, X., & Smeyne, R. J. (1999). Differential strain 
susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
administration acts in an autosomal dominant fashion: quantitative analysis in seven 
strains of Mus musculus. Brain Research, 828(1–2), 91–103. 
Hare, D. J., George, J. L., Grimm, R., Wilkins, S., Adlard, P. A., Cherny, R. A., … Doble, P. 
(2010). Three-dimensional elemental bio-imaging of Fe, Zn, Cu, Mn and P in a 6-
hydroxydopamine lesioned mouse brain. Metallomics, 2(11), 745. 
Hare, D. J., Lee, J. K., Beavis, A. D., Van Gramberg, A., George, J., Adlard, P. A., … Doble, 
P. A. (2012). Three-dimensional atlas of iron, copper, and zinc in the mouse cerebrum 
and brainstem. Analytical Chemistry, 84(9), 3990–3997. 
Harris, Z. L. (2019). Ceruloplasmin. In N. Kerkar & E. A. B. T.-C. and T. P. on W. D. 
Roberts (Eds.), Clinical and Translational Perspectives on WILSON DISEASE (pp. 77–
84). 
Haywood, S., Paris, J., Ryvar, R., & Botteron, C. (2008). Brain Copper Elevation and 
Neurological Changes in North Ronaldsay Sheep: a Model for Neurodegenerative 
Disease? Journal of Comparative Pathology, 139(4), 252–255. 
Hegde, S., Sinha, S., Rao, S., Taly, A., & Vasudev, M. (2010). Cognitive profile and 
structural findings in Wilson′s disease: A neuropsychological and MRI-based study. 
Neurology India, 58(5), 708. 
Helsel, M. E., & Franz, K. J. (2015). Pharmacological activity of metal binding agents that 
alter copper bioavailability. Dalton Transactions, 44(19), 8760–8770. 
Hickey, J. L., Lim, S., Hayne, D. J., Paterson, B. M., White, J. M., Villemagne, V. L., … 
Donnelly, P. S. (2013). Diagnostic Imaging Agents for Alzheimer’s Disease: Copper 
Radiopharmaceuticals that Target Aβ Plaques. Journal of the American Chemical 
Society, 135(43), 16120–16132. 
Hitchcock, S. A., & Pennington, L. D. (2006). Structure−Brain Exposure Relationships. 
Journal of Medicinal Chemistry, 49(26), 7559–7583. 
Horng, Y.-C., Cobine, P. A., Maxfield, A. B., Carr, H. S., & Winge, D. R. (2004). Specific 
Copper Transfer from the Cox17 Metallochaperone to Both Sco1 and Cox11 in the 
Assembly of Yeast Cytochrome c Oxidase. Journal of Biological Chemistry, 279(34), 
35334–35340. 
 131 
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. 
(2019). Ageing as a risk factor for neurodegenerative disease. Nature Reviews 
Neurology, 15(10), 565–581. 
Huang, D., Xu, J., Wang, J., Tong, J., Bai, X., Li, H., … Huang, F. (2017). Dynamic Changes 
in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson’s Disease. 
Parkinson’s Disease, 2017, 1–7. 
Hung, L. W., Villemagne, V. L., Cheng, L., Sherratt, N. A., Ayton, S., White, A. R., … 
Barnham, K. J. (2012). The hypoxia imaging agent Cu II (atsm) is neuroprotective and 
improves motor and cognitive functions in multiple animal models of Parkinson’s 
disease. The Journal of Experimental Medicine, 209(4), 837–854. 
Huster, D. (2019). Animal Models of Wilson Disease. In K. H. Weiss & M. B. T.-W. D. 
Schilsky (Eds.), Wilson Disease (pp. 51–63). 
Iannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., … Perani, 
D. (2013). In vivo microglia activation in very early dementia with Lewy bodies, 
comparison with Parkinson’s disease. Parkinsonism & Related Disorders, 19(1), 47–52. 
Ikawa, M., Okazawa, H., Kudo, T., Kuriyama, M., Fujibayashi, Y., & Yoneda, M. (2011). 
Evaluation of striatal oxidative stress in patients with Parkinson’s disease using [ 
62Cu]ATSM PET. Nuclear Medicine and Biology, 38(7), 945–951. 
Irvine, G. W., & Stillman, M. J. (2017). Residue Modification and Mass Spectrometry for the 
Investigation of Structural and Metalation Properties of Metallothionein and Cysteine-
Rich Proteins. International Journal of Molecular Sciences, 18(5), 913. 
Jackson-Lewis, V., & Przedborski, S. (2007). Protocol for the MPTP mouse model of 
Parkinson’s disease. Nature Protocols, 2(1), 141–151. 
Jackson, S. J., Andrews, N., Ball, D., Bellantuono, I., Gray, J., Hachoumi, L., … Chapman, 
K. (2017). Does age matter? The impact of rodent age on study outcomes. Laboratory 
Animals, 51(2), 160–169. 
Jagmag, S. A., Tripathi, N., Shukla, S. D., Maiti, S., & Khurana, S. (2016). Evaluation of 
Models of Parkinson’s Disease. Frontiers in Neuroscience, 9(6), 329. 
Jaiser, S. R., & Winston, G. P. (2010). Copper deficiency myelopathy. Journal of Neurology, 
257(6), 869–881. 
Jalilian, A. R., Rostampour, N., Rowshanfarzad, P., Shafaii, K., Kamali-Dehghan, M., & 
Akhlaghi, M. (2009). Preclinical studies of [61Cu]ATSM as a PET radiopharmaceutical 
for fibrosarcoma imaging. Acta Pharmaceutica, 59(1), 45–55. 
Johnson, M. (2012). Laboratory Mice and Rats. Materials and Methods, 2. 
Juárez Olguín, H., Calderón Guzmán, D., Hernández García, E., & Barragán Mejía, G. 
(2016). The role of dopamine and Its dysfunction as a consequence of oxidative stress. 
Oxidative Medicine and Cellular Longevity, 2016, 1–13. 
Jurado-Coronel, J. C., Cabezas, R., Ávila Rodríguez, M. F., Echeverria, V., García-Segura, L. 
M., & Barreto, G. E. (2018). Sex differences in Parkinson’s disease: Features on clinical 
symptoms, treatment outcome, sexual hormones and genetics. Frontiers in 
Neuroendocrinology, 50, 18–30. 
Kadar, H., Le Douaron, G., Amar, M., Ferrié, L., Figadère, B., Touboul, D., … Raisman-
Vozari, R. (2014). MALDI Mass Spectrometry Imaging of 1-Methyl-4-
phenylpyridinium (MPP+) in Mouse Brain. Neurotoxicity Research, 25(1), 135–145. 
 132 
Kaler, S. G. (2011). ATP7A-related copper transport diseasesg-emerging concepts and future 
trends. Nature Reviews Neurology, 7(1), 15–29. 
Kamatchi, T. S., Chitrapriya, N., Ashok Kumar, S. L., Jung, J. Y., Puschmann, H., Fronczek, 
F. R., & Natarajan, K. (2017). The effect of incorporating carboxylic acid functionalities 
into 2,2′-bipyridine on the biological activity of the complexes formed: synthesis, 
structure, DNA/protein interaction, antioxidant activity and cytotoxicity. RSC Advances, 
7(27), 16428–16443. 
Kanakoudi, F., Drossou, V., Tzimouli, V., Diamanti, E., Konstantinidis, T., Germenis, A., & 
Kremenopoulos, G. (1995). Serum concentrations of 10 acute-phase proteins in healthy 
term and preterm infants from birth to age 6 months. Clinical Chemistry, 41(4), 605–
608. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7536645 
Kardos, J., Héja, L., Simon, Á., Jablonkai, I., Kovács, R., & Jemnitz, K. (2018). Copper 
signalling: causes and consequences. Cell Communication and Signaling, 16(1), 71. 
Kilbride, Seán M, Gluchowska, S. A., Telford, J. E., O’Sullivan, C., & Davey, G. P. (2011). 
High-level inhibition of mitochondrial complexes III and IV is required to increase 
glutamate release from the nerve terminal. Molecular Neurodegeneration, 6(1), 53. 
Kilbride, Seán M., Telford, J. E., Tipton, K. F., & Davey, G. P. (2008). Partial inhibition of 
complex I activity increases Ca 2+ -independent glutamate release rates from 
depolarized synaptosomes. Journal of Neurochemistry, 106(2), 826–834. 
Kim, C.-H., Zabetian, C. P., Cubells, J. F., Cho, S., Biaggioni, I., Cohen, B. M., … Kim, K.-
S. (2002). Mutations in the dopamine ?-hydroxylase gene are associated with human 
norepinephrine deficiency. American Journal of Medical Genetics, 108(2), 140–147. 
Kolacheva, A. A., Kozina, E. A., Volina, E. V., & Ugryumov, M. V. (2014). Degeneration of 
nigrostriatal dopaminergic neurons in an experimental model of the early clinical stage 
of Parkinson’s disease. Neurochemical Journal, 8(3), 184–192. 
Kolacheva, A. A., & Ugrumov, M. V. (2018). Dopamine Synthesis as a Mechanism of Brain 
Plasticity in Nigrostriatal System Pathology. Doklady Biochemistry and Biophysics, 
479(1), 83–86. 
Kong, S. M. Y., Chan, B. K. K., Park, J.-S., Hill, K. J., Aitken, J. B., Cottle, L., … Cooper, 
A. A. (2014). Parkinson’s disease-linked human PARK9/ATP13A2 maintains zinc 
homeostasis and promotes α-Synuclein externalization via exosomes. Human Molecular 
Genetics, 23(11), 2816–2833. 
Konnova, E., & Swanberg, M. (2018). Animal Models of Parkinson’s Disease (T. Stoker & J. 
Greenland, Eds.). 
Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A. E., Stansell, J., Gasmi, M., & Bartus, 
R. T. (2006). Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer 
provides structural and functional neuroprotection and neurorestoration in MPTP-treated 
monkeys. Annals of Neurology, 60(6), 706–715. 
Kozina, E. A., Khakimova, G. R., Khaindrava, V. G., Kucheryanu, V. G., Vorobyeva, N. E., 
Krasnov, A. N., … Ugrumov, M. V. (2014). Tyrosine hydroxylase expression and 
activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the 
presymptomatic and symptomatic stages of parkinsonism. Journal of the Neurological 
Sciences, 340(1–2), 198–207. 
Kumar, N. (2006). Copper Deficiency Myelopathy (Human Swayback). Mayo Clinic 
Proceedings, 81(10), 1371–1384. 
 133 
Lambert, C., Beraldo, H., Lievre, N., Garnier-Suillerot, A., Dorlet, P., & Salerno, M. (2013). 
Bis(thiosemicarbazone) copper complexes: Mechanism of intracellular accumulation. 
Journal of Biological Inorganic Chemistry, 18(1), 59–69. 
Lan, A. P., Chen, J., Chai, Z. F., & Hu, Y. (2016). The neurotoxicity of iron, copper and 
cobalt in Parkinson’s disease through ROS-mediated mechanisms. BioMetals, 29(4), 
665–678. 
Langston, J., Ballard, P., Tetrud, J., & Irwin, I. (1983). Chronic Parkinsonism in humans due 
to a product of meperidine-analog synthesis. Science, 219(4587), 979–980. 
Langston, J. W., Forno, L. S., Tetrud, J., & Reeves,  a G. (1999). Evidence of Active Nerve 
Cell Degeneration in the Substantia Nigra of Humans Years after 1-methyl-phenyl-
1,2,3,6-tetrahydrophyridine exposure. Annals of Neurology, 46, 598–605. 
Lee, J., Prohaska, J. R., & Thiele, D. J. (2001). Essential role for mammalian copper 
transporter Ctr1 in copper homeostasis and embryonic development. Proceedings of the 
National Academy of Sciences, 98(12), 6842–6847. 
Lehner, A., Johnson, M., Simkins, T., Janis, K., Lookingland, K., Goudreau, J., & Rumbeiha, 
W. (2011). Liquid chromatographic–electrospray mass spectrometric determination of 
1-methyl-4-phenylpyridine (MPP + ) in discrete regions of murine brain. Toxicology 
Mechanisms and Methods, 21(3), 171–182. 
Lenartowicz, M., Krzeptowski, W., Lipiński, P., Grzmil, P., Starzyński, R., Pierzchała, O., & 
Møller, L. B. (2015). Mottled Mice and Non-Mammalian Models of Menkes Disease. 
Frontiers in Molecular Neuroscience, 8, 72. 
Lewis, J. S., McCarthy, D. W., McCarthy, T. J., Fujibayashi, Y., & Welch, M. J. (1999). 
Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. Journal of 
Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 40(1), 177–183. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9935074 
Lhermitte, J., Kraus, W. M., & McAlpine, D. (1924). Original Papers: On the occurrence of 
abnormal deposits of iron in the brain in parkinsonism with special referebce to its 
localisation. Journal of Neurology, Neurosurgery & Psychiatry, s1-5(19), 195–208. 
Li, K., & Reichmann, H. (2016). Role of iron in neurodegenerative diseases. Journal of 
Neural Transmission, 123(4), 389–399. 
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. 
G., … Przedborski, S. (1999). Inducible nitric oxide synthase stimulates dopaminergic 
neurodegeneration in the MPTP model of Parkinson disease. Nature Medicine, 5(12), 
1403–1409. 
Liguori, I., Russo, G., Curcio, F., Bulli, G., Aran, L., Della-Morte, D., … Abete, P. (2018). 
Oxidative stress, aging, and diseases. Clinical Interventions in Aging, 13, 757–772. 
Lin, S. J., & Culotta, V. C. (1995). The ATX1 gene of Saccharomyces cerevisiae encodes a 
small metal homeostasis factor that protects cells against reactive oxygen toxicity. 
Proceedings of the National Academy of Sciences, 92(9), 3784–3788. 
Linder, M. C., Wooten, L., Cerveza, P., Cotton, S., Shulze, R., & Lomeli, N. (1998). Copper 
transport. The American Journal of Clinical Nutrition, 67(5), 965S-971S. 
Litwin, T., Gromadzka, G., Szpak, G. M., Jabłonka-Salach, K., Bulska, E., & Członkowska, 
A. (2013). Brain metal accumulation in Wilson’s disease. Journal of the Neurological 
Sciences, 329(1–2), 55–58. 
Lothian, A., Hare, D. J., Grimm, R., Ryan, T. M., Masters, C. L., & Roberts, B. R. (2013). 
 134 
Metalloproteomics: principles, challenges and applications to neurodegeneration. 
Frontiers in Aging Neuroscience, 5. 
Lucero, H. A., & Kagan, H. M. (2006). Lysyl oxidase: an oxidative enzyme and effector of 
cell function. Cellular and Molecular Life Sciences, 63(19–20), 2304–2316. 
Luciano, M., & Bruckner, C. (2017). Modifications of Porphyrins and Hydroporphyrins for 
Their Solubilization in Aqueous Media. Molecules, 22(6), 980. 
Luo, Y., Ronk, M., Joubert, M. K., Semin, D., & Nashed-Samuel, Y. (2019). Determination 
of interactions between antibody biotherapeutics and copper by size exclusion 
chromatography (SEC) coupled with inductively coupled plasma mass spectrometry 
(ICP/MS). Analytica Chimica Acta, 1079, 252–259. 
Lutsenko, S., Washington-Hughes, C., Ralle, M., & Schmidt, K. (2019). Copper and the brain 
noradrenergic system. JBIC Journal of Biological Inorganic Chemistry, 24(8), 1179–
1188. 
Main, B. S., Zhang, M., Brody, K. M., Ayton, S., Frugier, T., Steer, D., … Taylor, J. M. 
(2016). Type-1 interferons contribute to the neuroinflammatory response and disease 
progression of the MPTP mouse model of Parkinson’s disease. Glia, 64(9), 1590–1604. 
Manning-Bog, A. B., McCormack, A. L., Li, J., Uversky, V. N., Fink, A. L., & Di Monte, D. 
A. (2002). The Herbicide Paraquat Causes Up-regulation and Aggregation of α-
Synuclein in Mice. Journal of Biological Chemistry, 277(3), 1641–1644. 
Markey, S. P., Johannessen, J. N., Chiueh, C. C., Burns, R. S., & Herkenham, M. A. (1984). 
Intraneuronal generation of a pyridinium metabolite may cause drug-induced 
parkinsonism. Nature, 311(5985), 464–467. 
Martin-Bastida, A., Ward, R. J., Newbould, R., Piccini, P., Sharp, D., Kabba, C., … Dexter, 
D. T. (2017). Brain iron chelation by deferiprone in a phase 2 randomised double-
blinded placebo controlled clinical trial in Parkinson’s disease. Scientific Reports, 7(1), 
1398. 
Martin, H. L., & Teismann, P. (2009). Glutathione—a review on its role and significance in 
Parkinson’s disease. The FASEB Journal, 23(10), 3263–3272. 
Maryon, E. B., Molloy, S. A., & Kaplan, J. H. (2013). Cellular glutathione plays a key role in 
copper uptake mediated by human copper transporter 1. American Journal of 
Physiology-Cell Physiology, 304(8), C768–C779. 
Massie, H. R., Aiello, V. R., & Iodice, A. A. (1979). Changes with age in copper and 
superoxide dismutase levels in brains of C57BL/6J mice. Mechanisms of Ageing and 
Development, 10(1), 93–99. 
Matak, P., Matak, A., Moustafa, S., Aryal, D. K., Benner, E. J., Wetsel, W., & Andrews, N. 
C. (2016). Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. 
Proceedings of the National Academy of Sciences of the United States of America, 
113(13), 3428–3435. 
Matson Dzebo, M., Ariöz, C., & Wittung-Stafshede, P. (2016). Extended functional 
repertoire for human copper chaperones. Biomolecular Concepts, 7(1), 29–39. 
Matusch, A., Depboylu, C., Palm, C., Wu, B., Höglinger, G. U., Schäfer, M. K.-H., & 
Becker, J. S. (2010). Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse 
model of Parkinson’s disease using laser ablation inductively coupled plasma mass 
spectrometry (LA-ICP-MS). Journal of the American Society for Mass Spectrometry, 
21(1), 161–171. 
 135 
Maynard, C. J., Cappai, R., Volitakis, I., Cherny, R. A., Masters, C. L., Li, Q. X., & Bush, A. 
I. (2006). Gender and genetic background effects on brain metal levels in APP 
transgenic and normal mice: Implications for Alzheimer β-amyloid pathology. Journal 
of Inorganic Biochemistry, 100(5–6), 952–962. 
Maynard, C. J., Cappai, R., Volitakis, I., Cherny, R. A., White, A. R., Beyreuther, K., … Li, 
Q.-X. (2002). Overexpression of Alzheimer’s disease amyloid-beta opposes the age-
dependent elevations of brain copper and iron. The Journal of Biological Chemistry, 
277(47), 44670–44676. 
Meredith, G. E., & Kang, U. J. (2006). Behavioral models of Parkinsons disease in rodents: A 
new look at an old problem. Movement Disorders, 21(10), 1595–1606. 
Meredith, G. E., & Rademacher, D. J. (2011). MPTP mouse models of Parkinson’s disease: 
an update. Journal of Parkinson’s Disease, 1(1), 19–33. 
Meredith, G. E., Totterdell, S., Potashkin, J. A., & Surmeier, D. J. (2008). Modeling PD 
pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism & Related 
Disorders, 14 Suppl 2(Suppl 2), S112–S115. 
Merisko-Liversidge, E. M., & Liversidge, G. G. (2008). Drug Nanoparticles: Formulating 
Poorly Water-Soluble Compounds. Toxicologic Pathology, 36(1), 43–48. 
Migocka, M. (2015). Copper-transporting ATPases: The evolutionarily conserved 
machineries for balancing copper in living systems. IUBMB Life, 67(10), 737–745. 
Miller, D. B., Ali, S. F., O’Callaghan, J. P., & Laws, S. C. (1998). The Impact of Gender and 
Estrogen on Striatal Dopaminergic Neurotoxicity. Annals of the New York Academy of 
Sciences, 844(1), 153–165. 
Miller, J. A., Trout, B. R., Sullivan, K. A., Bialecki, R. A., Roberts, R. A., & Tjalkens, R. B. 
(2011). Low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine causes inflammatory 
activation of astrocytes in nuclear factor-κB reporter mice prior to loss of dopaminergic 
neurons. Journal of Neuroscience Research, 89(3), 406–417. 
Montes, S., Rivera-Mancia, S., Diaz-Ruiz, A., Tristan-Lopez, L., & Rios, C. (2014). Copper 
and Copper Proteins in Parkinson’s Disease. Oxidative Medicine and Cellular 
Longevity, 2014, 1–15. 
Morfini, G., Pigino, G., Opalach, K., Serulle, Y., Moreira, J. E., Sugimori, M., … Brady, S. 
T. (2007). 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of 
caspase and protein kinase C. Proceedings of the National Academy of Sciences of the 
United States of America, 104(7), 2442–2447. 
Munabi, A. K., King, D., Bender, S., Bustillo, M., Dorfmann, A., & Schulman, J. D. (1990). 
Small increases in circulating luteinizing hormone (LH) concentrations shortly before 
human chorionic gonadotropin (hCG) are associated with reduced in vitro fertilization 
(IVF) pregnancy rate. Journal of in Vitro Fertilization and Embryo Transfer : IVF, 7(6), 
310–313. 
National Health and Medical Research Council. (2013). Australian code for the care and use 
of animals for scientific purposes - 8th Edition. Retrieved from 
https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ea28_code_care_use_
animals_131209.pdf 
Nelson, C., Erikson, K., Piñero, D. J., & Beard, J. L. (1997). In Vivo Dopamine Metabolism 
Is Altered in Iron-Deficient Anemic Rats. The Journal of Nutrition, 127(12), 2282–
2288. 
 136 
Obata, T. (2002). Semicarbazide-sensitive amine oxidase (SSAO) in the brain. 
Neurochemical Research, 27(4), 263–268. 
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., … Stoessl, 
A. J. (2017). Past, present, and future of Parkinson’s disease: A special essay on the 
200th Anniversary of the Shaking Palsy. Movement Disorders, 32(9), 1264–1310. 
Oeckl, P., & Ferger, B. (2016). Increased susceptibility of G-protein coupled receptor 6 
deficient mice to MPTP neurotoxicity. Neuroscience, 337, 218–223. 
Oertel, W., & Schulz, J. B. (2016). Current and experimental treatments of Parkinson disease: 
A guide for neuroscientists. Journal of Neurochemistry, 139 Suppl, 325–337. 
Ogra, Y., Aoyama, M., & Suzuki, K. T. (2006). Protective role of metallothionein against 
copper depletion. Archives of Biochemistry and Biophysics, 451(2), 112–118. 
Ohgami, R. S., Campagna, D. R., McDonald, A., & Fleming, M. D. (2006). The Steap 
proteins are metalloreductases. Blood, 108(4), 1388–1394. 
Öhrvik, H., & Wittung-Stafshede, P. (2015). Identification of New Potential Interaction 
Partners for Human Cytoplasmic Copper Chaperone Atox1: Roles in Gene Regulation? 
International Journal of Molecular Sciences, 16(8), 16728–16739. 
Ookubo, M., Yokoyama, H., Kato, H., & Araki, T. (2009). Gender differences on MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice. Molecular 
and Cellular Endocrinology, 311(1), 62–68. 
Osredkar, J. (2011). Copper and Zinc, Biological Role and Significance of Copper/Zinc 
Imbalance. Journal of Clinical Toxicology, s3(01). 
Pal, A., Badyal, R. K., Vasishta, R. K., Attri, S. V., Thapa, B. R., & Prasad, R. (2013). 
Biochemical, Histological, and Memory Impairment Effects of Chronic Copper 
Toxicity: A Model for Non-Wilsonian Brain Copper Toxicosis in Wistar Rat. Biological 
Trace Element Research, 153(1–3), 257–268. 
Pal, A., & Prasad, R. (2016). Regional Distribution of Copper, Zinc and Iron in Brain of 
Wistar Rat Model for Non-Wilsonian Brain Copper Toxicosis. Indian Journal of 
Clinical Biochemistry : IJCB, 31(1), 93–98. 
Pan-Montojo, F., Anichtchik, O., Dening, Y., Knels, L., Pursche, S., Jung, R., … Funk, R. H. 
W. (2010). Progression of Parkinson’s Disease Pathology Is Reproduced by Intragastric 
Administration of Rotenone in Mice. PLoS ONE, 5(1), e8762. 
Paris, I., Dagnino-Subiabre, A., Marcelain, K., Bennett, L. B., Caviedes, P., Caviedes, R., … 
Segura-Aguilar, J. (2001). Copper neurotoxicity is dependent on dopamine-mediated 
copper uptake and one-electron reduction of aminochrome in a rat substantia nigra 
neuronal cell line. Journal of Neurochemistry, 77(2), 519–529. 
Park, J.-S., Blair, N. F., & Sue, C. M. (2015). The role of ATP13A2 in Parkinson’s disease: 
Clinical phenotypes and molecular mechanisms. Movement Disorders, 30(6), 770–779. 
Park, J.-S., Koentjoro, B., Veivers, D., Mackay-Sim, A., & Sue, C. M. (2014). Parkinson’s 
disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis 
and mitochondrial dysfunction. Human Molecular Genetics, 23(11), 2802–2815. 
Paterson, B. M., Cullinane, C., Crouch, P. J., White, A. R., Barnham, K. J., Roselt, P. D., … 
Donnelly, P. S. (2019). Modification of Biodistribution and Brain Uptake of Copper 
Bis(thiosemicarbazonato) Complexes by the Incorporation of Amine and Polyamine 
Functional Groups. Inorganic Chemistry, 58(7), 4540–4552. 
 137 
Paterson, B. M., Karas, J. A., Scanlon, D. B., White, J. M., & Donnelly, P. S. (2010). 
Versatile New Bis(thiosemicarbazone) Bifunctional Chelators: Synthesis, Conjugation 
to Bombesin(7−14)-NH2, and Copper-64 Radiolabeling. Inorganic Chemistry, 49(4), 
1884–1893. 
Paul, B., Hare, D. J., Bishop, D. P., Paton, C., Nguyen, V. T., Cole, N., … Doble, P. A. 
(2015). Visualising mouse neuroanatomy and function by metal distribution using laser 
ablation-inductively coupled plasma-mass spectrometry imaging. Chem. Sci., 6(10), 
5383–5393. 
Paxinos, G., & Franklin, K. (2012). Paxinos and Franklin’s the Mouse Brain in Stereotaxic 
Coordinates, Fourth Edition (Fourth). Amsterdam: Academic Press. 
Perry, J. J. P., Shin, D. S., Getzoff, E. D., & Tainer, J. A. (2010). The structural biochemistry 
of the superoxide dismutases. Biochimica et Biophysica Acta (BBA) - Proteins and 
Proteomics, 1804(2), 245–262. 
Pham, A. N., & Waite, T. D. (2014). Cu(II)-catalyzed oxidation of dopamine in aqueous 
solutions: Mechanism and kinetics. Journal of Inorganic Biochemistry, 137, 74–84. 
Pham, A. N., Xing, G., Miller, C. J., & Waite, T. D. (2013). Fenton-like copper redox 
chemistry revisited: Hydrogen peroxide and superoxide mediation of copper-catalyzed 
oxidant production. Journal of Catalysis, 301, 54–64. 
Pi Yu Chao, & Allen, K. G. D. (1992). Gluthathione production in copper-deficient isolated 
rat hepatocytes. Free Radical Biology and Medicine, 12(2), 145–150. 
Pickrell, A. M., Fukui, H., Wang, X., Pinto, M., & Moraes, C. T. (2011). The striatum is 
highly susceptible to mitochondrial oxidative phosphorylation dysfunctions. The Journal 
of Neuroscience : The Official Journal of the Society for Neuroscience, 31(27), 9895–
9904. 
Pierson, H., Lutsenko, S., & Tümer, Z. (2015). Copper Metabolism, ATP7A and Menkes 
Disease. In eLS (pp. 1–15). 
Pino, J. M. V, da Luz, M. H. M., Antunes, H. K. M., Giampá, S. Q. de C., Martins, V. R., & 
Lee, K. S. (2017). Iron-Restricted Diet Affects Brain Ferritin Levels, Dopamine 
Metabolism and Cellular Prion Protein in a Region-Specific Manner. Frontiers in 
Molecular Neuroscience, 10, 145. 
Poduslo, J. F., & Curran, G. L. (1996). Polyamine Modification Increases the Permeability of 
Proteins at the Blood-Nerve and Blood-Brain Barriers. Journal of Neurochemistry, 
66(4), 1599–1609. 
Popescu, B. F., & Nichol, H. (2011). Mapping brain metals to evaluate therapies for 
neurodegenerative disease. CNS Neuroscience and Therapeutics, 17(4), 256–268. 
Portbury, S., & Adlard, P. (2017). Zinc Signal in Brain Diseases. International Journal of 
Molecular Sciences, 18(12), 2506. 
Portbury, S. D., Hare, D. J., Sgambelloni, C. J., Bishop, D. P., Finkelstein, D. I., Doble, P. A., 
& Adlard, P. A. (2017). Age modulates the injury-induced metallomic profile in the 
brain. Metallomics, 9(4), 402–410. 
Pozebon, D., Scheffler, G. L., Dressler, V. L., & Nunes, M. A. G. (2014). Review of the 
applications of laser ablation inductively coupled plasma mass spectrometry (LA-ICP-
MS) to the analysis of biological samples. Journal of Analytical Atomic Spectrometry, 
29(12), 2204–2228. 
Pozzi, C., Ciambellotti, S., Bernacchioni, C., Di Pisa, F., Mangani, S., & Turano, P. (2017). 
 138 
Chemistry at the protein–mineral interface in L-ferritin assists the assembly of a 
functional (μ 3 -oxo)Tris[(μ 2 -peroxo)] triiron(III) cluster. Proceedings of the National 
Academy of Sciences, 114(10), 2580–2585. 
Prohaska, J. R., & Gybina, A. A. (2005). Rat brain iron concentration is lower following 
perinatal copper deficiency. Journal of Neurochemistry, 93(3), 698–705. 
Prohaska, J. R., & Smith, T. L. (1982). Effect of dietary or genetic copper deficiency on brain 
catecholamines, trace metals and enzymes in mice and rats. The Journal of Nutrition, 
112(9), 1706–1717. 
Przedborski, S., & Jackson-Lewis, V. (1998). Mechanisms of MPTP toxicity. Movement 
Disorders : Official Journal of the Movement Disorder Society, 13 Suppl 1, 35–38. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9613716 
Przybyłkowski, A., Gromadzka, G., Wawer, A., Bulska, E., Jabłonka-Salach, K., 
Grygorowicz, T., … Członkowski, A. (2013). Neurochemical and Behavioral 
Characteristics of Toxic Milk Mice: An Animal Model of Wilson’s Disease. 
Neurochemical Research, 38(10), 2037–2045. 
Pushkar, Y., Robison, G., Sullivan, B., Fu, S. X., Kohne, M., Jiang, W., … Zheng, W. 
(2013). Aging results in copper accumulations in glial fibrillary acidic protein-positive 
cells in the subventricular zone. Aging Cell, 12(5), 823–832. 
Qi, X., Davis, B., Chiang, Y.-H., Filichia, E., Barnett, A., Greig, N. H., … Luo, Y. (2016). 
Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an 
experimental Parkinson’s disease model. Journal of Neurochemistry, 138(5), 746–757. 
Qi, Z., Miller, G. W., & Voit, E. O. (2008). Computational Systems Analysis of Dopamine 
Metabolism. PLoS ONE, 3(6), e2444. 
Quail, J. F., Tsai, C.-Y., & Howell, S. B. (2014). Characterization of a monoclonal antibody 
capable of reliably quantifying expression of Human Copper Transporter 1 (hCTR1). 
Journal of Trace Elements in Medicine and Biology, 28(2), 151–159. 
Rakhit, R., & Chakrabartty, A. (2006). Structure, folding, and misfolding of Cu,Zn 
superoxide dismutase in amyotrophic lateral sclerosis. Biochimica et Biophysica Acta 
(BBA) - Molecular Basis of Disease, 1762(11–12), 1025–1037. 
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., … 
Kubisch, C. (2006). Hereditary parkinsonism with dementia is caused by mutations in 
ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nature Genetics, 38(10), 1184–
1191. 
Ramonet, D., Podhajska, A., Stafa, K., Sonnay, S., Trancikova, A., Tsika, E., … Moore, D. J. 
(2012). PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and 
regulates cation homeostasis and neuronal integrity. Human Molecular Genetics, 21(8), 
1725–1743. 
Ramos, P., Santos, A., Pinto, N. R., Mendes, R., Magalhães, T., & Almeida, A. (2014a). 
Anatomical Region Differences and Age-Related Changes in Copper, Zinc, and 
Manganese Levels in the Human Brain. Biological Trace Element Research, 161(2), 
190–201. 
Ramos, P., Santos, A., Pinto, N. R., Mendes, R., Magalhães, T., & Almeida, A. (2014b). Iron 
levels in the human brain: A post-mortem study of anatomical region differences and 
age-related changes. Journal of Trace Elements in Medicine and Biology, 28(1), 13–17. 
Ramsay, R. R., & Singer, T. P. (1986). Energy-dependent uptake of N-methyl-4-
 139 
phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine, by mitochondria. The Journal of Biological Chemistry, 261(17), 
7585–7587. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/3486869 
Ramsey, A. J., Hillas, P. J., & Fitzpatrick, P. F. (1996). Characterization of the active site 
iron in tyrosine hydroxylase. Redox states of the iron. The Journal of Biological 
Chemistry, 271(40), 24395–24400. 
Rani, V., Asthana, S., Vadhera, M., Yadav, U. C. S., & Atale, N. (2015). Tools and 
Techniques to Measure Oxidative Stress. In V. Rani & U. C. S. Yadav (Eds.), Free 
Radicals in Human Health and Disease (pp. 43–56). 
Riessland, M., Kolisnyk, B., Kim, T. W., Cheng, J., Ni, J., Pearson, J. A., … Greengard, P. 
(2019). Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic 
Dopaminergic Neurons. Cell Stem Cell, 25(4), 514-530.e8. 
Rossi, L., Lombardo, M. F., Ciriolo, M. R., & Rotilio, G. (2004). Mitochondrial Dysfunction 
in Neurodegenerative Diseases Associated with Copper Imbalance. Neurochemical 
Research, 29(3), 493–504. 
Sales, T. A., Prandi, I. G., Castro, A. A. de, Leal, D. H. S., Cunha, E. F. F. da, Kuca, K., & 
Ramalho, T. C. (2019). Recent Developments in Metal-Based Drugs and Chelating 
Agents for Neurodegenerative Diseases Treatments. International Journal of Molecular 
Sciences, 20(8), 1829. 
Salustri, C., Barbati, G., Ghidoni, R., Quintiliani, L., Ciappina, S., Binetti, G., & Squitti, R. 
(2010). Is cognitive function linked to serum free copper levels? A cohort study in a 
normal population. Clinical Neurophysiology, 121(4), 502–507. 
Schapira, A. H., & Jenner, P. (2011). Etiology and pathogenesis of Parkinson’s disease. 
Movement Disorders : Official Journal of the Movement Disorder Society, 26(6), 1049–
1055. 
Scheiber, I. F., & Dringen, R. (2013). Astrocyte functions in the copper homeostasis of the 
brain. Neurochemistry International, 62(5), 556–565. 
Scheiber, I. F., Mercer, J. F. B., & Dringen, R. (2010). Copper accumulation by cultured 
astrocytes. Neurochemistry International, 56(3), 451–460. 
Scheiber, I. F., Mercer, J. F. B., & Dringen, R. (2014). Metabolism and functions of copper in 
brain. Progress in Neurobiology, 116, 33–57. 
Scheiber, I. F., Schmidt, M. M., & Dringen, R. (2012). Copper export from cultured 
astrocytes. Neurochemistry International, 60(3), 292–300. 
Schildknecht, S., Di Monte, D. A., Pape, R., Tieu, K., & Leist, M. (2017). Tipping Points and 
Endogenous Determinants of Nigrostriatal Degeneration by MPTP. Trends in 
Pharmacological Sciences, 38(6), 541–555. 
Sedelis, M., Hofele, K., Auburger, G. W., Morgan, S., Huston, J. P., & Schwarting, R. K. W. 
(2000a). Evidence for resistance to MPTP in C57BL/6 × BALA/c F1 hybrids as 
compared with their progenitor strains. NeuroReport, 11(5), 1093–1096. 
Sedelis, M., Hofele, K., Auburger, G. W., Morgan, S., Huston, J. P., & Schwarting, R. K. W. 
(2000b). MPTP Susceptibility in the Mouse: Behavioral, Neurochemical, and 
Histological Analysis of Gender and Strain Differences. Behavior Genetics, 30(3), 171–
182. 
Segura-Aguilar, J. (2019). The importance of choosing a preclinical model that reflects what 
happens in Parkinson’s disease. Neurochemistry International, 126, 203–209. 
 140 
Serlin, Y., Shelef, I., Knyazer, B., & Friedman, A. (2015). Anatomy and physiology of the 
blood–brain barrier. Seminars in Cell & Developmental Biology, 38, 2–6. 
Shahidi, F., & Zhong, Y. (2015). Measurement of antioxidant activity. Journal of Functional 
Foods, 18, 757–781. 
Sirois, J. J., Padgitt-Cobb, L., Gallegos, M. A., Beckman, J. S., Beaudry, C. M., & Hurst, J. 
K. (2018). Oxidative Release of Copper from Pharmacologic Copper 
Bis(thiosemicarbazonato) Compounds. Inorganic Chemistry, 57(15), 8923–8932. 
Sochocka, M., Diniz, B. S., & Leszek, J. (2017). Inflammatory Response in the CNS: Friend 
or Foe? Molecular Neurobiology, 54(10), 8071–8089. 
Spencer, W. A., Jeyabalan, J., Kichambre, S., & Gupta, R. C. (2011). Oxidatively generated 
DNA damage after Cu(II) catalysis of dopamine and related catecholamine 
neurotransmitters and neurotoxins: Role of reactive oxygen species. Free Radical 
Biology and Medicine, 50(1), 139–147. 
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018). Inflammation in CNS 
neurodegenerative diseases. Immunology, 154(2), 204–219. 
Sturtz, L. A., Diekert, K., Jensen, L. T., Lill, R., & Culotta, V. C. (2001). A fraction of yeast 
Cu,Zn-superoxide dismutase and its metallochaperone, CCS, localize to the 
intermembrane space of mitochondria. A physiological role for SOD1 in guarding 
against mitochondrial oxidative damage. The Journal of Biological Chemistry, 276(41), 
38084–38089. 
Swindell, W. R. (2011). Metallothionein and the biology of aging. Ageing Research Reviews, 
10(1), 132–145. 
Takada, M., Sugimoto, T., & Hattori, T. (1993). MPTP neurotoxicity to cerebellar Purkinje 
cells in mice. Neuroscience Letters, 150(1), 49–52. 
Takahashi, S., Takahashi, I., Sato, H., Kubota, Y., Yoshida, S., & Muramatsu, Y. (2001). 
Age-related changes in the concentrations of major and trace elements in the brain of 
rats and mice. Biological Trace Element Research, 80(2), 145–158. 
Takahashi, Y., Miyajima, H., Shirabe, S., Nagataki, S., Suenaga, A., & Gitlin, J. D. (1996). 
Characterization of a Nonsense Mutation in the Ceruloplasmin Gene Resulting in 
Diabetes and Neurodegenerative Disease. Human Molecular Genetics, 5(1), 81–84. 
Tambasco, N., Romoli, M., & Calabresi, P. (2018). Levodopa in Parkinson’s Disease: 
Current Status and Future Developments. Current Neuropharmacology, 16(8), 1239–
1252. 
Tapia, L., González-Agüero, M., Cisternas, M. F., Suazo, M., Cambiazo, V., Uauy, R., & 
González, M. (2004). Metallothionein is crucial for safe intracellular copper storage and 
cell survival at normal and supra-physiological exposure levels. The Biochemical 
Journal, 378(Pt 2), 617–624. 
Terwel, D., Löschmann, Y.-N., Schmidt, H. H. J., Schöler, H. R., Cantz, T., & Heneka, M. T. 
(2011). Neuroinflammatory and behavioural changes in the Atp7B mutant mouse model 
of Wilson’s disease. Journal of Neurochemistry, 118(1), 105–112. 
Trist, B. G., Davies, K. M., Cottam, V., Genoud, S., Ortega, R., Roudeau, S., … Double, K. 
L. (2017). Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is 
associated with neuronal loss in Parkinson’s disease brain. Acta Neuropathologica, 
134(1), 113–127. 
Tsednee, M., Huang, Y.-C., Chen, Y.-R., & Yeh, K.-C. (2016). Identification of metal 
 141 
species by ESI-MS/MS through release of free metals from the corresponding metal-
ligand complexes. Scientific Reports, 6(1), 26785. 
Tsunemi, T., & Krainc, D. (2014). Zn2+ dyshomeostasis caused by loss of ATP13A2/PARK9 
leads to lysosomal dysfunction and alpha-synuclein accumulation. Human Molecular 
Genetics, 23(11), 2791–2801. 
Umek, N., Geršak, B., Vintar, N., Šoštarič, M., & Mavri, J. (2018). Dopamine Autoxidation 
Is Controlled by Acidic pH   . Frontiers in Molecular Neuroscience  , Vol. 11, p. 467. 
Retrieved from https://www.frontiersin.org/article/10.3389/fnmol.2018.00467 
Verdier, J.-M., Acquatella, I., Lautier, C., Devau, G., Trouche, S., Lasbleiz, C., & Mestre-
Francés, N. (2015). Lessons from the analysis of nonhuman primates for understanding 
human aging and neurodegenerative diseases. Frontiers in Neuroscience, 9(MAR), 1–6. 
Villar, J., Lubenia, P., Mendoza, E., & Pilar-Arceo, C. (2019). Structural Stability Analysis of 
Models of Dopamine Synthesis and D1 Receptor Trafficking in RPT Cells using CRNT. 
Philippine Journal of Science, 148(3), 523–533. 
Walker, T., Michaelides, C., Ekonomou, A., Geraki, K., Parkes, H. G., Suessmilch, M., … 
So, P.-W. (2016). Dissociation between iron accumulation and ferritin upregulation in 
the aged substantia nigra: attenuation by dietary restriction. Aging, 8(10), 2488–2508. 
Walshe, J. M., & Gibbs, K. R. (1987). Brain copper in Wilson’s disease. The Lancet, 
330(8566), 1030. 
Wang, J.-Y., Zhuang, Q.-Q., Zhu, L.-B., Zhu, H., Li, T., Li, R., … Zhu, J.-H. (2016). Meta-
analysis of brain iron levels of Parkinson’s disease patients determined by postmortem 
and MRI measurements. Scientific Reports, 6, 36669. 
Wang, L.-M., Becker, J. S., Wu, Q., Oliveira, M. F., Bozza, F. A., Schwager, A. L., … 
Morton, K. A. (2010). Bioimaging of copper alterations in the aging mouse brain by 
autoradiography, laser ablation inductively coupled plasma mass spectrometry and 
immunohistochemistry. Metallomics, 2(5), 348. 
Wang, Y., Hodgkinson, V., Zhu, S., Weisman, G. A., & Petris, M. J. (2011). Advances in the 
Understanding of Mammalian Copper Transporters. Advances in Nutrition, 2(2), 129–
137. 
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014). The role of iron 
in brain ageing and neurodegenerative disorders. The Lancet Neurology, 13(10), 1045–
1060. 
Weekley, C. M., & He, C. (2017). Developing drugs targeting transition metal homeostasis. 
Current Opinion in Chemical Biology, 37, 26–32. 
Williams, D. R., & Litvan, I. (2013). Parkinsonian syndromes. CONTINUUM: Lifelong 
Learning in Neurology, 19, 1189–1212. 
Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and 
related parameters. Biostatistics, 20(2), 273–286. 
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., … Przedborski, 
S. (2002). Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-
Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease. The Journal of 
Neuroscience, 22(5), 1763–1771. 
Xiao, Z., Donnelly, P. S., Zimmermann, M., & Wedd, A. G. (2008). Transfer of copper 
between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. 
Insights into mechanisms of copper uptake and hypoxia selectivity. Inorganic 
 142 
Chemistry, 47(10), 4338–4347. 
Xu, Z., Cawthon, D., McCastlain, K. A., Slikker, W., & Ali, S. F. (2005). Selective 
alterations of gene expression in mice induced by MPTP. Synapse, 55(1), 45–51. 
Yabe, H., Choudhury, M. E., Kubo, M., Nishikawa, N., Nagai, M., & Nomoto, M. (2009). 
Zonisamide Increases Dopamine Turnover in the Striatum of Mice and Common 
Marmosets Treated With MPTP. Journal of Pharmacological Sciences, 110(1), 64–68. 
Yamada, H., & Yasunobu, K. T. (1962). Monoamine oxidase. II. Copper, one of the 
prosthetic groups of plasma monoamine oxidase. The Journal of Biological Chemistry, 
237(10), 3077–3082. 
Yoshii, Y., Yoneda, M., Ikawa, M., Furukawa, T., Kiyono, Y., Mori, T., … Fujibayashi, Y. 
(2012). Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state 
due to mitochondrial dysfunction: studies with mitochondrial DNA-less ρ0 cells and 
cybrids carrying MELAS mitochondrial DNA mutation. Nuclear Medicine and Biology, 
39(2), 177–185. 
You, H., Mariani, L.-L., Mangone, G., Le Febvre de Nailly, D., Charbonnier-Beaupel, F., & 
Corvol, J.-C. (2018). Molecular basis of dopamine replacement therapy and its side 
effects in Parkinson’s disease. Cell and Tissue Research, 373(1), 111–135. 
You, L.-H., Li, F., Wang, L., Zhao, S.-E., Wang, S.-M., Zhang, L.-L., … Chang, Y.-Z. 
(2015). Brain iron accumulation exacerbates the pathogenesis of MPTP-induced 
Parkinson’s disease. Neuroscience, 284, 234–246. 
Yu, W.-R., Jiang, H., Wang, J., & Xie, J. (2008). Copper (Cu2+) induces degeneration of 
dopaminergic neurons in the nigrostriatal system of rats. Neuroscience Bulletin, 24(2), 
73–78. 
Zeglis, B. M., Houghton, J. L., Evans, M. J., Viola-Villegas, N., & Lewis, J. S. (2014). 
Underscoring the Influence of Inorganic Chemistry on Nuclear Imaging with 
Radiometals. Inorganic Chemistry, 53(4), 1880–1899. 
Zhang, L., Lee, H.-K., Pruess, T. H., White, H. S., & Bulaj, G. (2009). Synthesis and 
applications of polyamine amino acid residues: improving the bioactivity of an analgesic 
neuropeptide, neurotensin. Journal of Medicinal Chemistry, 52(6), 1514–1517. 
Zhang, M. Y., Kagan, N., Sung, M. L. A., Zaleska, M. M., & Monaghan, M. (2008). 
Sensitive and selective liquid chromatography/tandem mass spectrometry methods for 
quantitative analysis of 1-methyl-4-phenyl pyridinium (MPP+) in mouse striatal tissue. 
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life 
Sciences, 874(1–2), 51–56. 
Zhang, S., Wang, R., & Wang, G. (2019). Impact of Dopamine Oxidation on Dopaminergic 
Neurodegeneration. ACS Chemical Neuroscience, 10(2), 945–953. 
Zheng, J., Jiang, R., Chen, M., Maimaitiming, Z., Wang, J., Anderson, G. J., … Chen, H. 
(2018). Multi-Copper Ferroxidase–Deficient Mice Have Increased Brain Iron 
Concentrations and Learning and Memory Deficits. The Journal of Nutrition, 148(4), 
643–649. 
Zhou, G., Ji, X., Cui, N., Cao, S., Liu, C., & Liu, J. (2015). Association between Serum 
Copper Status and Working Memory in Schoolchildren. Nutrients, 7(9), 7185–7196. 
 
